Helical anchor implantation

Information

  • Patent Grant
  • 11426155
  • Patent Number
    11,426,155
  • Date Filed
    Tuesday, November 12, 2019
    3 years ago
  • Date Issued
    Tuesday, August 30, 2022
    5 months ago
Abstract
A transluminal sheath is advanced into a femoral vein of a subject, through an inferior vena cava of the subject, into a right atrium of a heart of the subject, and transseptally into a left atrium of the heart. A surrounding-sheath is advanced out of a distal end of the transluminal sheath, into the left atrium, and toward a commissure of a mitral valve of the heart. A commissural helix is implanted at the commissure by advancing the commissural helix out of the surrounding-sheath and through the commissure into a left ventricle of the heart, such that the commissural helix wraps around at least some chordae tendineae at the commissure and facilitates sealing of the commissure. Subsequently to the implantation of the commissural helix, the surrounding-sheath is extracted from the heart. Other embodiments are also described.
Description
FIELD OF THE INVENTION

Embodiments of the present invention relate in general to valve replacement. More specifically, embodiments of the present invention relate to prosthetic valves for replacement of an atrioventricular valve.


BACKGROUND

Dilation of the annulus of the mitral valve prevents the valve leaflets from fully coapting when the valve is closed. Regurgitation of blood from the ventricle into the atrium results in increased total stroke volume and decreased cardiac output, and ultimate weakening of the ventricle secondary to a volume overload and a pressure overload of the atrium. Dilation of the annulus is sometimes treated by implanting a prosthetic mitral valve at a patient's native mitral valve.


SUMMARY

For some applications of the present invention, one or more guide members (e.g., wires, sutures, or strings) is configured to be anchored to respective commissures of a native atrioventricular valve of a patient, and each guide member facilitates the advancement therealong of respective commissural anchors. The commissural anchors are shaped so as to define a plurality of barbs or prongs which are expandable to restrict proximal movement of the anchors following their deployment. The guide members facilitate advancement of a collapsible prosthetic valve support (e.g., a skirt) which serves as a base for and receives a collapsible prosthetic mitral valve which is subsequently coupled to the support. The support comprises a proximal annular element, or ring, and a distal cylindrical element. The cylindrical element is configured to push aside and press against the native leaflets of the native valve, and the proximal annular element is shaped so as to define one or more holes for sliding the valve support along the one or more guide members. The proximal annular element is configured to be positioned along the annulus of the native valve.


The collapsible prosthetic valve is configured for implantation in and/or at least partial replacement (e.g., full replacement) of the native atrioventricular valve of the patient, such as a native mitral valve or a native tricuspid valve. The valve support and the prosthetic valve are configured to assume collapsed states for minimally-invasive delivery to the diseased native valve, such as by percutaneous or transluminal delivery using one or more catheters. For some applications, the valve support and the prosthetic valve are implanted during an open-heart procedure.


The prosthetic valve support is shaped so as to define a downstream skirt. The downstream skirt is configured to be placed at native valve, such that the downstream skirt passes through the orifice of the native valve and extends toward, and, typically partially into, a ventricle. The downstream skirt typically additionally pushes aside and presses against the native leaflets of the native valve, which are left in place during and after implantation of the prosthetic valve support and/or the prosthetic valve.


The proximal annular element has upper and lower surfaces. For some applications of the present invention, one or more, e.g., a plurality of, tissue anchors are coupled to the lower surface and facilitate anchoring of the proximal annular element to the annulus of the native valve. For some applications, the one or more anchors comprise at least first and second commissural anchors that are configured to be implanted at or in the vicinity of the commissures of the native valve.


The cylindrical element of the valve support has first and second ends and a cylindrical body disposed between the first and second ends. The first end of the cylindrical element is coupled to the annular element while the second end defines a free end of the cylindrical element. For some applications of the present invention, the cylindrical element of the valve support is invertible such that (1) during a first period, the second end and the cylindrical body of the cylindrical element are disposed above the annular element (e.g., in the atrium of the heart), and (2) during a second period, the second end and the cylindrical body of the cylindrical element are disposed below the annular element (e.g., in the ventricle of the heart).


For some applications, techniques are applied to facilitate sealing of the interface between the valve support and the native valve, and/or the interface between the prosthetic valve and the native valve. For example, a sealing balloon may be placed on a valve-facing, lower side of the annular element of the valve support, the sealing balloon being configured to be inflated such that the balloon seals the interface between the valve support and the native valve. Alternatively or additionally, commissural helices are wrapped around chordae tendineae of the patient in order to facilitate sealing of the valve commissures around the valve support and/or around the valve. Further alternatively or additionally, the valve commissures are grasped by grasping elements that act in order to facilitate sealing of the commissures around the valve support and/or around the valve. For some applications, one or more of the aforementioned sealing elements facilitates anchoring of the prosthetic valve to the native valve in addition to facilitating sealing.


For some applications, the prosthetic valve comprises an expandable frame (e.g., a wire frame), and a sealing material (such as latex) is disposed on the outer surface of the frame so as to form webbing between at least some of the struts of the wire frame, and to provide sealing between the wire frame and the native valve.


For some applications, an invertible prosthetic valve support is used to support a prosthetic valve. Typically, a sealing element is disposed circumferentially around a surface of the invertible prosthetic valve support that is initially an inner surface of the invertible prosthetic valve support. The invertible prosthetic valve support is anchored to the native valve, and is subsequently inverted. Subsequent to the inversion of the invertible prosthetic valve support, the sealing element is disposed on the outer surface of the invertible prosthetic valve support and acts to seal the interface between the outer surface and the native valve.


There is therefore provided, in accordance with some applications of the present invention, apparatus, including:


a prosthetic valve support configured to be placed at an annulus of a native atrioventricular valve of a patient, the prosthetic valve support defining an annular element that defines an inner cross-sectional area thereof;


an expandable prosthetic valve configured to be placed into a ventricle of the patient, the prosthetic valve including:

    • an expandable frame; and
    • prosthetic valve leaflets coupled to the expandable frame;


the expandable frame of the prosthetic valve being configured such that when the frame is in a non-constrained state thereof, a cross-sectional area of the frame, along at least a given portion of a length of the frame, is greater than the cross-sectional area defined by the annular element of the prosthetic valve support,


the prosthetic valve thereby being couplable to the prosthetic valve support at any location along the portion, responsively to radial forces acted upon the valve support by the expandable frame, by the expandable frame being expanded when the location along the portion is aligned with the annular element of the prosthetic valve support.


For some applications, the valve support is collapsible for transcatheter delivery.


For some applications, the native atrioventricular valve includes a mitral valve, and the prosthetic valve includes three prosthetic leaflets.


For some applications, the annular element of the valve support is asymmetrically shaped.


For some applications, the annular element is shaped to define a hole, and a center of the hole is disposed asymmetrically with respect to an outer perimeter of the annular element.


For some applications, the frame includes proximally-facing protrusions at a distal end thereof, the protrusions being configured to prevent proximal migration of the valve into an atrium.


For some applications, the protrusions are disposed at an angle from the frame of more than 40 degrees.


For some applications, the protrusions are disposed at an angle from the frame of less than 80 degrees.


For some applications, a length of each of the protrusions is less than 5 mm.


For some applications, the frame includes a single proximally-facing protrusion corresponding to each native valve leaflet of the valve, each of the protrusions having a width of less than 1 mm.


For some applications, the protrusions are disposed in a sinusoidal configuration such that the protrusions conform with a saddle shape of the patient's native annulus.


For some applications, the protrusions are configured to prevent the native leaflets from interfering with a left ventricular outflow tract of the patient.


For some applications, the frame includes first and second sets of one or more protrusions, each set of protrusions configured to ensnare a respective native leaflet of the native valve of the patient, the first set of protrusions being disposed within a first circumferential arc with respect to a longitudinal axis of the prosthetic valve, on a first side of a distal end of the frame, the second set of protrusions being disposed within a second circumferential arc with respect to the longitudinal axis of the prosthetic valve, on a second side of the distal end of the frame, the first and second sets being disposed so as to provide first and second gaps therebetween at the distal end of the frame, at least one of the gaps having a circumferential arc of at least 20 degrees, the apparatus further including one or more valve guide members configured to be delivered to one or more commissures of the native valve, and to guide the valve such that the first and second circumferential arcs are aligned with respective leaflets of the native valve and such that the first and second gaps are aligned with respective commissures of the native valve.


For some applications, the at least one of the gaps has a circumferential arc of at least 60 degrees.


For some applications, the first circumferential arc defines an angle of between 25 degrees and 90 degrees about the longitudinal axis of the prosthetic valve.


For some applications, the second circumferential arc defines an angle of between 25 degrees and 90 degrees about the longitudinal axis of the prosthetic valve.


For some applications, the first circumferential arc defines an angle of between 45 degrees and 75 degrees about the longitudinal axis of the prosthetic valve.


For some applications, the second circumferential arc defines an angle of between 45 degrees and 75 degrees about the longitudinal axis of the prosthetic valve.


For some applications, the expandable frame of the prosthetic valve is configured such that when the frame is in a non-constrained state thereof the frame has a maximum diameter of less than 25 mm.


For some applications, the expandable frame of the prosthetic valve is configured such that when the frame is in a non-constrained state thereof the frame has a maximum diameter of more than 15 mm.


For some applications, the expandable frame of the prosthetic valve is configured such that when the frame is in a non-constrained state thereof the frame has a maximum diameter of less than 20 mm.


For some applications, the expandable frame of the prosthetic valve is configured such that when the frame is in a non-constrained state thereof, a cross-sectional area of the frame at a proximal end of the frame is greater than a cross-sectional area of the frame at a distal end of the frame.


For some applications, the expandable frame of the prosthetic valve is configured such that when the frame is in the non-constrained state thereof the frame defines a frustoconical shape.


For some applications, the expandable frame of the prosthetic valve is configured such that when the frame is in the non-constrained state thereof the frame defines a trumpet shape.


There is further provided, in accordance with some applications of the present invention, a method, including:


placing a prosthetic valve support at an annulus of a native atrioventricular valve of a patient, the prosthetic valve support defining an annular element that defines an inner cross-sectional area thereof;


placing into a ventricle of the patient, an expandable prosthetic valve,

    • the prosthetic valve including an expandable frame, and prosthetic valve leaflets coupled to the expandable frame,
    • the expandable frame of the prosthetic valve being configured such that when the frame is in a non-constrained state thereof, a cross-sectional area of the frame, along at least a given portion of a length of the frame, is greater than the cross-sectional area defined by the annular element of the prosthetic valve support;


determining a location anywhere along the portion at which to couple the expandable valve the prosthetic valve support; and


in response thereto,


aligning the location along the portion of the expandable frame with the annular element of the prosthetic valve support; and


coupling the expandable valve to the prosthetic valve support at the location, responsively to radial forces acted upon the valve support by the expandable frame, by facilitating expansion of the expandable frame, when the location along the portion is aligned with the annular element of the prosthetic valve support.


For some applications, placing the valve support at the annulus includes transcatheterally placing the valve support at the annulus in a collapsed state.


For some applications, the native atrioventricular valve includes a mitral valve, and placing the prosthetic valve into the ventricle includes placing into the ventricle a prosthetic valve that includes three prosthetic leaflets.


For some applications, placing the prosthetic valve support at the annulus includes placing an asymmetrically-shaped prosthetic valve support at the annulus.


For some applications, placing the prosthetic valve support at the annulus includes placing at the annulus an annular element that is shaped to define a hole, a center of the hole being disposed asymmetrically with respect to an outer perimeter of the annular element, the annular element being placed such that a center of the hole is disposed asymmetrically with respect to the annulus.


For some applications, the frame includes proximally-facing protrusions at a distal end thereof, the protrusions being configured to prevent proximal migration of the valve into an atrium, and coupling the expandable valve to the prosthetic valve support includes preventing proximal migration of the valve by coupling the valve to the valve support such that the leaflets are disposed at least partially between the protrusions and the valve support.


For some applications, coupling the expandable valve to the prosthetic valve support includes preventing the native leaflets from interfering with a left ventricular outflow tract of the patient.


For some applications, coupling the expandable valve to the prosthetic valve support includes allowing movement of the leaflets with respect to the frame while preventing the proximal migration of the valve.


For some applications, the frame includes first and second sets of one or more protrusions, each set of protrusions configured to ensnare a respective native leaflet of the native valve of the patient, the first set of protrusions being disposed within a first circumferential arc with respect to a longitudinal axis of the prosthetic valve, on a first side of a distal end of the frame, the second set of protrusions being disposed within a second circumferential arc with respect to the longitudinal axis of the prosthetic valve, on a second side of the distal end of the frame, the first and second sets being disposed so as to provide first and second gaps therebetween at the distal end of the frame, at least one of the gaps having a circumferential arc of at least 20 degrees, the method further including guiding the valve such that the first and second circumferential arcs are aligned with respective leaflets of the native valve and such that the first and second gaps are aligned with respective commissures of the native valve.


For some applications, facilitating expansion of the frame includes facilitating expansion of the frame to a maximum diameter of less than 25 mm.


For some applications, facilitating expansion of the frame includes facilitating expansion of the frame to a maximum diameter of more than 15 mm.


For some applications, facilitating expansion of the frame includes facilitating expansion of the frame to a maximum diameter of less than 20 mm.


For some applications, facilitating expansion of the frame includes facilitating expansion of the frame such that a cross-sectional area of the frame at a proximal end of the frame is greater than a cross-sectional area of the frame at a distal end of the frame.


For some applications, facilitating expansion of the frame includes facilitating expansion of the frame such that the frame defines a frustoconical shape.


For some applications, facilitating expansion of the frame includes facilitating expansion of the frame such that the frame defines a trumpet shape.


There is additionally provided, in accordance with some applications of the present invention, a method, including:


determining an indication of an area defined by an annulus of a native atrioventricular valve of a patient;


selecting a prosthetic valve support by determining that the prosthetic valve support defines an annular element that defines an inner cross-sectional area that is less than the area defined by the annulus;


placing the prosthetic valve support at the annulus of the native atrioventricular valve;


placing into a ventricle of the patient, an expandable prosthetic valve, the prosthetic valve including an expandable frame, and prosthetic valve leaflets coupled to the expandable frame;


coupling the expandable valve to the prosthetic valve support at the location, responsively to radial forces acted upon the valve support by the expandable frame, by facilitating expansion of the expandable frame,


a cross-sectional area defined by the expandable frame of the prosthetic valve being limited by the cross-sectional area defined by the annular element of the prosthetic valve support, such as to facilitate sealing of the native valve with respect to the prosthetic valve by facilitating closing of leaflets of the native valve around the prosthetic valve, upon deployment of the prosthetic valve.


For some applications, facilitating closing of leaflets of the native valve around the prosthetic valve includes facilitating sealing of the native valve at commissures of the native valve.


For some applications, facilitating closing of leaflets of the native valve around the prosthetic valve includes facilitating closing of the leaflets of the native valve around an outer surface of the expandable frame.


For some applications, placing the valve support at the annulus includes transcatheterally placing the valve support at the annulus in a collapsed state.


For some applications, the native atrioventricular valve includes a mitral valve, and placing the prosthetic valve into the ventricle includes placing into the ventricle a prosthetic valve that includes three prosthetic leaflets.


For some applications, placing the prosthetic valve support at the annulus includes placing an asymmetrically-shaped prosthetic valve support at the annulus.


For some applications, placing the prosthetic valve support at the annulus includes placing at the annulus an annular element that is shaped to define a hole, a center of the hole being disposed asymmetrically with respect to an outer perimeter of the annular element, the annular element being placed such that a center of the hole is disposed asymmetrically with respect to the annulus.


For some applications, the frame includes proximally-facing protrusions at a distal end thereof, the protrusions being configured to prevent proximal migration of the valve into an atrium, and coupling the expandable valve to the prosthetic valve support includes preventing proximal migration of the valve by coupling the valve to the valve support such that the leaflets are disposed at least partially between the protrusions and the valve support.


For some applications, coupling the expandable valve to the prosthetic valve support includes preventing the native leaflets from interfering with a left ventricular outflow tract of the patient.


For some applications, coupling the expandable valve to the prosthetic valve support includes allowing movement of the leaflets with respect to the frame while preventing proximal migration of the valve.


For some applications, the frame includes first and second sets of one or more protrusions, each set of protrusions configured to ensnare a respective native leaflet of the native valve of the patient, the first set of protrusions being disposed within a first circumferential arc with respect to a longitudinal axis of the prosthetic valve, on a first side of a distal end of the frame, the second set of protrusions being disposed within a second circumferential arc with respect to the longitudinal axis of the prosthetic valve, on a second side of the distal end of the frame, the first and second sets being disposed so as to provide first and second gaps therebetween at the distal end of the frame, at least one of the gaps having a circumferential arc of at least 20 degrees, the method further including guiding the valve such that the first and second circumferential arcs are aligned with respective leaflets of the native valve and such that the first and second gaps are aligned with respective commissures of the native valve.


For some applications, facilitating expansion of the frame includes facilitating expansion of the frame to a maximum diameter of less than 25 mm.


For some applications, facilitating expansion of the frame includes facilitating expansion of the frame to a maximum diameter of more than 15 mm.


For some applications, facilitating expansion of the frame includes facilitating expansion of the frame to a maximum diameter of less than 20 mm.


For some applications, facilitating expansion of the frame includes facilitating expansion of the frame such that a cross-sectional area of the frame at a proximal end of the frame is greater than a cross-sectional area of the frame at a distal end of the frame.


For some applications, facilitating expansion of the frame includes facilitating expansion of the frame such that the frame defines a frustoconical shape.


For some applications, facilitating expansion of the frame includes facilitating expansion of the frame such that the frame defines a trumpet shape.


There is additionally provided, in accordance with some applications of the present invention, a method, including:


placing a prosthetic valve support at an annulus of a native atrioventricular valve of a patient;


placing a prosthetic valve into a ventricle of the patient, the prosthetic valve including protrusions at a distal end thereof;


ensnaring one or more native leaflets of the native valve of the patient with the protrusions; and


coupling the prosthetic valve to the native valve,

    • by sandwiching native leaflets of the native valve between the protrusions and the valve support, by pulling the prosthetic valve proximally with respect to the valve support, and
    • while the native leaflets are sandwiched between the protrusions and the valve support, coupling the prosthetic valve to the valve support, by facilitating radial expansion of the prosthetic valve such that the prosthetic valve is held in place with respect to the valve support responsively to radial forces acted upon the valve support by the prosthetic valve.


There is further provided, in accordance with some applications of the present invention, a method, including:


determining an indication of an area defined by an annulus of a native atrioventricular valve of a patient;


selecting a prosthetic valve to be placed in the native valve by determining that the valve defines a cross-sectional area that is less than 90% of the area defined by the annulus; and


deploying the prosthetic valve at the native valve,


the selecting of the prosthetic valve facilitating sealing of the native valve with respect to the prosthetic valve by facilitating closing of leaflets of the native valve around the prosthetic valve, upon deployment of the prosthetic valve.


For some applications, selecting the prosthetic valve includes selecting a prosthetic valve having a material disposed on an outer surface thereof.


For some applications, selecting the prosthetic valve includes selecting a prosthetic valve having a material that prevents tissue growth disposed on an outer surface thereof.


For some applications, selecting the prosthetic valve includes selecting a prosthetic valve having a material that promotes tissue growth disposed on an outer surface thereof.


For some applications, selecting the prosthetic valve to be placed in the native valve includes determining that the valve defines a cross-sectional area that is less than 80% of the area defined by the annulus.


For some applications, selecting the prosthetic valve to be placed in the native valve includes determining that the valve defines a cross-sectional area that is less than 60% of the area defined by the annulus.


There is further provided, in accordance with some applications of the present invention, apparatus, including:


one or more valve support guide members configured to be delivered to one or more commissures of a native atrioventricular valve of a patient;


one or more valve support anchors configured to be anchored to the one or more commissures of the native valve;


a prosthetic valve support advanceable toward the native valve along the one or more valve support guide members and anchored to the native valve at at least the one or more commissures; and


a prosthetic valve configured to be coupled to the valve support.


For some applications, the valve support is collapsible for transcatheter delivery and expandable to contact the native atrioventricular valve.


For some applications, the one or more valve support anchors are configured to be anchored to the one or more commissures from ventricular surfaces thereof.


For some applications, the one or more valve support guide members includes one valve support guide member that is looped through first and second commissures of the atrioventricular valve in a manner in which a looped portion of the valve support guide member is disposed in a ventricle of the patient and first and second free ends of the valve support guide member are accessible from a site outside a body of the patient.


For some applications, the one or more valve support anchors includes first and second tissue anchors, the first and second tissue anchors being configured to be anchored to respective first and second commissures of the atrioventricular valve of the patient.


For some applications:


the one or more valve support anchors each include one or more radially-expandable prongs, and


the one or more prongs are disposed within a sheath in a compressed state prior to the anchoring, and exposed from within the sheath in order to expand and facilitate anchoring of the valve support anchor to the respective commissures.


For some applications, the prosthetic valve includes two or more prosthetic leaflets.


For some applications, the native atrioventricular valve includes a mitral valve, and the prosthetic valve includes three prosthetic leaflets.


For some applications, the valve support guide members are removable from the patient following the anchoring of the prosthetic valve support at the atrioventricular valve.


For some applications, the valve support is shaped so as to define a distal portion which is configured to push aside, at least in part, native leaflets of the valve of the patient.


For some applications, the one or more valve support anchors are advanceable along the one or more valve support guide members.


For some applications, the valve support is shaped so as to define one or more holes, the one or more holes being configured to facilitate slidable passage therethrough of a respective one of the one or more valve support guide members.


For some applications, the prosthetic valve is shaped so as to define one or more snares configured to ensnare one or more native leaflets of the native valve of the patient.


For some applications, the one or more valve support anchors includes one or more ventricular anchors, and the apparatus further includes one or more atrial anchors, each atrial anchor being configured to be advanced toward an atrial surface of the valve support and anchor in place the valve support in a vicinity of a respective one of the ventricular anchors.


For some applications, the apparatus includes one or more delivery lumens, and:


each one of the one or more valve support anchors is removably coupled to a distal end of a respective delivery lumen,


the delivery lumen is configured to facilitate advancement of the one or more anchors along the one or more guide members, and


the delivery lumen is decoupled from the anchor following the anchoring of the anchor to the one or more commissures.


For some applications, the one or more valve support guide members are removable from the body of the patient following the advancement of the one or more anchors along the one or more guide members.


For some applications:


the valve support is shaped so as to define one or more holes,


the one or more holes are configured to facilitate slidable passage therethrough of a respective one of the one or more delivery lumens, and


the one or more delivery lumens are decoupleable from the respective valve support anchor following the anchoring of the valve support to at least the one or more commissures.


For some applications, the one or more delivery lumens are removable from the body of the patient following the anchoring of the valve support to at least the one or more commissures.


For some applications, the valve support includes an annular element and a generally cylindrical element coupled to the annular element, the generally cylindrical element being configured to push aside native leaflets of the native valve, the cylindrical element has first and second ends and a cylindrical body that is disposed between the first and second ends.


For some applications, the apparatus includes one or more annular element tissue anchors, the annular element has an upper surface and a lower surface, and the lower surface is coupled to the one or more annular element tissue anchors, the one or more annular element tissue anchors being configured to puncture tissue of a native annulus of the native valve of the patient.


For some applications, one or more annular element tissue anchors includes a plurality of annular element tissue anchors positioned around the lower surface of the annular element.


For some applications, the one or more annular element tissue anchors includes a first commissural anchor configured to puncture tissue of the native valve at a first commissure thereof, and a second commissural anchor configured to puncture tissue of the native valve at a second commissure thereof.


For some applications, each anchor of the one or more annular element tissue anchors includes a distal pointed tip and one or more radially-expandable prongs, the prongs being configured to expand and facilitate anchoring of the anchor and restrict proximal motion of the annular element tissue anchor.


For some applications, the apparatus includes one or more prosthetic valve guide members reversibly couplable to the cylindrical element in a vicinity of the second end of the cylindrical element, the prosthetic valve guide members being configured to facilitate advancement of the prosthetic valve therealong and toward the valve support.


For some applications:

    • the first end of the cylindrical element is coupled to the annular element,
    • during a first period, the second end of the cylindrical element is disposed above the annular element in a manner in which the body of the cylindrical element is disposed above the annular element, and
    • the cylindrical element is invertible in a manner in which, during a second period, the second end of the cylindrical element is disposed below the annular element and the body of the cylindrical element is disposed below the annular element.


For some applications:


during the first period, the second end of the cylindrical element is disposed in an atrium of a heart of the patient and the annular element is positioned along an annulus of the native valve,


the prosthetic valve is advanceable along the one or more prosthetic valve guide members into a ventricle of the heart of the patient, and


in response to advancement of the prosthetic valve into the ventricle, the one or more prosthetic valve guide members are pulled into the ventricle and pull the second end and the body of the cylindrical element into the ventricle to invert the cylindrical element.


There is further provided, in accordance with some applications of the present invention, a method, including:


advancing one or more valve support guide members toward one or more commissures of a native atrioventricular valve of a patient;


advancing along the one or more valve support guide members one or more valve support tissue anchors toward the one or more commissures;


anchoring the one or more valve support tissue anchors to the one or more commissures;


anchoring a prosthetic valve support at the native atrioventricular valve by anchoring the prosthetic valve support at at least the one or more commissures; and


coupling a prosthetic valve to the prosthetic valve support.


For some applications, the method includes removing the one or more valve support guide members following the anchoring of the prosthetic valve support at the native atrioventricular valve.


For some applications, advancing the one or more valve support guide members toward the one or more commissures includes advancing one guide member and looping the one guide member through first and second commissures of the native atrioventricular valve in a manner in which a looped portion of the guide member is disposed in a ventricle of the patient and first and second free ends of the guide member are accessible from a site outside a body of the patient.


For some applications, anchoring the one or more valve support anchors includes anchoring the one or more valve support anchors to ventricular surface of the respective commissures of the native valve.


For some applications, anchoring the one or more valve support anchors includes anchoring first and second tissue anchors to respective first and second commissures of the native valve.


For some applications:


advancing along the one or more valve support guide members the one or more valve support tissue anchors includes advancing the one or more valve support tissue anchors within a sheath, and


anchoring the one or more valve support tissue anchors includes exposing the one or more valve support anchors from within the sheath and facilitating radial expansion of one or more radially-expandable prongs of the one or more anchors.


For some applications, coupling the prosthetic valve to the prosthetic valve support includes coupling a prosthetic valve having two or more leaflets.


For some applications, the native atrioventricular valve includes a mitral valve of the patient, and coupling the prosthetic valve to the prosthetic valve support includes coupling a prosthetic valve having three leaflets.


For some applications, anchoring the prosthetic valve support includes pushing aside, at least in part, native leaflets of the valve of the patient by at least a portion of the support.


For some applications, the prosthetic valve support is coupled to one or more annulus tissue anchors, and anchoring the prosthetic valve support includes pushing the one or more annulus tissue anchors into tissue of an annulus of the native valve.


For some applications, coupling the prosthetic valve to the prosthetic valve support includes ensnaring one or more native leaflets of the native valve of the patient by a portion of the prosthetic valve.


For some applications, the one or more valve support anchors includes one or more, ventricular anchors, and the method further includes advancing one or more atrial anchors to an atrial surface of the valve support, and anchoring in place the valve support in a vicinity of a respective one of the ventricular anchors.


For some applications, the method includes advancing the valve support along the one or more valve support guide members prior to the anchoring of the valve support.


For some applications, the valve support is shaped so as to define one or more holes, and advancing the valve support along the one or more valve support guide members includes threading the one or more valve support guide members through the one or more holes of the valve support and sliding the valve support along the one or more guide members.


For some applications, the method includes removing the one or more valve support guide members from a body of the patient following the anchoring of the valve support.


For some applications,


the valve support includes:

    • an annular element, and
    • a generally cylindrical element having first and second ends and a cylindrical body that is disposed between the first and second ends, the first end being coupled to the annular element; and


anchoring of the valve support, including anchoring the valve support in a manner in which:

    • the annular element is positioned along an annulus of the native valve,
    • the second end of the cylindrical element is disposed above the annular element in an atrium of a heart of the patient, and
    • the body of the cylindrical element is disposed above the annular element.


For some applications, the method includes, following the anchoring, inverting the cylindrical element to pull the second end of the cylindrical element below the annular element and into a ventricle of the heart, in a manner in which the body of the cylindrical element is disposed below the annular element and pushes aside one or more native leaflets of the valve of the patient.


For some applications:


inverting the cylindrical element includes advancing the prosthetic valve along one or more prosthetic valve guide members reversibly coupled to the cylindrical element in a vicinity of the second end thereof,


advancing the prosthetic valve includes advancing the prosthetic valve into the ventricle to pull the prosthetic valve guide members and the second end of the cylindrical element into the ventricle, and


the method further includes following the advancing of the prosthetic valve into the ventricle, pulling proximally the prosthetic valve such that a proximal portion of the valve contacts the valve support.


For some applications, pulling the prosthetic valve proximally includes ensnaring the one or more leaflets of the valve by a portion of the prosthetic valve.


For some applications, advancing the one or more valve support anchors includes:


providing a respective delivery lumen coupled at a distal end thereof to each one of the one or more anchors,


advancing each delivery lumen along a respective one of the one or more valve support guide members,


facilitating anchoring of each one of the one or more anchors to the one or more commissures by the respective delivery lumen, and


decoupling the delivery lumen from each one of the one or more valve support anchors following the anchoring of the one or more valve support anchors.


For some applications, the method includes removing the one or more valve support guide members from a body of the patient following the anchoring of each one of the one or more valve support anchors to the one or more commissures.


For some applications, the method includes advancing the prosthetic valve support along the one or more delivery lumens prior to the anchoring the support at the native atrioventricular valve.


For some applications, the valve support is shaped so as to define one or more holes, and advancing the valve support along the one or more delivery lumens includes threading the one or more delivery lumens through the one or more holes of the valve support and sliding the valve support along the one or more delivery lumens.


For some applications, the method includes removing the one or more delivery lumens from a body of the patient following the anchoring the support at the atrioventricular valve.


There is additionally provided, in accordance with some applications of the present invention, apparatus including a valve support for receiving a prosthetic valve, the valve support including:


an annular element configured to be positioned along a native annulus of a native atrioventricular valve of a patient; and


a flexible generally cylindrical element configured to be positioned in the native atrioventricular valve of the patient and to push aside native leaflets of the native valve, the cylindrical element having first and second ends and a cylindrical body that is disposed between the first and second ends, and:

    • the first end of the cylindrical element is coupled to the annular element,
    • during a first period, the second end of the cylindrical element is disposed above the annular element in a manner in which the body of the cylindrical element is disposed above the annular element, and
    • the cylindrical element is invertible in a manner in which, during a second period, the second end of the cylindrical element is disposed below the annular element and the body of the cylindrical element is disposed below the annular element.


For some applications, the cylindrical element includes a flexible wireframe covered by a fabric.


For some applications, the valve support is collapsible for transcatheter delivery and expandable to contact the native atrioventricular valve.


For some applications, the annular element has an upper surface and a lower surface, the lower surface is coupled to one or more annular element tissue anchors configured to puncture tissue of the native annulus of the patient.


For some applications, the one or more annular element tissue anchors includes a plurality of annular element tissue anchors positioned around the lower surface of the annular element.


For some applications, the one or more annular element tissue anchors includes a first commissural annular element tissue anchor configured to puncture tissue of the native valve at a first commissure thereof, and a second commissural annular element tissue anchor configured to puncture tissue of the native valve at a second commissure thereof.


For some applications, each anchor of the one or more annular element tissue anchors includes a distal pointed tip and one or more radially-expandable prongs, the prongs being configured to expand and facilitate anchoring of the anchor and restrict proximal motion of the annular element tissue anchor.


For some applications, the apparatus includes one or more valve support guide members configured to be delivered to one or more commissures of the native atrioventricular valve of the patient, the one or more valve support guide members are configured to facilitate advancement of the valve support toward the native valve.


For some applications, the valve support is shaped so as to define one or more holes, the one or more holes configured to facilitate slidable passage therethrough of a respective one of the one or more valve support guide members.


For some applications, the one or more valve support guide members includes one valve support guide member that is looped through first and second commissures of the atrioventricular valve in a manner in which a looped portion of the valve support guide member is disposed in a ventricle of the patient and first and second free ends of the valve support guide member are accessible from a site outside a body of the patient.


For some applications, the apparatus includes one or more valve support tissue anchors configured to be advanceable along the one or more valve support guide members and anchored to the one or more commissures of the valve.


For some applications, the one or more valve support anchors includes one or more ventricular anchors, and the apparatus further includes one or more atrial anchors, each atrial anchor being configured to be advanced toward an atrial surface of the valve support and anchor in place the valve support in a vicinity of a respective one of the ventricular anchors.


For some applications, the valve support guide members are removable from the patient following the anchoring of the valve support at the atrioventricular valve.


For some applications, the one or more valve support anchors are configured to be anchored to the one or more commissures from ventricular surfaces thereof prior to advancement of the valve support.


For some applications, the one or more valve support tissue anchors includes first and second valve support tissue anchors, the first and second valve support tissue anchors being configured to be anchored to respective first and second commissures of the atrioventricular valve of the patient.


For some applications:


the one or more valve support tissue anchors each include one or more radially-expandable prongs, and


the one or more prongs are disposed within a sheath in a compressed state prior to the anchoring and exposed from within the sheath in order to expand and facilitate anchoring of the anchor to the respective commissures.


For some applications, the apparatus includes one or more prosthetic valve guide members reversibly couplable to the cylindrical element in a vicinity of the second end of the cylindrical element, the prosthetic valve guide members being configured to facilitate advancement of the prosthetic valve therealong and toward the valve support.


For some applications, the apparatus includes the prosthetic valve, and the prosthetic valve is couplable to the valve support.


For some applications:


during the first period, the second end of the cylindrical element is disposed in an atrium of a heart of the patient and the annular element is positioned along an annulus of the native valve,


the prosthetic valve is advanceable along the one or more prosthetic valve guide members into a ventricle of the heart of the patient, and


in response to advancement of the prosthetic valve into the ventricle, the one or more prosthetic valve guide members are pulled into the ventricle and pull the second end of the cylindrical element into the ventricle to invert the cylindrical element.


For some applications, the prosthetic valve is collapsible for transcatheter delivery and expandable when exposed from within a delivery catheter.


For some applications, the prosthetic valve includes two or more prosthetic leaflets.


For some applications, the native atrioventricular valve includes a mitral valve, and the prosthetic valve includes three prosthetic leaflets.


For some applications, the prosthetic valve guide members are removable from the patient following the anchoring of the prosthetic valve at the atrioventricular valve.


For some applications, the prosthetic valve is shaped so as to define one or more snares configured to ensnare one or more native leaflets of the native valve of the patient.


There is yet additionally provided, in accordance with some applications of the present invention, a method, including:


advancing toward a native atrioventricular valve of a heart of a patient, a valve support including:

    • an annular element, and
    • a generally cylindrical element having first and second ends and a cylindrical body that is disposed between the first and second ends, the first end being coupled to the annular element;


anchoring the annular element to an annulus of the native atrioventricular valve, following the anchoring, the second end of the cylindrical element is disposed above the annular element in an atrium of the heart, in a manner in which the body of the cylindrical element is disposed above the annular element; and


following the anchoring, inverting the cylindrical element to pull the second end of the cylindrical element below the annular element and into a ventricle of the heart, in a manner in which the body of the cylindrical element is disposed below the annular element and pushes aside one or more native leaflets of the valve of the patient.


For some applications, anchoring the annular element to the annulus of the native atrioventricular valve includes:


advancing one or more valve support anchors that are distinct from the valve support toward one or more commissures of the heart, and


anchoring the annular element to the annulus using the one or more positioning anchors.


For some applications, the annular element is coupled to one or more annular element tissue anchors, and anchoring the annular element includes pushing the one or more annular element tissue anchors into tissue of the annulus.


For some applications:


inverting the cylindrical element includes advancing a prosthetic valve along one or more valve guide members reversibly coupled to the cylindrical element in a vicinity of the second end thereof,


advancing the prosthetic valve includes advancing the prosthetic valve into the ventricle to pull the guide members and the second end of the cylindrical element into the ventricle, and


the method further includes following the advancing of the prosthetic valve into the ventricle, pulling proximally the prosthetic valve such that a proximal portion of the valve contacts the valve support.


For some applications, pulling the prosthetic valve proximally includes ensnaring the one or more leaflets of the valve by a portion of the prosthetic valve.


There is also provided, in accordance with some applications of the present invention, apparatus including a valve support for receiving a prosthetic valve, the valve support including:


an annular element configured to be positioned along a native annulus of a native atrioventricular valve of a patient, the annular element having upper and lower surfaces; and


one or more annular element tissue anchors coupled to the lower surface of the annular element, the one or more annular element tissue anchors being configured to puncture tissue of the native annulus of the patient.


For some applications, the valve support is collapsible for transcatheter delivery and expandable to contact the native atrioventricular valve.


For some applications, the one or more annular element tissue anchors includes a plurality of annular element tissue anchors positioned around the lower surface of the annular element.


For some applications, the one or more annular element tissue anchors includes a first commissural annular element tissue anchor configured to puncture tissue of the native valve at a first commissure thereof, and a second commissural annular element tissue anchor configured to puncture tissue of the native valve at a second commissure thereof.


For some applications, each anchor of the one or more annular element tissue anchors includes a distal pointed tip and one or more radially-expandable prongs, the prongs being configured to expand and facilitate anchoring of the anchor and restrict proximal motion of the anchor.


For some applications, the apparatus includes one or more valve support guide members configured to be delivered to one or more commissures of the native atrioventricular valve of the patient, the one or more valve support guide members are configured to facilitate advancement of the valve support toward the native valve.


For some applications, the valve support is shaped so as to define one or more holes, the one or more holes configured to facilitate slidable passage therethrough of a respective one of the one or more valve support guide members.


For some applications, the one or more valve support guide members includes one valve support guide member that is looped through first and second commissures of the atrioventricular valve in a manner in which a looped portion of the valve support guide member is disposed in a ventricle of the patient and first and second free ends of the valve support guide member are accessible from a site outside a body of the patient.


For some applications, the apparatus includes one or more valve support tissue anchors that are distinct from the valve support and are configured to be advanceable along the one or more valve support guide members and anchored to the one or more commissures of the valve.


For some applications, the one or more valve support anchors includes one or more ventricular anchors, and the apparatus further includes one or more atrial anchors, each atrial anchor being configured to be advanced toward an atrial surface of the valve support and anchor in place the valve support in a vicinity of a respective one of the ventricular anchors.


For some applications, the one or more valve support guide members are removable from the patient following the anchoring of the valve support at the atrioventricular valve.


For some applications, the one or more valve support tissue anchors are configured to be anchored to the one or more commissures from ventricular surfaces thereof prior to advancement of the valve support.


For some applications, the one or more valve support tissue anchors includes first and second valve support tissue anchors, the first and second valve support tissue anchors being configured to be anchored to respective first and second commissures of the atrioventricular valve of the patient.


For some applications:


the one or more valve support tissue anchors each include one or more radially-expandable prongs, and


the one or more prongs are disposed within a sheath in a compressed state prior to the anchoring and exposed from within the sheath in order to expand and facilitate anchoring of the anchor to the respective commissures.


For some applications, the valve support further includes a flexible generally cylindrical element coupled to the annular element and configured to be positioned in the native atrioventricular valve of the patient and to push aside native leaflets of the native valve, the cylindrical element having first and second ends and a cylindrical body that is disposed between the first and second ends.


For some applications, the cylindrical element includes a flexible wireframe covered by a fabric.


For some applications, the apparatus includes one or more prosthetic valve guide members reversibly couplable to the cylindrical element in a vicinity of the second end of the cylindrical element, the prosthetic valve guide members being configured to facilitate advancement of the prosthetic valve therealong and toward the valve support.


For some applications, the apparatus includes the prosthetic valve, and the prosthetic valve is couplable to the valve support.


For some applications:

    • the first end of the cylindrical element is coupled to the annular element,
    • during a first period, the second end of the cylindrical element is disposed above the annular element in a manner in which the body of the cylindrical element is disposed above the annular element, and
    • the cylindrical element is invertible in a manner in which, during a second period, the second end of the cylindrical element is disposed below the annular element and the body of the cylindrical element is disposed below the annular element.


For some applications:


during the first period, the second end of the cylindrical element is disposed in an atrium of a heart of the patient,


the prosthetic valve is advanceable along the one or more prosthetic valve guide members into a ventricle of the heart of the patient, and


in response to advancement of the prosthetic valve into the ventricle, the one or more prosthetic valve guide members are pulled into the ventricle and pull the second end of the cylindrical element into the ventricle to invert the cylindrical element.


There is additionally provided, in accordance with some applications of the present invention, apparatus, including:


one or more valve support guide members configured to be delivered to one or more commissures of a native atrioventricular valve of a patient;


a prosthetic valve support configured to be advanced toward the native valve along the one or more valve support guide members and placed at the native valve;


a prosthetic valve configured to be coupled to the valve support; and


one or more sealing elements configured to facilitate sealing of an interface between the prosthetic valve support and the native valve.


For some applications, the sealing element includes a balloon disposed circumferentially around an outer surface of the prosthetic valve support.


For some applications, the sealing element includes one or more helices that are configured to facilitate sealing of commissures of the native valve with respect to the valve support by being wrapped around chordae tendineae of the native valve.


For some applications, the sealing element includes grasping elements that are configured to facilitate sealing of commissures of the native valve with respect to the valve support by grasping the commissures.


For some applications, the sealing element is configured to facilitate anchoring of the support to the native valve.


For some applications, the valve support is collapsible for transcatheter delivery and expandable to contact the native atrioventricular valve.


For some applications, the prosthetic valve includes two or more prosthetic leaflets.


For some applications, the native atrioventricular valve includes a mitral valve, and the prosthetic valve includes three prosthetic leaflets.


For some applications, the valve support guide members are removable from the patient following coupling of the prosthetic valve to the valve support.


For some applications, the valve support is shaped so as to define a distal portion which is configured to push aside, at least in part, native leaflets of the valve of the patient.


For some applications, the valve support is shaped so as to define one or more holes, the one or more holes being configured to facilitate slidable passage therethrough of a respective one of the one or more valve support guide members.


For some applications, the one or more valve support guide members includes one valve support guide member that is looped through first and second commissures of the atrioventricular valve in a manner in which a looped portion of the valve support guide member is disposed in a ventricle of the patient and first and second free ends of the valve support guide member are accessible from a site outside a body of the patient.


For some applications, the apparatus further includes:


a guide wire configured to be advanced, via the native atrioventricular valve, into a ventricle of the patient, and coupled to an inner wall of the patient's ventricle; and


a valve support guide member tube coupled to the guide wire,


and a distal portion of the valve support guide member is configured to loop through the valve support guide member tube, such that, in response to the valve support guide member being pushed distally, portions of the valve support guide member are pushed to respective commissures of the native valve.


For some applications, the prosthetic valve is shaped so as to define one or more protrusions configured to ensnare one or more native leaflets of the native valve of the patient.


For some applications, the protrusions are disposed in a sinusoidal configuration such that the protrusions conform with a saddle shape of the patient's native annulus.


For some applications, the protrusions are configured to prevent the native leaflets from interfering with a left ventricular outflow tract of the patient, by sandwiching the leaflets between the protrusions and the prosthetic valve support.


For some applications, the valve support includes:


a first end that is configured to be placed on an atrial side of a native atrioventricular valve of a patient; and


a second end that is configured, during a first period, to be disposed inside the patient's atrium, above the first end of the valve support,


the valve support being at least partially invertible in a manner in which, during a second period, the second end of the valve support is disposed at least partially inside a ventricle of the patient, below the first end of the valve support.


For some applications, the valve support includes an annular element and a generally cylindrical element coupled to the annular element, the generally cylindrical element being configured to push aside native leaflets of the native valve, and the cylindrical element has first and second ends and a cylindrical body that is disposed between the first and second ends.


For some applications, the sealing element includes a balloon disposed underneath the annular element and configured to facilitate sealing of an interface between the annular element and the native valve.


For some applications, the apparatus further includes one or more prosthetic valve guide members, the prosthetic valve guide members being configured to facilitate advancement of the prosthetic valve therealong and toward the valve support.


For some applications:


the first end of the cylindrical element is coupled to the annular element,


during a first period, the second end of the cylindrical element is disposed above the annular element in a manner in which the body of the cylindrical element is disposed above the annular element, and


the cylindrical element is invertible in a manner in which, during a second period, the second end of the cylindrical element is disposed below the annular element and the body of the cylindrical element is disposed below the annular element.


For some applications:


during the first period, the second end of the cylindrical element is disposed in an atrium of a heart of the patient and the annular element is positioned along an annulus of the native valve,


the prosthetic valve is advanceable along the one or more prosthetic valve guide members into a ventricle of the heart of the patient, and


in response to advancement of the prosthetic valve into the ventricle, the one or more prosthetic valve guide members are pulled into the ventricle and pull the second end and the body of the cylindrical element into the ventricle to invert the cylindrical element.


There is further provided, in accordance with some applications of the present invention, apparatus, including:


a prosthetic valve support configured to be advanced toward a native atrioventricular valve of a patient and placed at the native valve;


a prosthetic valve configured to be coupled to the valve support, the prosthetic valve being shaped so as to define first and second sets of one or more protrusions, each set of protrusions configured to ensnare a respective native leaflet of the native valve of the patient, the first set of protrusions being disposed within a first circumferential arc with respect to a longitudinal axis of the prosthetic valve, on a first side of a distal end of the prosthetic valve, the second set of protrusions being disposed within a second circumferential arc with respect to the longitudinal axis of the prosthetic valve, on a second side of the distal end of the prosthetic valve, the first and second sets being disposed so as to provide first and second gaps therebetween at the distal end of the prosthetic valve, at least one of the gaps having a circumferential arc of at least 20 degrees; and


one or more valve guide members configured to be delivered to one or more commissures of the native valve, and to guide the valve such that the first and second circumferential arcs are aligned with respective leaflets of the native valve and such that the first and second gaps are aligned with respective commissures of the native valve.


For some applications, the at least one of the gaps has a circumferential arc of at least 60 degrees.


For some applications, the first circumferential arc defines an angle of between 25 degrees and 90 degrees about the longitudinal axis of the prosthetic valve.


For some applications, the second circumferential arc defines an angle of between 25 degrees and 90 degrees about the longitudinal axis of the prosthetic valve.


For some applications, the first circumferential arc defines an angle of between 45 degrees and 75 degrees about the longitudinal axis of the prosthetic valve.


For some applications, the second circumferential arc defines an angle of between 45 degrees and 75 degrees about the longitudinal axis of the prosthetic valve.


There is additionally provided, in accordance with some applications of the present invention, a method, including:


determining an area defined by an annulus of a native atrioventricular valve of a patient;


selecting a prosthetic valve to be placed in the native valve by determining that the valve defines a cross-sectional area that is less than 90% of the area defined by the annulus; and


deploying the prosthetic valve at the native valve,


the selecting of the prosthetic valve facilitating sealing of the native valve with respect to the prosthetic valve by facilitating closing of leaflets of the native valve around the prosthetic valve, upon deployment of the prosthetic valve.


For some applications, selecting the prosthetic valve includes selecting a prosthetic valve having a material disposed on an outer surface thereof.


For some applications, selecting the prosthetic valve includes selecting a prosthetic valve having a material that prevents tissue growth disposed on an outer surface thereof.


For some applications, selecting the prosthetic valve includes selecting a prosthetic valve having a material that promotes tissue growth disposed on an outer surface thereof.


For some applications, selecting the prosthetic valve to be placed in the native valve includes determining that the valve defines a cross-sectional area that is less than 80% of the area defined by the annulus.


For some applications, selecting the prosthetic valve to be placed in the native valve includes determining that the valve defines a cross-sectional area that is less than 60% of the area defined by the annulus.


There is further provided, in accordance with some applications of the present invention, apparatus including:


a valve support for receiving a prosthetic valve, the valve support including:

    • a first end that is configured to be placed on an atrial side of a native atrioventricular valve of a patient; and
    • a second end that is configured, during a first period, to be disposed inside the patient's atrium, above the first end of the valve support,
    • the valve support being at least partially invertible in a manner in which, during a second period, the second end of the cylindrical element is disposed at least partially inside a ventricle of the patient, below the first end of the valve support.


For some applications, the valve support includes a flexible wireframe covered by a fabric.


For some applications, the valve support is collapsible for transcatheter delivery and expandable to contact the native atrioventricular valve.


For some applications, the valve support defines a surface that is an inner surface of the valve support during the first period, and an outer surface of the valve support during the second period, and the apparatus further includes a sealing material that is disposed on the surface, such that during the second period the sealing material facilitates sealing between the valve support and the native valve.


For some applications, the first end includes a coupling element configured to couple the valve support to tissue of the native valve on the atrial side of the native valve.


For some applications, the first end is shaped to define barbs that are configured to couple the valve support to tissue of the native valve on the atrial side of the native valve


For some applications, the valve support includes:


an annular element configured to be positioned along a native annulus of the native atrioventricular valve; and


a flexible generally cylindrical element configured to be positioned in the native atrioventricular valve of the patient and to push aside native leaflets of the native valve, the first end of the cylindrical element defining the first end of the valve support, and the first end of the cylindrical element being coupled to the annular element.


For some applications, the apparatus further includes one or more valve support guide members configured to be delivered to one or more commissures of the native atrioventricular valve of the patient, and the one or more valve support guide members are configured to facilitate advancement of the valve support toward the native valve.


For some applications, the valve support is shaped so as to define one or more holes, the one or more holes configured to facilitate slidable passage therethrough of a respective one of the one or more valve support guide members.


For some applications, the one or more valve support guide members includes one valve support guide member that is looped through first and second commissures of the atrioventricular valve in a manner in which a looped portion of the valve support guide member is disposed in a ventricle of the patient and first and second free ends of the valve support guide member are accessible from a site outside a body of the patient.


For some applications, the apparatus further includes:


a guide wire configured to be advanced, via the native atrioventricular valve, into a ventricle of the patient, and coupled to an inner wall of the patient's ventricle; and


a valve support guide member tube coupled to the guide wire,


and a distal portion of the valve support guide member is configured to loop through the valve support guide member tube, such that, in response to the valve support guide member being pushed distally, portions of the valve support guide member are pushed to respective commissures of the native valve.


For some applications, the apparatus further includes one or more prosthetic valve guide members reversibly couplable to the cylindrical element in a vicinity of the second end of the cylindrical element, the prosthetic valve guide members being configured to facilitate advancement of the prosthetic valve therealong and toward the valve support.


For some applications, the apparatus further includes the prosthetic valve, and the prosthetic valve is couplable to the valve support.


For some applications:


during the first period, the second end of the cylindrical element is disposed in an atrium of a heart of the patient and the annular element is positioned along an annulus of the native valve,


the prosthetic valve is advanceable along the one or more prosthetic valve guide members into a ventricle of the heart of the patient, and


in response to advancement of the prosthetic valve into the ventricle, the one or more prosthetic valve guide members are pulled into the ventricle and pull the second end of the cylindrical element into the ventricle to invert the cylindrical element.


For some applications, the apparatus further includes one or more sealing elements configured to facilitate sealing of an interface between the prosthetic valve support and the native valve.


For some applications, the sealing element includes a balloon disposed circumferentially around a surface of the prosthetic valve support.


For some applications, the sealing element includes one or more helices that are configured to facilitate sealing of commissures of the native valve with respect to the valve support by being wrapped around chordae tendineae of the native valve.


For some applications, the sealing element includes grasping elements that are configured to facilitate sealing of commissures of the native valve with respect to the valve support by grasping the commissures.


For some applications, the sealing element is configured to facilitate anchoring of the support to the native valve.


For some applications, the apparatus further includes the prosthetic valve, and the prosthetic valve is couplable to the valve support.


For some applications, the prosthetic valve is collapsible for transcatheter delivery and expandable when exposed from within a delivery catheter.


For some applications, the prosthetic valve includes two or more prosthetic leaflets.


For some applications, the native atrioventricular valve includes a mitral valve, and the prosthetic valve includes three prosthetic leaflets.


For some applications, the prosthetic valve is shaped so as to define one or more protrusions configured to ensnare one or more native leaflets of the native valve of the patient.


For some applications, the protrusions are disposed in a sinusoidal configuration such that the protrusions conform with a saddle shape of the patient's native annulus.


For some applications, the protrusions are configured to prevent the native leaflets from interfering with a left ventricular outflow tract of the patient, by sandwiching the leaflets between the protrusions and the prosthetic valve support.


There is further provided, in accordance with some applications of the present invention, apparatus, including:


a guide wire configured to be advanced into a patient's ventricle via a native atrioventricular valve of the patient, and coupled to an inner wall of the patient's ventricle;


a valve support guide member tube coupled to the guide wire;


a valve support guide member, a distal portion of the valve support guide member looping through the valve support guide member tube, such that, in response to the valve support guide member being pushed distally, portions of the valve support guide member are pushed to respective commissures of the native valve;


a prosthetic valve support configured to be advanced toward the commissures of the native valve along the valve support guide member portions; and


a prosthetic valve configured to be coupled to the valve support.


For some applications, first and second free ends of the valve support guide member are accessible from a site outside a body of the patient.


For some applications, the valve support includes:


an annular element configured to be positioned along a native annulus of the native atrioventricular valve; and


a generally cylindrical element configured to be positioned in the native atrioventricular valve of the patient and to push aside native leaflets of the native valve, the cylindrical element being coupled to the annular element, at a first end of the cylindrical element.


For some applications, the valve support is shaped so as to define one or more holes, the one or more holes configured to facilitate slidable passage therethrough of respective portions of the portions of the valve support guide member.


For some applications, the guide member is configured to facilitate advancement of the prosthetic valve therealong and toward the valve support.


For some applications, the prosthetic valve is collapsible for transcatheter delivery and expandable when exposed from within a delivery catheter.


For some applications, the prosthetic valve includes two or more prosthetic leaflets.


For some applications, the native atrioventricular valve includes a mitral valve, and the prosthetic valve includes three prosthetic leaflets.


For some applications, the guide member is removable from the patient following the coupling of the prosthetic valve to the valve support.


For some applications, the prosthetic valve is shaped so as to define one or more protrusions configured to ensnare one or more native leaflets of the native valve of the patient.


For some applications, the protrusions are disposed in a sinusoidal configuration such that the protrusions conform with a saddle shape of the patient's native annulus.


For some applications, the protrusions are configured to prevent the native leaflets from interfering with a left ventricular outflow tract of the patient, by sandwiching the leaflets between the protrusions and the prosthetic valve support.


For some applications, the apparatus further includes one or more sealing elements configured to facilitate sealing of an interface between the prosthetic valve support and the native valve.


For some applications, the sealing element includes a balloon disposed circumferentially around a surface of the prosthetic valve support.


For some applications, the sealing element includes one or more helices that are configured to facilitate sealing of commissures of the native valve with respect to the valve support by being wrapped around chordae tendineae of the native valve.


For some applications, the sealing element includes grasping elements that are configured to facilitate sealing of commissures of the native valve with respect to the valve support by grasping the commissures.


For some applications, the sealing element is configured to facilitate anchoring of the support to the native valve.


There is additionally provided, in accordance with some applications of the present invention, apparatus, including:


one or more valve guide members configured to be delivered to one or more commissures of a native atrioventricular valve of a patient;


a prosthetic valve configured to be advanced to be advanced toward the native valve along the one or more valve guide members and placed at the native valve at at least the one or more commissures; and


one or more proximally-facing grasping elements that are configured to facilitate sealing of commissures of the native valve with respect to the valve by:

    • being inserted into a ventricle of the patient; and
    • being pulled proximally and being closed around tissue in a vicinity of the commissures.


For some applications, the grasping elements include two surfaces that are hingedly coupled to one another, and that are configured to facilitate the sealing of the commissures of the native valve with respect to the prosthetic valve by being closed about the hinge with respect to one another.


There is further provided, in accordance with some applications of the present invention, a method, including:


advancing one or more valve support guide members toward one or more commissures of a native atrioventricular valve of a patient;


placing a prosthetic valve support at the native atrioventricular valve by advancing the valve support along the one or more valve support guide members;


coupling a prosthetic valve to the prosthetic valve support; and


facilitating sealing of an interface between the prosthetic valve support and the native valve by deploying a sealing element in a vicinity of the interface.


There is additionally provided, in accordance with some applications of the present invention, a method including:


placing a first end of a prosthetic valve support on an atrial side of a native atrioventricular valve of a patient, such that a second end of the valve support is disposed, during a first period, inside the patient's atrium, above the first end of the valve support; and


subsequent to the placing of the valve support, inverting at least a portion of the valve support such that, during a second period, the second end of the valve support is disposed at least partially inside a ventricle of the patient, below the first end of the valve support.


There is additionally provided, in accordance with some applications of the present invention, a method, including:


advancing a guide wire, via a native atrioventricular valve, into a ventricle of the patient, a valve support guide member tube being coupled to the guide wire;


coupling a distal end of the guide wire to an inner wall of the patient's ventricle; and


causing portions of a valve support guide member to be pushed to respective commissures of the native valve, by pushing the guide member distally, a distal portion of the valve support guide member looping through the valve support guide member tube;


advancing a prosthetic valve support toward the commissures of the native valve along the valve support guide member portions; and


coupling a prosthetic valve to the valve support.


There is further provided, in accordance with some applications of the present invention, a method, including:


advancing one or more valve guide members toward one or more commissures of a native atrioventricular valve of a patient;


placing a prosthetic valve at the native atrioventricular valve by advancing the valve along the one or more valve guide members; and


facilitating sealing of commissures of the native valve with respect to the valve by:

    • inserting into a ventricle of the patient one or more grasping elements that are coupled to the prosthetic valve;
    • pulling the grasping elements proximally; and
    • closing the grasping elements around tissue in a vicinity of the commissures.


The present invention will be more fully understood from the following detailed description of embodiments thereof, taken together with the drawings, in which:





BRIEF DESCRIPTION OF THE DRAWINGS


FIGS. 1A-B are schematic illustrations of advancement of one or more guide members toward respective commissures of a mitral valve, in accordance with some applications of the present invention;



FIGS. 1C-D are schematic illustrations of the advancement and deployment of commissural anchors via the guide members, in accordance with some applications of the present invention;



FIGS. 2A-D are schematic illustrations of the advancement of a prosthetic valve support toward a native atrioventricular valve of a patient, in accordance with some applications of the present invention;



FIGS. 2E-F are schematic illustrations of locking of the prosthetic valve support at the native valve, in accordance with some applications of the present invention;



FIGS. 2G-K are schematic illustrations of the advancement of a prosthetic valve and the coupling of the prosthetic valve to the valve support, in accordance with some applications of the present invention;



FIGS. 3A-B are schematic illustrations of the advancement of a prosthetic valve support toward a native atrioventricular valve of a patient, the valve support including a sealing balloon, in accordance with some applications of the present invention;



FIGS. 3C-D are schematic illustrations of locking of the prosthetic valve support at the native valve, the valve support including the sealing balloon, in accordance with some applications of the present invention;



FIGS. 4A-C are schematic illustrations of a valve support being used with commissural helices that facilitate anchoring and/or sealing of the valve support, in accordance with some applications of the present invention;



FIGS. 5A-D are schematic illustrations of grasping elements being used to anchor and/or provide sealing of a prosthetic valve, in accordance with some applications of the present invention;



FIGS. 6A-B are schematic illustrations of a prosthetic valve that includes a sealing material, in accordance with some applications of the present invention;



FIGS. 7A-F are schematic illustrations of a guide wire delivery system, in accordance with some applications of the present invention;



FIGS. 8A-C are schematic illustrations of a valve support that has a cylindrical element that is invertible, in accordance with some applications of the present invention;



FIGS. 9A-D are schematic illustrations of the advancement of an invertible prosthetic valve support toward a native atrioventricular valve of a patient, in accordance with some applications of the present invention;



FIG. 9E is a schematic illustration of inversion of the invertible prosthetic valve support at the native valve, in accordance with some applications of the present invention;



FIGS. 9F-H are schematic illustrations of the advancement of a prosthetic valve and the coupling of the prosthetic valve to the invertible valve support, in accordance with some applications of the present invention;



FIG. 10 is a schematic illustration of a prosthetic valve, the cross-sectional area of which is smaller than the area defined by the patient's native valve annulus, in accordance with some applications of the present invention;



FIGS. 11A-D are schematic illustrations of a prosthetic valve that defines protrusions from portions of the distal end of the valve, in accordance with some applications of the present invention;



FIGS. 12A-C are schematic illustrations of a prosthetic valve that defines distal protrusions that are disposed sinusoidally around the circumference of the valve, in accordance with some applications of the present invention;



FIGS. 13A-E are schematic illustrations of respective configurations of a frame of a prosthetic valve, in accordance with some applications of the present invention;



FIGS. 14A-D are schematic illustrations of respective configurations of a prosthetic valve support, in accordance with some applications of the present invention;



FIGS. 15A-E are schematic illustrations of respective steps of a procedure for deploying a prosthetic valve, in accordance with some applications of the present invention;



FIGS. 16A-H are schematic illustrations of respective steps of an alternative procedure for deploying a prosthetic valve, in accordance with some applications of the present invention;



FIGS. 17A-C are schematic illustrations of leaflets of a prosthetic valve, in accordance with some applications of the present invention;



FIGS. 18A-B are schematic illustrations of a valve support coupled to a plurality of tissue anchors, in accordance with some applications of the present invention;



FIGS. 19A-D are schematic illustrations of the valve support of FIGS. 18A-B being implanted in the native valve of the patient and facilitating implantation of a prosthetic valve, in accordance with some applications of the present invention; and



FIGS. 20A-B are schematic illustrations of a prosthetic valve and a prosthetic valve support deployed, respectively, at a tricuspid valve, and at an aortic valve, in accordance with some applications of the present invention.





DETAILED DESCRIPTION OF THE EMBODIMENTS

Reference is now made to FIGS. 1A-B, which are schematic illustrations of a system 20 for replacing an atrioventricular valve 5 of a patient comprising one or more guide members 21a and 21b which are advanced toward first and second commissures 8 and 10 of valve 5 of a heart 2 of the patient, in accordance with some applications of the present invention. For some applications, guide members 21a and 21b comprise distinct guide members. Alternatively (as shown in FIGS. 7A-F), only one guide member is looped through commissures 8 and 10 in a manner in which the guide member defines a looped portion between commissures 8 and 10 (i.e., a portion of the guide member that is disposed in a ventricle 6 of heart 2), and first and second free ends which are disposed and accessible at a site outside the body of the patient. For such applications, the guide member defines portions 21a and 21b.


It is noted that for applications in which valve 5 is the patient's mitral valve, first and second commissures 8 and 10 are the anterior and posterior commissures. For applications in which valve 5 is the patient's tricuspid valve (which includes three commissures), the first and second commissures are typically the anterior and posterior commissures of the tricuspid valve.


For some applications, guide members 21a and 21b comprise guide wires having a diameter of 0.035 inches.


The transcatheter procedure typically begins with the advancing of a semi-rigid guide wire into a right atrium 4 of the patient. The semi-rigid guide wire provides a guide for the subsequent advancement of a sheath 25 therealong and into the right atrium. Once sheath 25 has entered the right atrium, the semi-rigid guide wire is retracted from the patient's body. Sheath 25 typically comprises a 13-20 F sheath, although the size may be selected as appropriate for a given patient. Sheath 25 is advanced through vasculature into the right atrium using a suitable point of origin typically determined for a given patient. For example:

    • sheath 25 may be introduced into the femoral vein of the patient, through an inferior vena cava, into the right atrium, and into the left atrium transseptally, typically through the fossa ovalis;
    • sheath 25 may be introduced into the basilic vein, through the subclavian vein to the superior vena cava, into the right atrium, and into the left atrium transseptally, typically through the fossa ovalis; or
    • sheath 25 may be introduced into the external jugular vein, through the subclavian vein to the superior vena cava, into the right atrium, and into the left atrium transseptally, typically through the fossa ovalis.


In some applications of the present invention, sheath 25 is advanced through the inferior vena cava of the patient and into the right atrium using a suitable point of origin typically determined for a given patient.


Sheath 25 is advanced distally until sheath 25 reaches the interatrial septum. For some applications, a resilient needle and a dilator (not shown) are advanced through the sheath and into the heart. In order to advance the sheath transseptally into the left atrium, the dilator is advanced to the septum, and the needle is pushed from within the dilator and is allowed to puncture the septum to create an opening that facilitates passage of the dilator and subsequently the sheath therethrough and into the left atrium. The dilator is passed through the hole in the septum created by the needle. Typically, the dilator is shaped to define a hollow shaft for passage along the needle, and the hollow shaft is shaped to define a tapered distal end. This tapered distal end is first advanced through the hole created by the needle. The hole is enlarged when the gradually increasing diameter of the distal end of the dilator is pushed through the hole in the septum.


The advancement of sheath 25 through the septum and into the left atrium is followed by the extraction of the dilator and the needle from within sheath 25.



FIGS. 1C-D and 2A-B show advancement of one or more tissue anchors 30a and 30b along guide members 21a and 21b, respectively. Anchors 30a and 30b comprise a flexible, biocompatible material (e.g., nitinol) and comprise one or more (e.g., a plurality of) radially-expandable prongs 32 (e.g., barbs). Each anchor 30a and 30b is reversibly coupled to a respective delivery lumen 27a and 27b. Each delivery lumen 27 slides around a respective guide member 21. A respective surrounding sheath 26a and 26b surrounds each delivery lumen 27a and 27b and around anchors 30a and 30b at least in part in order to compress and prevent expansion of prongs 32 of tissue anchors 30a and 30b.


As shown in FIG. 1D, the distal ends of lumens 27a and 27b are reversibly coupled to ribbed crimping structures 34. As described hereinbelow, anchors 30a and 30b are anchored to ventricular surfaces of commissures 8 and 10. Following the anchoring, ribbed crimping structures 34 extend from anchors 30a and 30b through commissures 8 and 10, respectively, and toward the atrial surfaces of commissures 8 and 10. Ribbed crimping structures 34 are configured to facilitate anchoring of a valve support (described hereinbelow) to the atrial surfaces of commissures 8 and 10.


Anchors 30a and 30b, ribbed crimping structures 34, and the distal ends of surrounding sheaths 26a and 26b are advanced into ventricle 6. Subsequently, anchors 30a and 30b are pushed distally from within sheaths 26a and 26b, (or sheaths 26a and 26b are pulled proximally with respect to anchors 30a and 30b) to expose anchors 30a and 30b. As anchors 30a and 30b are exposed from within sheaths 26a and 26b, prongs 32 are free to expand, as shown in FIG. 1D. Prongs 32 expand such that anchors 30a and 30b assume a flower shape. Prongs 32, collectively in their expanded state, create a larger surface area to engage tissue than in their compressed states. Following the exposing of anchors 30a and 30b, sheaths 26a and 26b are extracted.


As shown in FIG. 2B, lumens 27a and 27b are pulled proximally so that prongs 32 of anchors 30a and 30b engage respective ventricular surface of commissures 8 and 10. Prongs 32 create a large surface area which restricts proximal motion of anchors 30a and 30b from commissures 8 and 10, respectively.


For some applications, following the anchoring of anchors 30a and 30b to commissures 8 and 10, respectively, guide members 21a and 21b are removed from the body of the patient.


Reference is now made to FIGS. 2C-F, which are schematic illustrations of the advancement of a prosthetic valve support 40 along lumens 27a and 27b, in accordance with some applications of the present invention. In such a manner, lumens 27a and 27b function as valve support guide members. Support 40 comprises a collapsible skirt having a proximal annular element 44 and a distal cylindrical element 42. Support 40 is configured to assume a collapsed state (e.g., surrounded by a sheath or overtube 50 shown in FIG. 2C) for minimally-invasive delivery to the diseased native valve, such as by percutaneous or transluminal delivery using one or more catheters. FIG. 2C and the other figures show support 40 in an expanded state after delivery in right atrium 4 and advancement toward the native valve. As shown in FIG. 2D, support 40 is shaped so as to define one or more (e.g., two, as shown in View A) holes 46a and 46b for slidable advancement of support 40 along lumens 27a and 27b, respectively. That is, prior to introduction of support 40 into the body of the patient, lumens 27a and 27b are threaded through holes 46a and 46b, respectively, and support 40 is slid along lumens 27a and 27b. Support 40 is slid by pushing elements 52a and 52b which surround delivery lumens 27a and 27b, respectively.


It is to be noted that support 40 is slid along lumens 27a and 27b by way of illustration and not limitation. That is, for some applications, following the anchoring of anchors 30a and 30b to commissures 8 and 10, respectively, guide members 21a and 21b are not removed from the body of the patient, but rather lumens 27a and 27b are removed (e.g., by being decoupled from crimping structures 34) leaving behind anchors 30a and 30b and guide members 21a and 21b. Guide members 21a and 21b may then be threaded through holes 46a and 46b, respectively, and support 40 is slid along guide members 21a and 21b. In such a manner, guide members 21a and 21b function as valve support guide members.


Support 40 comprises a collapsible flexible support frame 48, which is at least partially covered by a covering 49. Support 40 is configured to be placed at native valve 5, such that cylindrical element 42 passes through the orifice of the native valve and extends towards, and, typically partially into, ventricle 6 (as shown in FIG. 2E). Cylindrical element 42 typically pushes aside and presses against native leaflets of native valve 5 at least in part, which are left in place during and after implantation of the prosthetic valve. Annular element 44 is configured to be placed around a native annulus 11 of the native valve, and to extend at least partially into an atrium 4 such that annular element 44 rests against the native annulus. Annular element 44 is typically too large to pass through the annulus, and may, for example, have an outer diameter of between 30 and 60 mm.


For some applications, collapsible support frame 48 comprises a stent, which comprises a plurality of struts. The struts may comprise, for example, a metal such as nitinol or stainless steel. For some applications, frame 48 comprises a flexible metal, e.g., nitinol, which facilitates compression of support 40 within a delivery sheath or overtube 50. For some applications, covering 49 comprises a fabric, such as a woven fabric, e.g., Dacron. Covering 49 is typically configured to cover at least a portion of cylindrical element 42, and at least a portion of annular element 44. The covering may comprise a single piece, or a plurality of pieces sewn together.


As shown in FIG. 2D, pushing elements 52a and 52b are each coupled to locking crimping elements 64a and 64b, respectively. Locking crimping elements 64a and 64b are disposed adjacently, proximally to holes 46a and 46b respectively of valve support 40. These techniques enable the surgeon to readily bring crimping elements 64a and 64b to the appropriate sites along annular element 44, without the need for excessive imaging, such as fluoroscopy.



FIG. 2E shows valve support 40 prior to implantation at annulus 11. As shown, ribbed crimping structures 34 project away from anchors 30a and 30b, through commissures 8 and 10, and toward atrium 4. Valve support 40 is advanced along lumens 27a and 27b toward structures 34 by being pushed by pushing elements 52a and 52b and locking crimping elements 64a and 64b.


In FIG. 2F, valve support 40 is further pushed by pushing elements 52a and 52b and locking crimping elements 64a and 64b such holes 46a and 46b of support 40 advance around ribbed crimping structures 34. As holes 46a and 46b are advanced around ribbed crimping structures 34, locking crimping elements 64a and 64b advance over and surround ribbed crimping elements 34 to lock in place valve support 40 from an atrial surface of valve 5.


Responsively to the placement of valve support 40 at native valve 5, cylindrical element 42 is positioned partially within ventricle 6 and native leaflets 12 and 14 of native valve 5 are pushed aside.


As shown in section A-A, ribbed crimping structures 34 are shaped so as to define a plurality of male couplings. Locking crimping elements 64a and 64b each comprise a cylindrical element having an inner lumen that is shaped so as to surround a respective ribbed crimping structure 34. Each inner lumen of locking crimping elements 64a and 64b is shaped so as to define female couplings to receive the male couplings of ribbed crimping structure 34. The female couplings of locking crimping element 64 are directioned such that they facilitate distal advancement of locking crimping element 64 while restricting proximal advancement of locking crimping element 64. When the female couplings of locking crimping element 64 receive the male couplings of ribbed crimping structure 34, valve support 40 is locked in place from an atrial surface of valve 5. It is to be noted that for some applications, ribbed crimping elements 34 comprise female couplings, and locking crimping elements 64 comprise male couplings.


Reference is now made to FIGS. 2G-K which are schematic illustrations of the coupling of a prosthetic atrioventricular valve 80 to valve support 40, in accordance with some applications of the present invention. Support 40 receives the prosthetic valve and functions as a docking station. Thus, the docking station is a coupling element that provides coupling between two other elements (in this case, between annulus 11 and the prosthetic valve.)


Following the placement of support 40 at annulus 11, pushing elements 52a and 52b and sheath or overtube 50 are removed from the body of the patient, leaving behind lumens 27a and 27b, as shown in FIG. 2G.


As shown in FIG. 2G, a guide wire 72 is advanced toward ventricle 6 and facilitates the advancement of an overtube 70 through sheath 25 and the positioning of a distal end of overtube 70 within ventricle 6. Overtube 70 facilitates the advancement of prosthetic valve 80 in a compressed state, toward valve support 40.



FIG. 2H shows partial deployment of valve 80 within ventricle 6 of heart 2. Valve 80 is shown comprising an expandable frame 79 comprising a plurality of stent struts by way of illustration and not limitation. The wireframe of valve 80 comprises a flexible metal, e.g., nitinol or stainless steel. It is to be noted that the wireframe of valve 80 is covered by a covering (not shown for clarity of illustration) comprising a braided mesh or in a fabric such as a woven fabric, e.g., Dacron. The covering is typically configured to cover at least a portion of the frame. The covering may comprise a single piece, or a plurality of pieces sewn together. Expandable frame 79 is typically self-expandable, although the scope of the present invention includes using a prosthetic valve that includes a balloon expandable frame, mutatis mutandis.


Following the partial deployment of valve 80 in ventricle 6, overtube 70 is pulled proximally to pull valve 80 proximally such that cylindrical element 42 and/or annular element 44 of valve support 40 surrounds a proximal portion of prosthetic valve 80. Valve 80 has a tendency to expand such that valve 80 is held in place with respect to valve support 40 responsively to radial forces acted upon valve support 40 by prosthetic valve 80.


Valve 80 comprises a plurality of distal protrusions 84 (e.g., snares). When valve 80 is pulled proximally, as described hereinabove, protrusions 84 ensnare and engage the native leaflets of the atrioventricular valve. By the ensnaring of the native leaflets, protrusions 84 sandwich the native valve between protrusions 84 and prosthetic valve support 40. Such ensnaring helps further anchor prosthetic valve 80 to the native atrioventricular valve. The scope of the present invention includes using any sort of protrusions (e.g., hooks) that protrude from the distal end of expandable frame 79 of prosthetic valve 80 and that are configured such that the native valve is sandwiched between the protrusions and valve support 40. Typically, the protrusions cause sandwiching of the native valve leaflets, such that the leaflets do not interfere with the left ventricular outflow tract (LVOT).


For some applications, protrusions 84 are such as to (a) prevent proximal migration of the valve into the patient's atrium, while (b) allowing movement of the native leaflets with respect to the frame of the prosthetic valve. For example, the protrusions may have the aforementioned functionalities by having lengths of less than 5 mm, and/or by a total width of each set of protrusions corresponding to respective leaflets of the native valve being less than 5 mm. For example, the valve may include a single protrusion corresponding to each leaflet of the native valve, the width of each of the single protrusions being less than 1 mm. Thus, the valve may be stopped from proximally migrating into the atrium, by the protrusions preventing the distal end of the valve from migrating further proximally than edges of native leaflets of the valve. Furthermore, the protrusions may allow movement of the native leaflets with respect to the frame of the prosthetic valve by not generally squeezing the native leaflets between the protrusions and the frame of the valve. For some applications, by allowing movement of the native leaflets with respect to the frame of the prosthetic valve, sealing of the native leaflets against the outer surface of the frame of the prosthetic valve is facilitated, in accordance with the techniques described hereinbelow with reference to FIG. 10. Typically, valve support 40 prevents the valve from migrating distally into the patient's ventricle.


For some applications, during the procedure, the prosthetic valve is pulled back proximally with respect to valve support, as described hereinabove. The prosthetic valve is pulled back to a position with respect to valve support that is such that protrusions 84 prevent the native leaflets from interfering with the LVOT, by sandwiching the native leaflets between the protrusions and the valve support, and/or by anchoring ends of the native leaflets as described hereinabove. The prosthetic valve is then deployed at this position.


For some applications, protrusions are disposed on the valve on the sides of the valve that are adjacent to the anterior and posterior leaflets of the native valve, and the valve does not includes protrusions on the portions of the valve that are adjacent to the commissures of the native valve, as described with reference to FIGS. 11A-D. For some applications, the protrusions are disposed in a sinusoidal configuration in order to conform with the saddle shape of the native valve, as described hereinbelow with reference to FIGS. 12A-C.


Additionally, as shown in FIG. 2J, valve 80 comprises one or more (e.g., a plurality, as shown) coupling elements 81 at the proximal end of valve 80. Overtube 70, which facilitates the advancement of prosthetic valve 80, is reversibly coupled to valve 80, via coupling elements 81.


Prosthetic valve 80 is configured for implantation in and/or at least partial replacement of a native atrioventricular valve 5 of the patient, such as a native mitral valve or a native tricuspid valve. Prosthetic valve 80 is configured to assume a collapsed state for minimally-invasive delivery to the diseased native valve, such as by percutaneous or transluminal delivery using one or more catheters. FIG. 2J shows prosthetic valve 80 in an expanded state after delivery to the native valve.


Reference is now made to FIG. 2K which shows a bird's-eye view of valve 80. Prosthetic valve 80 further comprises a plurality of valve leaflets 82, which may be artificial or tissue-based. The leaflets are typically coupled to an inner surface of the valve prosthesis. Leaflets 82 are coupled, e.g., sewn, to expandable frame 79 and/or to the covering. For applications in which the prosthetic valve is configured to be implanted at the native mitral valve, the prosthetic valve typically comprises three leaflets 82a, 82b, and 82c, as shown in FIG. 2K.


Reference is now made to FIGS. 3A-D, which are schematic illustrations of the advancement of prosthetic valve support 40 toward native atrioventricular valve 5 of a patient, the valve support including a sealing balloon 90, in accordance with some applications of the present invention. The steps shown in FIGS. 3A-C are generally similar to those shown in FIGS. 2C-F. For some applications, sealing balloon 40 is disposed on the valve-facing, lower side of annular element 44 of the prosthetic valve support. FIG. 3D shows valve support 40, the valve support having been implanted at annulus 11. Typically, at this stage, balloon 40 is inflated, as shown in the transition from FIG. 3C to FIG. 3D. The balloon is inflated via an inflation lumen 92, shown in FIG. 3C, for example. For some applications, the balloon seals the interface between the prosthetic valve support and native annulus 11, thereby reducing retrograde blood flow from ventricle 6 into atrium 4, relative to retrograde blood flow in the absence of a sealing balloon. For some applications, the balloon is inflated prior to the placement of the prosthetic support at annulus 11.


Reference is now made to FIGS. 4A-C, which are schematic illustrations of prosthetic valve support 40 being used with commissural helices 100a and 100b that facilitate anchoring and/or sealing of the valve support, in accordance with some applications of the present invention. For some applications, commissural helices are used as an alternative or in addition to anchors 30a and 30b and/or other anchoring elements described herein, in order to facilitate the anchoring of valve support 40.


Commissural helices 100a and 100b are typically placed at commissures 8 and 10 in a generally similar technique to that described with reference to anchors 30a and 30b. Typically, each helix 30a and 30b is reversibly coupled to a respective delivery lumen 27a and 27b. As described above, each delivery lumen 27 slides around a respective guide member 21, and a respective surrounding sheath 26a and 26b surrounds each delivery lumen 27a and 27b.


Commissural helices 100a and 100b (optionally, ribbed crimping structures 34), and the distal ends of surrounding sheaths 26a and 26b are advanced into ventricle 6. The helices are pushed out of the distal ends of surrounding sheaths 26a and 26b. Subsequently, the helices are rotated proximally such that the helices wrap around at least some chordae tendineae 102 of the patient. Following the advancement of the helices out of sheaths 26a and 26b, the sheaths are extracted. For some applications the helices are conical helices (as shown), and the wider end of the conical helix is disposed at the proximal end of the helix.


Subsequent to the placement of commissural helices 100a and 100b around the chordae tendineae, prosthetic valve support 40 is placed at annulus 11, in accordance with the techniques described hereinabove, and as shown in FIG. 4B. Subsequently, prosthetic valve 80 is coupled to the prosthetic valve support, in accordance with the techniques described hereinabove, and as shown in FIG. 4C.


Typically, commissural helices 100a and 100b facilitate sealing of native commissures 8 and 10, thereby reducing retrograde blood flow via the commissures, relative to retrograde blood flow in the absence of the helices. Further typically, the sealing of the native commissures facilitates anchoring of the prosthetic valve support to native valve 5.


Reference is now made to FIGS. 5A-D, which are schematic illustrations of grasping elements 106a and 106b being used to anchor prosthetic valve 80, in accordance with some applications of the present invention. For some applications, guide members 21a and 21b are advanced toward first and second commissures 8 and 10 of valve 5 of the patient, as described hereinabove. Grasping elements 106a and 106b are reversibly coupled to distal ends of delivery lumen 27a and 27b, the delivery lumens being advanced over respective guide members, as described hereinabove. For some applications, the guiding members and the grasping elements are advanced toward the patient's commissures via surrounding sheaths 26a and 26b, the surrounding sheaths being generally as described hereinabove. The grasping elements are typically placed distally to the commissures in a proximally-facing configuration, as shown in FIG. 5A. For example, as shown, the grasping elements may be configured to be proximally facing due to the coupling of the grasping elements to the guide members.


Subsequent to the placement of grasping elements 106a and 106b distally to native commissures 8 and 10, prosthetic valve 80 is advanced toward native valve 5, as shown in FIG. 5B. For example, the prosthetic valve may be advanced over delivery lumens 27a and 27b, as shown. The prosthetic valve is placed at the native valve and, subsequently, the grasping elements are retracted proximally toward commissures 8 and 10, as shown in the transition from FIG. 5B to FIG. 5C. For some applications, the grasping elements are coupled to valve 80 via coupling tubes 107a and 107b, the coupling tubes being coupled to the sides of the valve, as shown. The grasping elements are closed such that the native commissures are grasped and sealed by the grasping elements, as shown in FIG. 5D. Typically, the grasping elements define two surfaces that are hingedly coupled to each other. For example, the grasping elements may include forceps, as shown. The grasping elements are closed by closing the surfaces about the hinge, with respect to one another.


Typically, grasping elements 106a and 106b facilitate sealing of native commissures 8 and 10, thereby reducing retrograde blood flow via the commissures, relative to retrograde blood flow in the absence of the grasping elements. Further typically, the sealing of the native commissures facilitates anchoring of the prosthetic valve to native valve 5.


Although not shown, for some applications, prosthetic valve support 40 is used in addition to grasping elements 106a and 106b, in order to anchor prosthetic valve 80 to native valve 5. For some applications, the grasping elements are used to anchor and/or provide sealing for prosthetic valve support 40 (instead of, or in addition to, being used to anchor prosthetic valve 80, as shown). For such applications, generally similar techniques are used to those described with respect to the use of the grasping elements for anchoring the prosthetic valve, mutatis mutandis.


Reference is now made to FIGS. 6A-B, which are schematic illustrations of prosthetic valve 80, the prosthetic valve comprising a sealing material 110 on an outer surface of the valve, in accordance with some applications of the present invention. For some applications, prosthetic valve 80 is used in conjunction with prosthetic valve support 40, as described hereinabove. The techniques for implanting prosthetic valve 80 as shown in FIGS. 6A-B are generally similar to those described hereinabove. Typically, sealing material 110 seals the interface between the prosthetic valve and native valve 5. The sealing material reduces retrograde blood flow from ventricle 6 into atrium 4, relative to retrograde blood flow in the absence of the sealing material. Typically, the sealing material is composed of latex, dacron, and/or any other suitable biocompatible material. The sealing material is typically placed around at least a portion of expandable frame 79 of the prosthetic valve so as to form a webbing between struts of the expandable frame.


Reference is now made to FIGS. 7A-F, which are schematic illustrations of a guide wire delivery system, in accordance with some applications of the present invention. As described hereinabove (e.g., with reference to FIGS. 2C-F), for some applications, guide members 21a and 21b, function as valve support guide members, by support 40 being slid along guide members 21a and 21b. For some applications, only one guide member 21 is looped through commissures 8 and 10 in a manner in which the guide member defines a looped portion between commissures 8 and 10 (i.e., a portion of the guide member that is disposed in a ventricle 6 of heart 2), and first and second free ends, which are disposed and accessible at a site outside the body of the patient. For such applications, the guide member defines portions 21a and 21b.


For some applications, an anchor 302 is advanced toward the vicinity of apex 304 of heart 2, via sheath 25, and is anchored to the vicinity of the apex, as shown in FIG. 7A. A guidewire 306 extends proximally from anchor. Guide member 21 passes through a guide member tube 320, the guide member tube being coupled to guidewire 306. Guide member 21 is pushed distally. Guide member tube 320 is unable to advance distally over guidewire 306, due to the coupling of the guide member tube to the guidewire. Therefore, the pushing of guide member 21 distally, causes portions 21a and 21b to spread apart from one another and to be pushed against commissures 8 and 10 of native valve 5. Portions 21a and 21b are then used to guide valve support 40 to the commissures, as shown in FIGS. 7B-C, using generally similar techniques to those described hereinabove, except for the differences described hereinbelow.


As shown in FIG. 7B, valve support 40 is slid over guide member portions 21a and 21b, by pushing elements 52a and 52b. Since the guide member portions are positioned at commissures 8 and 10, the guide member portions guide the distal ends of pushing elements 52a and 52b, such that the pushing elements push the valve support against the commissures, as shown in FIG. 7C.


Subsequent to the placement of valve support 40 at the native valve, prosthetic atrioventricular valve 80 is coupled to valve support 40. For some applications, pushing elements 52a and 52b continue to push the valve support against the native valve, during the coupling of the prosthetic valve to the valve support. As described hereinabove, overtube 70 is advanced into ventricle 6, as shown in FIG. 7D. FIG. 7E shows prosthetic valve having been partially deployed in the ventricle. Following the partial deployment of valve 80 in ventricle 6, overtube 70 is pulled proximally to pull valve 80 proximally such that cylindrical element 42 and/or annular element 44 of valve support 40 surrounds a proximal portion of prosthetic valve 80. Valve 80 has a tendency to expand such that valve 80 is held in place with respect to valve support 40 responsively to radial forces acted upon valve support 40 by prosthetic valve 80. During the pulling back of overtube 70, pushing elements 52a and 52b push valve support 40 against the valve, thereby providing a counter force against which overtube 70 is pulled back. For some applications, the pushing of the valve support against the commissures is such that it is not necessary to use anchors for anchoring the valve support to the native valve during the coupling of the prosthetic valve to the valve support. Alternatively, in addition to the pushing elements providing a counter force against which the prosthetic valve is pulled, anchors are used to anchor the valve support to the native valve during the coupling of the prosthetic valve to the valve support.


As described hereinabove, valve 80 comprises a plurality of distal protrusions 84. When valve 80 is pulled proximally, as described hereinabove, protrusions 84 ensnare and engage the native leaflets of the atrioventricular valve. By the ensnaring of the native leaflets, protrusions 84 sandwich the native valve between protrusions 84 and prosthetic valve support 40. Such ensnaring helps further anchor prosthetic valve 80 to the native atrioventricular valve.


For some applications, as described hereinabove, protrusions 84 are such as to (a) prevent proximal migration of the valve into the patient's atrium, while (b) allowing movement of the native leaflets with respect to the frame of the prosthetic valve. For example, the protrusions may have the aforementioned functionalities by having lengths of less than 5 mm and/or by a total width of each set of protrusions corresponding to respective leaflets of the native valve being less than 5 mm. For example, the valve may include a single protrusion corresponding to each leaflet of the native valve, the width of each of the single protrusions being less than 1 mm. Thus, the valve may be stopped from proximally migrating into the atrium, by the protrusions preventing the distal end of the valve from migrating further proximally than edges of native leaflets of the valve. Furthermore, the protrusions may allow movement of the native leaflets with respect to the frame of the prosthetic valve by not generally squeezing the native leaflets between the protrusions and the frame of the valve. For some applications, by allowing movement of the native leaflets with respect to the frame of the prosthetic valve, sealing of the native leaflets against the outer surface of the frame of the prosthetic valve is facilitated, in accordance with the techniques described hereinbelow with reference to FIG. 10.


Subsequent to the placement of the prosthetic valve at the native valve, sheath 25, overtube 70, pushing elements 52a and 52b, guide member 21, anchor 302, and guidewire 306 are removed from the patient's body, as shown in FIG. 7F, which shows the prosthetic valve in its deployed state. For some applications, in order to remove guide member 21 from the patient's body, guide member portions 21a and 21b are decoupled from guide member tube 320. For example, the guide member portions may be coupled to the guide member tube via threading, the guide member portions being decoupled from the guide member tube by unscrewing the guide member portions from the guide member tube.


Reference is now made to FIGS. 8A-C which are schematic illustrations of a system 120 comprising an invertible valve support 140, in accordance with some applications of the present invention. Invertible valve support 140 is identical to valve support 40 described herein, with the exception that the cylindrical element of valve support 140 is invertible, as is described hereinbelow. Additionally, the method of advancing toward and implanting valve support 140 at annulus 11 is identical to the methods of advancing toward and implanting valve support 40 at annulus 11, as described hereinabove.


Valve support 140 comprises an annular element 144 (that is identical to annular element 44 described hereinabove) and a cylindrical element 142. Cylindrical element 142 has a first end 150, a second end 152, and a cylindrical body 153 disposed between first and second ends 150 and 152. Cylindrical element 142 is attached to annular element 144 at first end 150 of cylindrical element 142.


During and following implantation of support 140 at annulus 11, as shown in FIG. 8A, cylindrical element 142 is disposed above annular element 144 in a manner in which second end 152 and cylindrical body 153 are disposed above annular element 144 and within atrium 4. One or more elongate guide members 146a and 146b are reversibly coupled to cylindrical element 142 in a vicinity of second end 152. Elongate guide members 146a and 146b facilitate (a) advancement of prosthetic valve 80 therealong and toward valve support 140, and (b) inversion of cylindrical element 142 toward ventricle 6 when at least a portion of valve 80 is deployed within ventricle 6 (as shown in FIG. 8B).


The configuration of valve support 140 as shown in FIG. 8A (i.e., the configuration in which cylindrical element 142 is disposed within atrium 4) eliminates the obstruction of native valve 5 and of leaflets 12 and 14 by any portion of valve support 140. In this manner, valve support 140 may be implanted at valve 5 while valve 5 resumes its native function and leaflets 12 and 14 resume their natural function (as shown by the phantom drawing of leaflets 12 and 14 in FIG. 8A which indicates their movement). This atrially-inverted configuration of valve support 140 reduces and even eliminates the amount of time the patient is under cardiopulmonary bypass. Only once prosthetic valve 80 is delivered and coupled to valve support 140 and cylindrical element 142 is thereby ventricularly-inverted, native leaflets 12 and 14 are pushed aside (FIG. 8B).



FIG. 8B shows the inversion of cylindrical element 142 by the partial positioning and deployment of prosthetic valve 80 within ventricle 6. Elongate guide members 146a and 146b are reversibly coupled to prosthetic valve 80 and extend within overtube 70. Following the full deployment of valve 80 and the coupling of valve 80 to valve support 140, elongate guide members 146a and 146b are decoupled from prosthetic valve 80 and from cylindrical element 142. For example, a cutting tool may be used to decouple elongate members 146a and 146b from the valve support 140. Alternatively, elongate members 146a and 146b may be looped through the cylindrical element 142, such that both ends of each elongate member 146a and 146b remain outside of the patient's body. The operating physician decouples elongate members 146a and 146b from valve support 140 by releasing one end of each of elongate members 146a and 146b and pulling on the other end, until elongate members 146a and 146b are drawn from valve support 140 and removed from within the body of the patient.



FIG. 8C shows prosthetic valve 80 coupled to valve support 140. Valve 80 is identical to the valve described hereinabove.


Reference is now made to FIGS. 9A-E, which are schematic illustrations of the advancement of an invertible prosthetic valve support 300 toward a native atrioventricular valve of a patient, and inversion of the valve support, in accordance with some applications of the present invention. Prosthetic valve support 300 is used to anchor prosthetic valve 80 to native valve 5 in a generally similar manner to that described with reference to prosthetic valve support 40.


During a typical procedure, anchor 302 is advanced toward the vicinity of apex 304 of heart 2, via sheath 25, and is anchored to the vicinity of the apex, as shown in FIG. 8A. A guidewire 306 extends proximally from anchor. A distal tensioning element 308 (e.g., a plunger) is advanced over guidewire 306 into ventricle 6, and prosthetic valve support 300 is advanced out of the distal end of sheath 25, as shown in FIG. 9B. A first end 310 of prosthetic valve support 300 (which at this stage is the distal end of the prosthetic valve support), comprises barbs 314 (shown in FIG. 9B), or other anchoring elements for anchoring the first end of the prosthetic valve support to tissue of native valve 5. Prosthetic valve support 300 is pushed distally such that the barbs are pushed into the native valve tissue, thereby anchoring the first end of the prosthetic valve support to the native valve, as shown in FIG. 9C. A plurality of wires 309 pass from distal tensioning element 308 to a proximal tensioning element 311 (shown in FIG. 9D), via a second end 312 of valve support 300 (which at this stage is the proximal end of the prosthetic valve support). For some applications, a sealing element 316 is disposed circumferentially around a surface of the invertible prosthetic valve support that is initially an inner surface of the invertible prosthetic valve support (a shown in FIGS. 8A-D). For example, the sealing material may be latex, dacron, or another suitable biocompatible sealing material.


Subsequent to the anchoring of first end 310 of prosthetic valve support 300 to native valve tissue (as shown in FIG. 9C), distal tensioning element 308 is further advanced distally into ventricle 6, and proximal tensioning element 311 is advanced toward the ventricle. As shown in the transition from FIG. 9D-F, as the proximal tensioning element passes through the valve support, wires 309 cause valve support 300 to invert, by pulling second end 312 of the valve support through first end 310 of the valve support. Subsequent to the inversion of the valve support, sealing material 316 is disposed circumferentially around the outside of the valve support, thereby providing a seal at the interface between valve support 300 and native valve 5.


Reference is now made to FIGS. 9G-H, which are schematic illustrations of the deployment of prosthetic valve 80 and the coupling of the prosthetic valve to invertible valve support 300, in accordance with some applications of the present invention.


The deployment of prosthetic valve 80 is generally similar to the techniques described hereinabove with reference to FIGS. 2H-J. The valve is partially deployed in ventricle 6, via overtube 70. Following the partial deployment of valve 80 in ventricle 6, overtube 70 is pulled proximally (as shown in FIG. 8G) to pull valve 80 proximally such that valve support 300 surrounds a proximal portion of prosthetic valve 80, as shown in FIG. 8H. Valve 80 has a tendency to expand such that valve 80 is held in place with respect to valve support 300 responsively to radial forces acted upon valve support 300 by prosthetic valve 80.


As described hereinabove, for some applications, valve 80 comprises a plurality of distal protrusions 84. When valve 80 is pulled proximally, protrusions 84 ensnare and engage the native leaflets of the atrioventricular valve. By the ensnaring of the native leaflets, protrusions 84 sandwich the native valve between protrusions 84 and prosthetic valve support 300. Such ensnaring helps further anchor prosthetic valve 80 to the native atrioventricular valve.


For some applications, as described hereinabove, protrusions 84 are such as to (a) prevent proximal migration of the valve into the patient's atrium, while (b) allowing movement of the native leaflets with respect to the frame of the prosthetic valve. For example, the protrusions may have the aforementioned functionalities by having lengths of less than 5 mm, and/or by a total width of each set of protrusions corresponding to respective leaflets of the native valve being less than 5 mm. For example, the valve may include a single protrusion corresponding to each leaflet of the native valve, the width of each of the single protrusions being less than 1 mm. Thus, the valve may be stopped from proximally migrating into the atrium, by the protrusions preventing the distal end of the valve from migrating further proximally than edges of native leaflets of the valve. Furthermore, the protrusions may allow movement of the native leaflets with respect to the frame of the prosthetic valve by not generally squeezing the native leaflets between the protrusions and the frame of the valve. For some applications, by allowing movement of the native leaflets with respect to the frame of the prosthetic valve, sealing of the native leaflets against the outer surface of the frame of the prosthetic valve is facilitated, in accordance with the techniques described hereinbelow with reference to FIG. 10.


Additionally, as shown in FIG. 9H, and as described hereinabove, valve 80 comprises one or more coupling elements 81 (for example, a plurality of coupling elements, as shown) at the proximal end of valve 80. Overtube 70, which facilitates the advancement of prosthetic valve 80, is reversibly coupled to valve 80, via coupling elements 81.


Subsequent to the coupling of valve 80 to valve support 300, overtube 70, distal and proximal tensioning elements 308 and 311, and wires 309 are removed from the patient's body, via sheath 25. Typically, wires 309 are cut, in order to facilitate the removal of the wires from the patient's body. Guidewire 306 and anchor 302 are removed from the patient's body by detaching the anchor from apex 304, and withdrawing the anchor and the guidewire, via sheath 25.


Reference is now made to FIG. 10, which is a schematic illustration of prosthetic valve 80, for placing inside atrioventricular valve 5 of the patient, in accordance with some applications of the present invention. The expandable frame 79 of the prosthetic valve has a diameter d, and a corresponding cross-sectional area. Native annulus 11, which is typically saddle-shaped, defines an area A, as shown. For some applications, area A, which is defined by the native annulus is measured, e.g., using a measuring ring. A prosthetic valve is chosen to be placed in the annulus, the cross-sectional area of the prosthetic valve being less than 90% (e.g., less than 80%, or less than 60%) of area A. For some applications, diameter d of the prosthetic valve is less than 25 mm, e.g., less than 20 mm, and/or more than 15 mm, e.g., 15-25 mm. For some applications, placing a prosthetic valve inside the native valve with the dimensions of the native valve annulus and the prosthetic valve as described, facilitates sealing of the prosthetic valve with respect to the native valve, by the native valve leaflets closing around the outer surface of the prosthetic valve.


For some applications, a prosthetic valve support 40 that includes annular element 44 (e.g., as shown in FIGS. 14A-C) is chosen to be placed at the annulus, the annular element defining an inner cross-sectional area that is less than 90% (e.g., less than 80%, or less than 60%) of area A. Prosthetic valve 80 is deployed at the native valve by coupling the prosthetic valve to the prosthetic valve support at the location, responsively to radial forces acted upon the valve support by the expandable frame, by facilitating expansion of the expandable frame, as described herein. The cross-sectional area defined by the expandable frame of the prosthetic valve, upon expansion of the expandable frame, is limited by the cross-sectional area defined by the annular element of the prosthetic valve support to less than 90% (e.g., less than 80%, or less than 60%) of area A. For some applications, placing a prosthetic valve support at the annulus with the dimensions of the native valve annulus and valve support 40, as described, facilitates sealing of the prosthetic valve with respect to the native valve, by the native valve leaflets closing around the outer surface of the prosthetic valve.


Typically, placing a prosthetic valve inside the native valve with the dimensions of the native valve annulus, the prosthetic valve 80, and/or valve support 40 as described in the above paragraphs, facilitates sealing of the prosthetic valve with respect to the native valve. For some applications, the sealing is facilitated by the native leaflets being pushed against, and closing against, the outer surface of the frame of the valve during systole, in a similar manner to the manner in which native valve leaflets coapt during systole, in a healthy mitral valve. Typically, as the diameter of the prosthetic valve is increased, the length of the native leaflets that is pushed against the outer surface of the valve during systole is increased, thereby enhancing the sealing of the native leaflets with respect to the frame of the prosthetic valve. However, beyond a given diameter, as the diameter of the prosthetic valve is increased, the native valve leaflets are pushed apart at the commissures, thereby causing retrograde leakage of blood through the commissures. Therefore, in accordance with some applications of the present invention, prosthetic valve 80, and/or valve support 40 are chosen such that the cross-sectional area of the prosthetic valve when expanded inside the valve support is less than 90% (e.g., less than 80%, or less than 60%) of area A. Thus the valve support facilitates sealing of the prosthetic valve with respect to the native valve, by the native valve leaflets closing around the outer surface of the prosthetic valve, while not causing retrograde leakage of blood through the commissures.


For some applications, in order to facilitate the sealing of the native valve around the outer surface of the prosthetic valve, a material is placed on the outer surface of the prosthetic valve in order to provide a sealing interface between the prosthetic valve and the native valve. For example, a smooth material that prevents tissue growth (e.g., polytetrafluoroethylene (PTFE), and/or pericardium) may be placed on the outer surface of the prosthetic valve. Alternatively or additionally, a material that facilitates tissue growth (such as dacron) may be placed on the outer surface of the prosthetic valve, in order to (a) act as a sealing interface between the native valve and the prosthetic valve, and (b) facilitate tissue growth around the prosthetic valve to facilitate anchoring and/or sealing of the prosthetic valve.


Reference is now made to FIGS. 11A-D, which are schematic illustrations of prosthetic valve 80, in accordance with some applications of the present invention. For some applications, protrusions 84 are disposed on the valve on portions 400 of the valve that are placed adjacent to the anterior and posterior leaflets of the native valve, and the valve does not includes protrusions on portions 402 of the valve that are placed adjacent to the commissures of the native valve.



FIGS. 11B-D show bottom views (i.e., views of the distal ends) of respective configurations of prosthetic valve 80 and protrusions 84. The protrusions converge from the proximal ends 404 of the protrusion to the distal ends 406 of the protrusions. The protrusions are configured such as to ensnare chordae tendineae, and to pull the chordae tendineae toward each other when the prosthetic valve is pulled proximally, due to the convergence of the snares with respect to each other. FIG. 11D shows the prosthetic valve deployed at native valve 5. As shown, the protrusions ensnare chordae tendineae 102 of the patient. The protrusions facilitate sealing and anchoring of the prosthetic valve with respect to the native valve by pulling the chordae tendinae toward each other, as described. As described hereinabove, for some applications the prosthetic valve does not define protrusions 84 on portions 402 that are placed next to the native commissures, e.g., commissure 8, shown in FIG. 11D.


For some applications, as described hereinabove, protrusions 84 are such as to (a) prevent proximal migration of the valve into the patient's atrium, while (b) allowing movement of the native leaflets with respect to the frame of the prosthetic valve. For example, the protrusions may have the aforementioned functionalities by having lengths of less than 5 mm, and/or by a total width of each set of protrusions corresponding to respective leaflets of the native valve being less than 5 mm. For example, the valve may include a single protrusion corresponding to each leaflet of the native valve, the width of each of the single protrusions being less than 1 mm. Thus, the valve may be stopped from proximally migrating into the atrium, by the protrusions preventing the distal end of the valve from migrating further proximally than edges of native leaflets of the valve. Furthermore, the protrusions may allow movement of the native leaflets with respect to the frame of the prosthetic valve by not generally squeezing the native leaflets between the protrusions and the frame of the valve. For some applications, by allowing movement of the native leaflets with respect to the frame of the prosthetic valve, sealing of the native leaflets against the outer surface of the frame of the prosthetic valve is facilitated, in accordance with the techniques described hereinabove with reference to FIG. 10.


For some applications, a first set of protrusions 84 from the distal end of prosthetic valve 80 are disposed within a first circumferential arc with respect to a longitudinal axis of the prosthetic valve, on a first side of the distal end of the prosthetic valve, the first side of the distal end being configured to be placed adjacent to the anterior leaflet of the native valve. A second set of protrusions are disposed within a second circumferential arc with respect to a longitudinal axis of the prosthetic valve, on a second side of the distal end of the prosthetic valve, the second side of the distal end being configured to be placed adjacent to the posterior leaflet of the native valve.


The first and second sets of protrusions are disposed so as to provide first and second gaps therebetween at the distal end of the prosthetic valve. Typically, at least one of the gaps between the two sets of protrusions has a circumferential arc of at least 20 degrees (e.g., at least 60 degrees, or at least 100 degrees), and/or less than 180 degrees (e.g., less than 140 degrees), e.g., 60-180 degrees, or 100-140 degrees. Further typically, one or both of the first and second circumferential arcs defines an angle of at least 25 degrees (e.g., at least 45 degrees), and/or less than 90 degrees (e.g., less than 75 degrees), e.g., 25-90 degrees, or 45-75 degrees.


Valve guide members (e.g., guide members 21a and 21b, and/or delivery lumen 27a and 27b, as described hereinabove) are delivered to commissures of the native valve, and guide the valve such that the first and second circumferential arc are aligned with respective leaflets of the native valve and such that the first and second gaps are aligned with respective commissures of the native valve.


Reference is now made to FIGS. 12A-C, which are schematic illustrations of prosthetic valve 80, the valve defining distal protrusions 84 that are disposed sinusoidally around the circumference of the valve, in accordance with some applications of the present invention. For some applications the protrusions are shaped sinusoidally, in order to conform with the saddle-shape of native valve annulus 11, thereby facilitating the sandwiching of the native valve leaflets between the protrusions and valve support 40. As shown, the peaks of the sinusoid that is defined by the protrusions is disposed on portions 402 that are placed next to the native commissures and the troughs of the sinusoid is placed on portions of the valve that are placed in the vicinity of the centers of the anterior and posterior leaflets of the native valve. As shown in FIG. 12C, for some applications the distal end of the prosthetic valve defines a sinusoidal shape.


Reference is now made to FIGS. 13A-E, which are schematic illustrations of respective configurations of expandable frame 79 of prosthetic valve 80, in accordance with some applications of the present invention. As described hereinabove, for some applications, valve 80 defines distal protrusions 84 that are configured to facilitate sandwiching of the native valve leaflets between the protrusions and valve support 40. For some applications, tips of the distal protrusions are shaped so as to prevent the tips from piercing, and/or otherwise damaging, tissue of the native leaflets. For example, the tips of the protrusions may be curved, as shown in FIG. 13A. Or, the distal tips of the protrusions may be shaped as balls, as shown in FIG. 13, and/or a different rounded shape. For some applications, the distal tip of each of the protrusions is joined to the distal tip of an adjacent protrusion by an arch 410, as shown in FIGS. 13C and 13D.


For some applications, the protrusions are configured to be distally-facing during the insertion of prosthetic valve 80 into the subject's left ventricle. For example, the valve may be inserted through overtube 70 (shown in FIG. 7E, for example). The valve is crimped during the insertion of the valve through the overtube, and the protrusions are constrained in their distally-facing configurations by the overtube. The protrusions are pre-shaped such that in the resting state of the protrusions, the protrusions assume proximally-facing configurations, as shown in FIG. 13D, for example. Thus, upon emerging from overtube 70, the protrusions assume proximally-facing configurations. For some applications, when the protrusions assume the proximally-facing configurations, the protrusions are disposed at an angle theta (FIG. 13D) from expandable frame 79 of more than 40 degrees (e.g., more than 50 degrees), and/or less than 80 degrees (e.g., less than 70 degrees).


Typically, protrusions 84 are coupled to frame 79 of valve 80 at joints 412. For some applications, joints 412 are thinner than portions of the protrusions and of the frame surrounding the joints, as shown in FIG. 13D. For some applications, the thinness of the joints with respect to the surrounding portions facilitates the crimping of the protrusions into distally-facing configuration during the insertion of the valve into the heart.


For some applications, barbs 416 extend from a proximal portion of expandable frame 79 of valve 80, as shown in FIG. 13E. For example, the barbs may be configured to anchor the prosthetic valve to the native valve by piercing tissue of the native valve. Alternatively or additionally, the barbs may be configured to anchor the prosthetic valve to the valve support 40, by becoming coupled to portions of the valve support. For some applications the barbs protrude from the top-central corner of respective cells of expandable frame 79. Typically, when the prosthetic valve is crimped, the barbs fit within gaps of respective cells of the expandable frame, and do not substantially increase the crimping profile of the prosthetic valve, relative to a generally similar prosthetic valve that does not include barbs.


For some applications, the barbs are not generally used for coupling prosthetic valve support 80 to valve support 40. Rather, the prosthetic valve is coupled to the valve support by virtue of radial expansion of the prosthetic valve against annular element 44 of the valve support. Barbs 416 are used to prevent prosthetic valve from migrating distally into the patient's left ventricle, and/or to prevent valve support 40 from migrating proximally into the subject's left atrium.


For some applications (not shown), barbs protrude from coupling elements 81 of prosthetic valve 80, the barbs being generally similar in shape and function to that described with reference to barbs 416. For some applications (not shown), radially-inwardly facing barbs 45 protrude from annular element 44 of valve support 40, as shown in FIG. 14D. As described with reference to barbs 416, the barbs that protrude from annular element 44 may facilitate coupling of the prosthetic valve to the valve support. Alternatively or additionally, the barbs that protrude from annular element 44 are used to prevent prosthetic valve from migrating distally into the patient's left ventricle, and/or to prevent valve support 40 from migrating proximally into the subject's left atrium.


For some applications, a proximal end of expandable frame 79 of prosthetic valve 80 defines a larger cross-section area than more distal portions of the expandable frame. For example, the expandable frame may have a frustoconical shape, the walls of the expandable frame diverging from a distal end of the frame to a proximal end of the frame. Alternatively, the expandable frame may have a trumpet shape (i.e., the frame may be generally tubular, with a dilated proximal end). For some applications, the larger cross-sectional area of the proximal end of the frame prevents the prosthetic valve from migrating distally into the patient's left ventricle, and/or prevents valve support 40 from migrating proximally into the subject's left atrium.


Reference is now made to FIGS. 14A-D, which are schematic illustrations of respective configurations of prosthetic valve support 40, in accordance with some applications of the present invention. As described hereinabove, for some applications, the valve support comprises a collapsible skirt having a proximal annular element 44 and a distal cylindrical element 42 (e.g., as shown in FIG. 2D). Alternatively, the valve support does not include a distal cylindrical element. For example, the valve support may only include annular element 44. As described hereinabove, annular element 44 is configured to be placed around native annulus 11 of the native valve, and to extend at least partially into atrium 4 such that annular element 44 rests against the native annulus. Annular element 44 is typically too large to pass through the annulus, and may, for example, have an outer diameter of between 30 and 60 mm.



FIGS. 14A-D show annular element 44 of valve support 40 in respective configurations, in accordance with some applications of the present invention. For some applications, the annular element is D-shaped, as shown in FIG. 14A. Alternatively or additionally, the annular element has a generally round shape, as shown in FIGS. 14B-C. For some applications the annular element is asymmetrical. For example, FIG. 14B shows a generally rounded annular element that is wider on a first side 420 of the element than on a second side 422 of the element. Typically, the wider side of the annular element is placed on the anterior side of the native annulus. In accordance with some applications, the annular element is symmetrical, asymmetrical, oval, round, defines a hole that is centered with respect to the annular element, and/or defines a hole that is off-center with respect to the annular element. For some applications, the stiffness of the annular element varies around the circumference of the annular element.


For some applications, annular element 44 is asymmetrical, as shown in FIG. 14B. Typically, the asymmetry of the annular element is such that the center of the hole defined by the annular element is disposed asymmetrically (i.e., off-center) with respect to the center of the annular element, as defined by the outer perimeter of the annular element. For some applications, the asymmetric disposition of the center of the hole defined by the annular element is such that when the prosthetic valve is placed inside the annular element, the longitudinal axis of the prosthetic valve is disposed asymmetrically (i.e., off-center) with respect to the center of the annular element, as defined by the outer perimeter of the annular element. Typically, the annular element is shaped such that, when the annular element is placed on the patient's mitral annulus, and the prosthetic valve is expanded inside the annular element, the longitudinal axis of the prosthetic valve is disposed in the vicinity of the location at which the patient's native leaflets coapt (this location being off-center with respect to the patient's native mitral annulus).


For some applications (not shown), radially-inwardly facing barbs 45 protrude from annular element 44 of valve support 40, as shown in FIG. 14D. As described with reference to barbs 416 shown protruding from prosthetic valve 80 in FIG. 13E, the barbs that protrude from annular element 44 may facilitate coupling of the prosthetic valve to the valve support. Alternatively or additionally, the barbs that protrude from annular element 44 are used to prevent prosthetic valve from migrating distally into the patient's left ventricle, and/or to prevent valve support 40 from migrating proximally into the subject's left atrium. For some applications, some or all of barbs 102 are curved. Typically, the curved barbs curve away from the plane of annular element 40, such that, when implanted, barbs 102 point into the patient's atrium.


Typically, the annular element includes frame 48, the frame being covered at least in part with covering 49, e.g., fabric. Typically, the upper surface of annular element 44 is covered with fabric, for example, in order to provide a generally smooth surface for coming into contact with the patient's blood flow. Further typically, the lower surface of the annular element (i.e., the side of the annular element that is placed in contact with the native annulus) is not covered with fabric, for example, in order to reduce a crimped volume (or cross-sectional area) of the annular element, relative to the volume of the annular element if the lower surface of the annular element were covered in fabric. Typically, a thickness of the fabric layer is less than 0.2 mm, e.g., less than 0.1 mm, or less than 0.05 mm.


For some applications, the side of the annular element that is placed in contact with the native annulus is covered with the fabric, the fabric being configured to facilitate coupling of the annular element to the native annulus, by facilitating fibrosis at the interface between the annular element and the native annulus. For some applications, the upper surface of the annular element is not covered with fabric. For example, the upper surface may not be covered in fabric in order to reduce a crimped volume (or cross-sectional area) of the annular element, relative to the volume of the annular element if the upper surface of the annular element were covered in fabric.


For some applications, annular element 44 is not covered with fabric, and/or is not configured to form a seal against frame 79 of prosthetic valve 80. For some applications, the annular element is configured to allow leakage of blood between the annular element and frame 79 of prosthetic valve 80. For example, the annular element may be configured to allow leakage of blood through the interface between the annular element and the frame of the prosthetic valve, in order to accommodate a flow of blood between the patient's atrium and the patient's ventricle that is greater than can be accommodated by blood flowing through the leaflets of the prosthetic valve.


Reference is now made to FIGS. 15A-E, which are schematic illustrations of respective steps of a procedure for deploying a prosthetic valve, in accordance with some applications of the present invention. As described hereinabove and hereinbelow (for example, with reference to FIGS. 2A-K, 7A-F, 8A-C, 9A-H, and 16A-G), for some procedures, valve support 40 is placed on the valve annulus and, subsequently, prosthetic valve 80 is inserted into the subject's left ventricle through the valve support. Alternatively, any of the procedures described herein (for example, procedures described with reference to FIGS. 2A-K, 7A-F, 8A-C, 9A-H, and 16A-G) may be performed by first placing the prosthetic valve inside the subject's left ventricle, and, subsequently, deploying the valve support at the annulus. For example, FIGS. 15A-E show a procedure in which the prosthetic valve is placed inside the subject's left ventricle, and, subsequently, the valve support is deployed at the annulus.


As shown in FIG. 15A, for some applications, prosthetic valve 80 is placed in the subject's ventricle, before prosthetic valve support 40 is placed at the native valve. The prosthetic valve is typically placed in the left ventricle in an undeployed state, via overtube 70. Subsequently, the valve support is placed at the native valve using pushing elements, as shown in FIG. 15B. For some applications, three pushing elements 52a, 52b, and 52c are used to push the valve support against the native valve, as shown in FIG. 15B.


Subsequent to the placement of valve support 40 at the native valve, prosthetic valve 80 is coupled to valve support 40. For some applications, pushing elements 52a, 52b, and 52c continue to push the valve support against the native valve, during the coupling of the prosthetic valve to the valve support. FIG. 15C shows prosthetic valve having been partially deployed in the ventricle.


Following the partial deployment of valve 80 in ventricle 6, overtube 70 is pulled proximally to pull valve 80 proximally such that annular element 44 of valve support 40 surrounds a proximal portion of prosthetic valve 80, as shown in FIG. 15D. Valve 80 has a tendency to expand such that valve 80 is held in place with respect to valve support 40 responsively to radial forces acted upon valve support 40 by prosthetic valve 80. During the pulling back of overtube 70, pushing elements 52a, 52b, and 52c push valve support 40 against the valve, thereby providing a counter force against which overtube 70 is pulled back. For some applications, the pushing of the valve support against the commissures is such that it is not necessary to use anchors for anchoring the valve support to the native valve during the coupling of the prosthetic valve to the valve support. Alternatively, in addition to the pushing elements providing a counter force against which the prosthetic valve is pulled, anchors are used to anchor the valve support to the native valve during the coupling of the prosthetic valve to the valve support.


As described hereinabove, valve 80 comprises a plurality of distal protrusions 84. When valve 80 is pulled proximally, as described hereinabove, protrusions 84 ensnare and engage the native leaflets of the atrioventricular valve. By the ensnaring of the native leaflets, protrusions 84 sandwich the native valve between protrusions 84 and prosthetic valve support 40. Such ensnaring helps further anchor prosthetic valve 80 to the native atrioventricular valve.


It is noted with reference to FIG. 15D that, typically, annular element 44 of prosthetic valve support 40 defines an inner cross-sectional area thereof. As described hereinabove, prosthetic valve 80 includes expandable frame 79, and prosthetic leaflets 82. The expandable frame of the prosthetic valve is configured such that when the frame is in a non-constrained state thereof, the cross-sectional area of the frame, along at least a given portion L (shown in FIG. 15D) of the length of the frame, is greater than the inner cross-sectional area defined by the annular element of the prosthetic valve support. Typically, during a valve-deployment procedure, a location anywhere along portion L at which to couple the expandable valve to the prosthetic valve support is selected. In response thereto, the location along the portion of the expandable frame is aligned with the annular element of the prosthetic valve support. The expandable valve is then coupled to the prosthetic valve support at the location, responsively to radial forces acted upon the valve support by the expandable frame, by facilitating expansion of the expandable frame, when the location along the portion is aligned with the annular element of the prosthetic valve support.


As described hereinabove, for some applications, expandable frame 79 of prosthetic valve 80 has a frustoconical shape. For some applications, the prosthetic valve is coupled to valve support 40 responsively to radial forces acted upon the valve support by the expandable frame, when a given location along portion L is aligned with annular element 44 of the prosthetic valve support. For some applications, the portion immediately proximal to the given location along portion L has a greater cross-sectional area than the frame at the given location, due to the frustoconical shape of the expandable frame. Typically, the greater cross-sectional area of the portion immediately proximal to the given location along portion L relative to the cross-sectional area of the frame at the given location, reduces distal migration of the prosthetic valve toward the subject's left ventricle.


For some applications, the location along portion L at which to couple prosthetic valve 80 to valve support 40 is selected, based upon a distance D between protrusions 84 and annular element 44 that would result from coupling the prosthetic valve to the annular element at that location. For example, the location along portion L at which to couple prosthetic valve 80 to valve support 40 may be selected, such that distance D is such as to anchor the prosthetic valve to the patient's native valve by squeezing the patient's native valve leaflets between the protrusions and the annular element, and/or by ensnaring the patient's chordae tendinae between the protrusions and the annular element. Alternatively or additionally, the location along portion L at which to couple prosthetic valve 80 to valve support 40 may be selected, such that distance D is such that protrusions 84 (a) prevent proximal migration of the valve into the patient's atrium, while (b) allowing movement of the native leaflets with respect to the frame of the prosthetic valve. Typically, the location along portion L is selected such that distance D is such that the valve may be stopped from proximally migrating into the atrium, by the protrusions preventing the distal end of the valve from migrating further proximally than edges of native leaflets of the valve, while the protrusions allow movement of the native leaflets with respect to the frame of the prosthetic valve by not generally squeezing the native leaflets between the protrusions and the frame of the valve. For some applications, by allowing movement of the native leaflets with respect to the frame of the prosthetic valve sealing of the native leaflets against the outer surface of the frame of the prosthetic valve is facilitated, in accordance with the techniques described hereinabove with reference to FIG. 10.


Subsequent to the placement of the prosthetic valve at the native valve, overtube 70, and pushing elements 52a, 52b, and 52c are removed from the patient's body, as shown in FIG. 15E, which shows the prosthetic valve in its deployed state.


Reference is now made to FIGS. 16A-G, which are schematic illustrations of respective steps of an alternative procedure for deploying prosthetic valve 80, in accordance with some applications of the present invention. As described hereinabove, with reference to FIGS. 7A-F, for some applications, a looped guide member 21 is looped through commissures 8 and 10 in a manner in which the guide member defines a looped portion between commissures 8 and 10. For some applications, the looped guide member has steering functionality. The steering functionality of the looped guide member is used to guide the guide member to the commissures, and/or to guide other portions of the apparatus to the native valve and/or to ventricle 6. The looped guide member is typically advanced toward ventricle 6 over guidewire 306, e.g., as described hereinabove with reference to FIG. 7A.


Typically, as shown in FIG. 16A, portions 21a and 21b of the looped guide member are independently manipulable. The portions of the looped guide member are manipulated (e.g., expanded and contracted) so as to guide the looped guide member to the subject's native valve, by pushing against inner surfaces of the subject's heart, as shown in FIG. 16A.



FIG. 16B shows the looped guide member looped through commissures 8 and 10 of the subject's native valve. When the looped guide member is disposed at the native valve, the guide member is used to guide and to anchor valve support 40, as described hereinbelow.


As shown in FIG. 16C, for some applications, looped guide member 21 is coupled to valve support 40 via coupling wires 500 and coupling mechanisms 502. For example, as shown, the coupling mechanism may include an anchor. A suture 504, or a different looped element, protrudes from the bottom surface of annular element 44 of valve support 40 and is anchored by the anchor. Thus, when looped guide member 21 is pushed distally into ventricle 6, the valve support is pulled against the annulus of the native valve by coupling wires 500 pulling on the valve support.


Typically, coupling mechanisms 502, which are used to couple looped guide member 21 to valve support 40 are detachable coupling mechanisms. For example, as shown, the coupling mechanism may include an anchor that defines an opening 506 through which suture 504 is inserted. The opening is closed by a closing member 508, such as a rod, or a wire. In order to detach the guide member from valve support, closing member 508 is opened (e.g., by being pulled proximally) such that suture 504 is released through opening 506.


Subsequent to the placement of valve support 40 at the native valve, prosthetic atrioventricular valve 80 is placed in ventricle 6, by advancing overtube 70 into the ventricle, as shown in FIG. 16D. FIG. 16E shows prosthetic valve having been partially deployed in the ventricle. Following the partial deployment of valve 80 in ventricle 6, overtube 70 is pulled proximally to pull valve 80 proximally such that annular element 44 of valve support 40 surrounds a proximal portion of prosthetic valve 80, as shown in FIGS. 16E-F. Valve 80 has a tendency to expand such that valve 80 is held in place with respect to valve support 40 responsively to radial forces acted upon valve support 40 by prosthetic valve 80.


During the pulling back of overtube 70, looped guide member 21 is pushed distally, thereby pulling valve support 40 against the native annulus and providing a counter force against which overtube 70 is pulled back. For some applications, pulling of the valve support against the native annulus is such that it is not necessary to use anchors for anchoring the valve support to the native valve during the coupling of the prosthetic valve to the valve support. Alternatively, in addition to the pulling of the valve support against the native annulus providing a counter force against which the prosthetic valve is pulled, anchors are used to anchor the valve support to the native valve during the coupling of the prosthetic valve to the valve.



FIG. 16G shows prosthetic valve 80 and valve support 40 coupled to the native valve. At this stage, coupling mechanism 502 is typically detached from the valve support. For example, as shown, closing member 508 is pulled, such that opening 506 is opened, and suture 504 is released through the opening. Subsequently, looped guide member 21, and overtube 70 are removed from the subject's body, as shown in FIG. 16H, which shows the prosthetic valve in its deployed state.


As described with reference to FIGS. 16A-H, for some applications, prosthetic valve 80 is coupled to a native valve, by (a) placing valve support 40 on an atrial side of the native annulus, (b) placing the prosthetic valve inside the ventricle, and then, simultaneously, (c) pulling the prosthetic valve toward the atrium, and pulling the valve support toward the ventricle.


Reference is now made to FIGS. 17A-C, which are schematic illustrations of leaflets 82 of prosthetic valve 80, in accordance with some applications of the present invention. FIG. 17A shows the leaflets before the leaflets are sutured to expandable frame 79 of the valve. As shown, in this state, the leaflets have a diameter D1, and the leaflets are not fully closed. FIG. 17B shows the leaflets when the leaflets have been sutured to expandable frame 79 of the prosthetic valve. The expandable frame constrains the leaflets, such that the leaflets define a diameter D2, which is smaller than diameter D1, thereby closing the leaflets. FIG. 17C shows the leaflets subsequent to the deployment of valve 80 inside valve support 40, the valve support constraining the expansion of the prosthetic valve. Due to the valve support constraining the prosthetic valve, the valve leaflets are constrained so as define a diameter D3, which is smaller than diameter D2.


Typically, valve leaflets 82 are selected to be used in prosthetic valve 80, the leaflets being sized such that both at diameter D2 (when the leaflets are constrained by expandable frame 79 but are not constrained by valve support 40) and at diameter D3 (when the leaflets are constrained by both expandable frame 79 and valve support 40), the valve leaflets fully coapt.


Reference is now made to FIGS. 18A-B which are schematic illustrations of a system 220 comprising a valve support 240 comprising an annular element 244 and a cylindrical element 242 and one or more (e.g., a plurality, as shown, of) tissue anchors 230, in accordance with some applications of the present invention. Annular element 244 has an upper surface 241 and a lower surface 243. Tissue anchors 230 are coupled to lower surface 234 of annular element. Tissue anchors 230 are shaped so as to define a pointed distal tip 234 and one or more (e.g., three, as shown) radially-expandable prongs 232. Prongs 232 comprise a flexible metal, e.g., nitinol or stainless steel, and have a tendency to expand radially. Anchors 230 facilitate coupling of valve support 240 to annulus 11 of native valve 5, such as the mitral valve or the tricuspid valve. Anchors 230 are typically distributed approximately evenly around lower surface 243 of annular element 244. For some applications, one or more anchors 230 are disposed at a location of annular element that is configured to be positioned adjacently to commissures 8 and 10 of valve 5.


Reference is now made to FIGS. 19A-D which are schematic illustrations of valve support 240 being implanted at valve 5 and the subsequent coupling of prosthetic valve 80 to valve support 240. Valve support 240 is advanced toward native valve 5 by pushing elements 52a and 52b, as described hereinabove with respect to valve support 40 with reference to FIGS. 2D-F. In response to the pushing force to valve support 240 by pushing elements 52a and 52b, anchors 230 are pushed into tissue of annulus 11 of valve 5. The pushing force by elements 52a and 52b is sufficient to implant each one of the plurality of anchors that are distributed around lower surface 243 of annular element 244.



FIG. 19A shows initial penetration of tissue of annulus 11 by pointed distal tip 234 of anchor 230. In FIG. 19B, the initial force of the tissue on prongs 232 pushes inwardly prongs 232. Finally, in FIG. 19C, prongs 232 expand within tissue of annulus 11 to assume a flower shape and a larger surface area to restrict proximal motion of anchor 230 and thereby anchor valve support 240 in tissue of annulus 11. As shown in FIGS. 19A-C, the cylindrical element of valve support 240 pushes aside native leaflets 12 and 14 of valve 5.


In FIG. 19D, prosthetic valve 80 is coupled to valve support 240, in a manner as described hereinabove.


It is noted that, in general, prosthetic valve 80 is self-expandable. When the prosthetic valve is deployed (i.e., when the valve self-expands) inside the subject's heart, the expansion of the valve is typically constrained by valve support 40. Further typically, the expansion of the valve is not constrained by the native annulus.


For some application, by constraining the expansion of the prosthetic valve with the valve support, the deployed cross-sectional area of the prosthetic valve may be fixed at a given area, by using a valve support that defines a hole having the given cross-sectional area. As described hereinabove with reference to FIG. 10, for some applications, the area defined by the native annulus is measured, and the cross-sectional area of the prosthetic valve that is to be deployed in the valve is selected based upon the measured area of the native annulus. Alternatively or additionally, valve support 40 is selected based upon the measured area of the native annulus.


For example, a valve support may be selected such that the valve support constrains the expansion of the prosthetic valve, when the cross-sectional area of the prosthetic valve is less than 90% (e.g., less than 80%, or less than 60%) of the area defined by the native annulus. As described hereinabove, for some applications, placing a prosthetic valve inside the native valve with the dimensions of the native valve annulus and the prosthetic valve being as described, facilitates sealing of the prosthetic valve with respect to the native valve, by the native valve leaflets closing around the outer surface of the prosthetic valve.


For some applications, the expansion of prosthetic valve 80 against valve support 40 couples the prosthetic valve to the valve support, and/or couples the valve and the valve support to the native mitral valve. Typically, the expansion of the prosthetic valve against the valve support couples the prosthetic valve to the valve support, and sandwiching of the native valve leaflets between protrusions from the distal end of the valve and the valve support couples the prosthetic valve and the valve support to the native valve.


Reference is now made to FIGS. 1A-D, 2A-K, 3A-D, 4A-C, 5A-D, 6A-B, 7A-F, 8A-C, 9A-H, 10, 11A-D, and 12A-C. It is to be noted that valve support 40 may be invertible as described hereinabove with respect to valve supports 140 and 300, with reference to FIGS. 8A-C, and 9A-H. It is to be further noted that valve supports 140 and 300 may be used in conjunction with one or more of the elements for facilitating sealing of the native valve with respect to a valve support or a valve that is described with reference to FIGS. 3A-D, 4A-C, 5A-D, and 6A-B. For example, valve supports 140 and 300 may be used with sealing balloon 90, commissural anchors 100a and 100b, grasping elements 106a and 106b, and/or sealing material 110. It is still further noted that valve supports 140 and 300 may be implanted using a guide member that defines a looped portion between commissures 8 and 10, as described with reference to FIGS. 7A-F. It is further noted that any of the applications described herein can be used in conjunction with valves having configurations as described with reference to FIGS. 10-12C.


The systems described herein are advanced toward valve 5 in a transcatheter procedure, as shown. It is to be noted, however, that the systems described herein may be advanced using any suitable procedure, e.g., minimally-invasively (e.g., via a transeptal, a transatrial, a transapical, and/or a transaortic approach), or using an open-heart procedure. It is to be further noted that valve supports and prosthetic valves herein may be used to replace native mitral valves or native tricuspid valves.


Reference is now made to FIGS. 20A-B, which are schematic illustrations of valve support 40 and prosthetic valve 80 coupled respectively to a tricuspid valve, and to an aortic valve, in accordance with some applications of the present invention. For some applications, valve support 40 and prosthetic valve 80 are deployed at a tricuspid valve and/or at an aortic valve using generally similar techniques to those described herein with reference to the deployment of the valve support and the prosthetic valve at the mitral valve, mutatis mutandis.


It will be appreciated by persons skilled in the art that the present invention is not limited to what has been particularly shown and described hereinabove. Rather, the scope of the present invention includes both combinations and subcombinations of the various features described hereinabove, as well as variations and modifications thereof that are not in the prior art, which would occur to persons skilled in the art upon reading the foregoing description.

Claims
  • 1. A method, for use at a mitral valve of a heart of a subject, the method comprising: advancing a transluminal sheath into a femoral vein of the subject, through an inferior vena cava of the subject, into a right atrium of the subject, and transseptally into a left atrium of the subject;advancing a distal end of a surrounding-sheath out of a distal end of the transluminal sheath, into the left atrium, and toward a commissure of the mitral valve;at the commissure, advancing a distal end of a delivery lumen and an anchor out of the distal end of the surrounding-sheath, into a left ventricle of the subject, and, while the distal end of the delivery lumen is in the left ventricle, helically implanting the anchor by wrapping the anchor around at least some chordae tendineae that are at the commissure;subsequently to helically implanting the anchor, extracting the surrounding-sheath and the delivery lumen from the heart; andsubsequently, implanting a prosthetic valve in the mitral valve such that the anchor facilitates anchoring of the prosthetic valve and sealing of the commissure.
  • 2. The method according to claim 1, wherein the anchor is a first anchor and the commissure is a first commissure of the mitral valve, wherein the method further comprises, subsequently to helically implanting the first anchor at the first commissure, helically implanting a second anchor by wrapping the second anchor around at least some chordae tendineae that are at a second commissure of the mitral valve, and wherein implanting the prosthetic valve in the mitral valve comprises implanting the prosthetic valve in the mitral valve such that the first and second anchors facilitate anchoring of the prosthetic valve and sealing of the first and second commissures.
  • 3. The method according to claim 2, wherein: the surrounding-sheath is a first surrounding-sheath,the delivery lumen is a first delivery lumen,the method further comprises advancing a distal end of a second surrounding-sheath out of the distal end of the transluminal sheath, into the left atrium, and toward the second commissure, andhelically implanting the second anchor comprises, at the second commissure, advancing a distal end of a second delivery lumen out of the distal end of the second surrounding-sheath, into the left ventricle.
  • 4. The method according to claim 1, wherein the is conical, having a wider end and a narrower end, and wherein helically implanting the anchor comprises helically implanting the anchor that is conical, having a wider end and a narrower end.
  • 5. The method according to claim 4, wherein helically implanting the anchor comprises helically implanting the anchor such that the wider end is upstream of the narrower end.
  • 6. The method according to claim 1, further comprising, prior to the advancing of the distal end of the surrounding-sheath, advancing a guide member to the commissure, and wherein advancing the distal end of the surrounding-sheath comprises sliding the distal end of the surrounding-sheath around the guide member.
  • 7. The method according to claim 1, wherein helically implanting the anchor comprises positioning the anchor such that a wider end of the anchor is upstream of a narrower end of the anchor.
  • 8. The method according to claim 1, wherein helically implanting the anchor comprises positioning the anchor such that a curved portion of the anchor having a greater radius of curvature is upstream of a curved portion of the anchor having a smaller radius of curvature.
  • 9. The method according to claim 1, further comprising, subsequently to the extracting of the surrounding-sheath, advancing a guide wire through the transluminal sheath.
  • 10. The method according to claim 9, further comprising, subsequently to the advancing of the guide wire, advancing the prosthetic valve along the guide wire.
CROSS-REFERENCES TO RELATED APPLICATIONS

The present application is a Continuation of U.S. Ser. No. 15/691,032 to HaCohen et al., filed Aug. 30, 2017 (now U.S. Pat. No. 10,512,456), which is a Continuation of U.S. patent application Ser. No. 14/689,608 to HaCohen et al., filed Apr. 17, 2015 (now U.S. Pat. No. 9,763,657), which is a Continuation of U.S. patent application Ser. No. 13/811,308 to Gross et al. (now U.S. Pat. No. 9,017,399), which is the US National Phase of PCT application IL2011/000582 to Gross et al., filed Jul. 21, 2011, which published as WO 2012/011108, and which: (1) claims priority and is a continuation-in-part of: (a) U.S. Ser. No. 12/840,463 to Hacohen et al., filed Jul. 21, 2010, entitled “Guide wires with commissural anchors to advance a prosthetic valve” (now U.S. Pat. No. 9,132,009), and(b) U.S. Ser. No. 13/033,852 to Gross et al., filed Feb. 24, 2011, entitled “Techniques for percutaneous mitral valve replacement and sealing” (now U.S. Pat. No. 8,992,604), which is a continuation-in-part of U.S. Ser. No. 12/840,463, and(2) claims priority from U.S. Provisional Patent Application 61/492,449 to Gross et al., filed Jun. 2, 2011, and entitled “Techniques for percutaneous mitral valve replacement and sealing.”

US Referenced Citations (1094)
Number Name Date Kind
3874388 King et al. Apr 1975 A
4222126 Boretos et al. Sep 1980 A
4261342 Aranguren Guo Apr 1981 A
4340091 Skelton et al. Jul 1982 A
4423525 Vallana et al. Jan 1984 A
4853986 Allen Aug 1989 A
4892541 Alonso Jan 1990 A
4972494 White et al. Nov 1990 A
5108420 Marks Apr 1992 A
5201757 Heyn et al. Apr 1993 A
5314473 Godin May 1994 A
5405378 Strecker Apr 1995 A
5443500 Sigwart Aug 1995 A
5607444 Lam Mar 1997 A
5607470 Milo Mar 1997 A
5647857 Anderson et al. Jul 1997 A
5713948 Uflacker Feb 1998 A
5716417 Girard et al. Feb 1998 A
5741297 Simon Apr 1998 A
5765682 Bley et al. Jun 1998 A
5776140 Cottone Jul 1998 A
5868777 Lam Feb 1999 A
5873906 Lau et al. Feb 1999 A
5954766 Zadno-Azizi et al. Sep 1999 A
5957949 Leonhardt et al. Sep 1999 A
5980565 Jayaraman Nov 1999 A
6010530 Goicoechea Jan 2000 A
6019787 Richard et al. Feb 2000 A
6042607 Williamson, IV et al. Mar 2000 A
6074417 Peredo Jun 2000 A
6113612 Swanson et al. Sep 2000 A
6120534 Ruiz Sep 2000 A
6126686 Badylak et al. Oct 2000 A
6152937 Peterson et al. Nov 2000 A
6165183 Kuehn et al. Dec 2000 A
6165210 Lau et al. Dec 2000 A
6172898 Kajiyama Jan 2001 B1
6187020 Zegdi et al. Feb 2001 B1
6193745 Fogarty et al. Feb 2001 B1
6254609 Vrba et al. Jul 2001 B1
6264700 Kilcoyne et al. Jul 2001 B1
6287339 Vazquez et al. Sep 2001 B1
6312465 Griffin et al. Nov 2001 B1
6332893 Mortier et al. Dec 2001 B1
6334873 Lane et al. Jan 2002 B1
6346074 Roth Feb 2002 B1
6350278 Lenker et al. Feb 2002 B1
6352561 Leopold et al. Mar 2002 B1
6391036 Berg et al. May 2002 B1
6402780 Williamson, IV et al. Jun 2002 B2
6409755 Vrba Jun 2002 B1
6419696 Ortiz et al. Jul 2002 B1
6428550 Vargas et al. Aug 2002 B1
6440164 DiMatteo et al. Aug 2002 B1
6454799 Schreck Sep 2002 B1
6458153 Bailey et al. Oct 2002 B1
6511491 Grudem et al. Jan 2003 B2
6530952 Vesely Mar 2003 B2
6540782 Snyders Apr 2003 B1
6551350 Thornton et al. Apr 2003 B1
6558418 Inoue May 2003 B2
6569196 Vesely May 2003 B1
6602263 Swanson et al. Aug 2003 B1
6616675 Evard et al. Sep 2003 B1
6652556 VanTassel et al. Nov 2003 B1
6669724 Park et al. Dec 2003 B2
6682558 Tu et al. Jan 2004 B2
6699256 Logan et al. Mar 2004 B1
6716244 Klaco Apr 2004 B2
6719781 Kim Apr 2004 B1
6730118 Spenser et al. May 2004 B2
6730121 Ortiz et al. May 2004 B2
6733525 Yang et al. May 2004 B2
6752813 Goldfarb et al. Jun 2004 B2
6764518 Godin Jul 2004 B2
6767362 Schreck Jul 2004 B2
6797002 Spence et al. Sep 2004 B2
6821297 Snyders Nov 2004 B2
6830585 Artof et al. Dec 2004 B1
6830638 Boylan et al. Dec 2004 B2
6893460 Spenser et al. May 2005 B2
6926715 Hauck et al. Aug 2005 B1
6951571 Srivastava et al. Oct 2005 B1
6960217 Bolduc Nov 2005 B2
6964684 Ortiz et al. Nov 2005 B2
6974476 McGuckin, Jr. et al. Dec 2005 B2
7011681 Vesely Mar 2006 B2
7018406 Seguin et al. Mar 2006 B2
7041132 Quijano et al. May 2006 B2
7074236 Rabkin et al. Jul 2006 B2
7077861 Spence Jul 2006 B2
7101395 Tremulis et al. Sep 2006 B2
7101396 Artof et al. Sep 2006 B2
7137184 Schreck Nov 2006 B2
7172625 Shu et al. Feb 2007 B2
7198646 Figulla et al. Apr 2007 B2
7201772 Schwammenthal et al. Apr 2007 B2
7226467 Lucatero et al. Jun 2007 B2
7226477 Cox Jun 2007 B2
7261686 Couvillon, Jr. Aug 2007 B2
7288097 Séguin Oct 2007 B2
7288111 Holloway et al. Oct 2007 B1
7316716 Egan Jan 2008 B2
7318219 Hall Jan 2008 B2
7329279 Haug et al. Feb 2008 B2
7335213 Hyde et al. Feb 2008 B1
7351256 Hojeibane et al. Apr 2008 B2
7374573 Gabbay May 2008 B2
7377938 Sarac et al. May 2008 B2
7381218 Schreck Jun 2008 B2
7404824 Webler et al. Jul 2008 B1
7422603 Lane Sep 2008 B2
7429269 Schwammenthal et al. Sep 2008 B2
7442204 Schwammenthal et al. Oct 2008 B2
7445630 Lashinski et al. Nov 2008 B2
7455677 Vargas et al. Nov 2008 B2
7455688 Furst et al. Nov 2008 B2
7462162 Phan et al. Dec 2008 B2
7481838 Carpentier et al. Jan 2009 B2
7510575 Spenser et al. Mar 2009 B2
7513909 Lane et al. Apr 2009 B2
7524331 Birdsall Apr 2009 B2
7527646 Rahdert et al. May 2009 B2
7556632 Zadno Jul 2009 B2
7556646 Yang et al. Jul 2009 B2
7563267 Goldfarb et al. Jul 2009 B2
7563273 Goldfarb et al. Jul 2009 B2
7582111 Krolik et al. Sep 2009 B2
7585321 Cribier et al. Sep 2009 B2
7597711 Drews et al. Oct 2009 B2
7608091 Goldfarb et al. Oct 2009 B2
7611534 Kapadia et al. Nov 2009 B2
7621948 Hermann et al. Nov 2009 B2
7625403 Krivoruchko et al. Dec 2009 B2
7632302 Vreeman et al. Dec 2009 B2
7635329 Goldfarb et al. Dec 2009 B2
7648528 Styrc Jan 2010 B2
7655015 Goldfarb et al. Feb 2010 B2
7682380 Thornton et al. Mar 2010 B2
7708775 Rowe et al. May 2010 B2
7717952 Case et al. May 2010 B2
7717955 Lane et al. May 2010 B2
7731741 Eidenschink Jun 2010 B2
7736388 Goldfarb et al. Jun 2010 B2
7748389 Salahieh et al. Jul 2010 B2
7753922 Starksen Jul 2010 B2
7753949 Lamphere et al. Jul 2010 B2
7758595 Allen et al. Jul 2010 B2
7758632 Hojeibane et al. Jul 2010 B2
7758640 Vesely Jul 2010 B2
7771467 Svensson Aug 2010 B2
7771469 Liddicoat Aug 2010 B2
7776083 Vesely Aug 2010 B2
7780726 Seguin Aug 2010 B2
7799069 Bailey et al. Sep 2010 B2
7803181 Furst et al. Sep 2010 B2
7811296 Goldfarb et al. Oct 2010 B2
7811316 Kalmann et al. Oct 2010 B2
7824442 Salahieh et al. Nov 2010 B2
7837645 Bessler et al. Nov 2010 B2
7837727 Goetz et al. Nov 2010 B2
7842081 Yadin Nov 2010 B2
7850725 Vardi et al. Dec 2010 B2
7871432 Bergin Jan 2011 B2
7871436 Ryan et al. Jan 2011 B2
7887583 Macoviak Feb 2011 B2
7892281 Seguin et al. Feb 2011 B2
7896915 Guyenot et al. Mar 2011 B2
7914544 Nguyen et al. Mar 2011 B2
7914569 Nguyen et al. Mar 2011 B2
7927370 Webler et al. Apr 2011 B2
7942927 Kaye et al. May 2011 B2
7947072 Yang et al. May 2011 B2
7947075 Goetz et al. May 2011 B2
7951195 Antonsson et al. May 2011 B2
7955375 Agnew Jun 2011 B2
7955377 Melsheimer Jun 2011 B2
7955384 Rafiee et al. Jun 2011 B2
7959666 Salahieh et al. Jun 2011 B2
7959672 Salahieh et al. Jun 2011 B2
7967833 Sterman et al. Jun 2011 B2
7967857 Lane Jun 2011 B2
7981151 Rowe Jul 2011 B2
7981153 Fogarty et al. Jul 2011 B2
7992567 Hirotsuka et al. Aug 2011 B2
7993393 Carpentier et al. Aug 2011 B2
8002825 Letac et al. Aug 2011 B2
8002826 Seguin Aug 2011 B2
8016877 Seguin et al. Sep 2011 B2
8016882 Macoviak et al. Sep 2011 B2
8021420 Dolan Sep 2011 B2
8021421 Fogarty et al. Sep 2011 B2
8025695 Fogarty et al. Sep 2011 B2
8029518 Goldfarb et al. Oct 2011 B2
8029557 Sobrino-Serrano et al. Oct 2011 B2
8029564 Johnson et al. Oct 2011 B2
8034104 Carpentier et al. Oct 2011 B2
8038720 Wallace et al. Oct 2011 B2
8043360 McNamara et al. Oct 2011 B2
8048138 Sullivan et al. Nov 2011 B2
8048140 Purdy Nov 2011 B2
8048153 Salahieh et al. Nov 2011 B2
8052592 Goldfarb et al. Nov 2011 B2
8052741 Bruszewski et al. Nov 2011 B2
8052749 Salahieh et al. Nov 2011 B2
8057493 Goldfarb et al. Nov 2011 B2
8057532 Hoffman Nov 2011 B2
8057540 Letac et al. Nov 2011 B2
8062355 Figulla et al. Nov 2011 B2
8062359 Marquez et al. Nov 2011 B2
8070708 Rottenberg et al. Dec 2011 B2
8070800 Lock et al. Dec 2011 B2
8070802 Lamphere et al. Dec 2011 B2
8070804 Hyde et al. Dec 2011 B2
8075611 Millwee et al. Dec 2011 B2
8080054 Rowe Dec 2011 B2
8083793 Lane et al. Dec 2011 B2
D652927 Braido et al. Jan 2012 S
D653341 Braido et al. Jan 2012 S
8092518 Schreck Jan 2012 B2
8092520 Quadri Jan 2012 B2
8092521 Figulla et al. Jan 2012 B2
8105377 Liddicoat Jan 2012 B2
8109996 Stacchino et al. Feb 2012 B2
8118866 Hermann et al. Feb 2012 B2
8133270 Kheradvar et al. Mar 2012 B2
8136218 Millwee et al. Mar 2012 B2
8137398 Tuval et al. Mar 2012 B2
8142492 Forster et al. Mar 2012 B2
8142494 Rahdert et al. Mar 2012 B2
8142496 Berreklouw Mar 2012 B2
8142497 Friedman Mar 2012 B2
8147504 Ino et al. Apr 2012 B2
8157852 Bloom et al. Apr 2012 B2
8157853 Laske et al. Apr 2012 B2
8157860 McNamara et al. Apr 2012 B2
8163008 Wilson et al. Apr 2012 B2
8163014 Lane et al. Apr 2012 B2
D660433 Braido et al. May 2012 S
D660967 Braido et al. May 2012 S
8167894 Miles et al. May 2012 B2
8167932 Bourang et al. May 2012 B2
8167935 McGuckin, Jr. et al. May 2012 B2
8172896 McNamara et al. May 2012 B2
8177836 Lee et al. May 2012 B2
8182528 Salahieh et al. May 2012 B2
8211169 Lane et al. Jul 2012 B2
8216256 Raschdorf, Jr. et al. Jul 2012 B2
8216301 Bonhoeffer et al. Jul 2012 B2
8221492 Case et al. Jul 2012 B2
8221493 Boyle et al. Jul 2012 B2
8226710 Nguyen et al. Jul 2012 B2
8231670 Salahieh et al. Jul 2012 B2
8236045 Benichou et al. Aug 2012 B2
8236049 Rowe et al. Aug 2012 B2
8252042 McNamara et al. Aug 2012 B2
8252051 Chau et al. Aug 2012 B2
8252052 Salahieh et al. Aug 2012 B2
8257390 Carley et al. Sep 2012 B2
8267988 Hamer et al. Sep 2012 B2
8277501 Chalekian et al. Oct 2012 B2
8287591 Keidar et al. Oct 2012 B2
8298280 Yadin et al. Oct 2012 B2
8303653 Bonhoeffer et al. Nov 2012 B2
8308798 Pintor et al. Nov 2012 B2
8317853 Agnew Nov 2012 B2
8317855 Gregorich et al. Nov 2012 B2
8323335 Rowe et al. Dec 2012 B2
8328868 Paul et al. Dec 2012 B2
8337541 Quadri et al. Dec 2012 B2
8343174 Goldfarb et al. Jan 2013 B2
8343213 Salahieh et al. Jan 2013 B2
8348999 Kheradvar et al. Jan 2013 B2
8366767 Zhang Feb 2013 B2
8372140 Hoffman et al. Feb 2013 B2
8377119 Drews et al. Feb 2013 B2
8398708 Meiri et al. Mar 2013 B2
8403981 Forster et al. Mar 2013 B2
8403983 Quadri et al. Mar 2013 B2
8408214 Spenser Apr 2013 B2
8414644 Quadri et al. Apr 2013 B2
8425593 Braido et al. Apr 2013 B2
8430934 Das Apr 2013 B2
8444689 Zhang May 2013 B2
8449599 Chau et al. May 2013 B2
8449625 Campbell et al. May 2013 B2
8454686 Alkhatib Jun 2013 B2
8460365 Haverkost et al. Jun 2013 B2
8474460 Barrett et al. Jul 2013 B2
8500821 Sobrino-Serrano et al. Aug 2013 B2
8512400 Tran et al. Aug 2013 B2
8539662 Stacchino et al. Sep 2013 B2
8545544 Spenser et al. Oct 2013 B2
8551160 Figulla et al. Oct 2013 B2
8551161 Dolan Oct 2013 B2
8562672 Bonhoeffer et al. Oct 2013 B2
8568475 Nguyen et al. Oct 2013 B2
8579964 Lane et al. Nov 2013 B2
8579965 Bonhoeffer et al. Nov 2013 B2
8585755 Chau et al. Nov 2013 B2
8585756 Bonhoeffer et al. Nov 2013 B2
8591460 Wilson et al. Nov 2013 B2
8591570 Revuelta et al. Nov 2013 B2
8623075 Murray, III et al. Jan 2014 B2
8623080 Fogarty et al. Jan 2014 B2
8628569 Benichou et al. Jan 2014 B2
8628570 Seguin Jan 2014 B2
8628571 Hacohen et al. Jan 2014 B1
8652203 Quadri et al. Feb 2014 B2
8652204 Quill et al. Feb 2014 B2
8657872 Seguin Feb 2014 B2
8663322 Keranen Mar 2014 B2
8673020 Sobrino-Serrano et al. Mar 2014 B2
8679174 Ottma et al. Mar 2014 B2
8685086 Navia et al. Apr 2014 B2
8696742 Pintor et al. Apr 2014 B2
8728155 Montorfano et al. May 2014 B2
8734507 Keranen May 2014 B2
8747460 Tuval et al. Jun 2014 B2
8771345 Tuval et al. Jul 2014 B2
8784472 Eidenschink Jul 2014 B2
8784479 Tuval et al. Jul 2014 B2
8784481 Alkhatib et al. Jul 2014 B2
8795355 Alkhatib Aug 2014 B2
8795356 Quadri et al. Aug 2014 B2
8795357 Yohanan et al. Aug 2014 B2
8801776 House et al. Aug 2014 B2
8808366 Braido et al. Aug 2014 B2
8840663 Salahieh et al. Sep 2014 B2
8840664 Karapetian et al. Sep 2014 B2
8845722 Gabbay Sep 2014 B2
8852261 White Oct 2014 B2
8852272 Gross et al. Oct 2014 B2
8870948 Erzberger et al. Oct 2014 B1
8870949 Rowe Oct 2014 B2
8870950 Hacohen Oct 2014 B2
8876800 Behan Nov 2014 B2
8894702 Quadri et al. Nov 2014 B2
8900294 Paniagua et al. Dec 2014 B2
8900295 Migliazza et al. Dec 2014 B2
8906083 Obermiller et al. Dec 2014 B2
8911455 Quadri et al. Dec 2014 B2
8911489 Ben-Muvhar Dec 2014 B2
8911493 Rowe et al. Dec 2014 B2
8932343 Alkhatib et al. Jan 2015 B2
8961595 Alkhatib Feb 2015 B2
8979922 Jayasinghe et al. Mar 2015 B2
8986370 Annest Mar 2015 B2
8986373 Chau et al. Mar 2015 B2
8986375 Garde et al. Mar 2015 B2
8992599 Thubrikar et al. Mar 2015 B2
8992604 Gross et al. Mar 2015 B2
8998982 Richter et al. Apr 2015 B2
9005273 Salahieh et al. Apr 2015 B2
9011468 Ketai et al. Apr 2015 B2
9011527 Li et al. Apr 2015 B2
9017399 Gross et al. Apr 2015 B2
D730520 Braido et al. May 2015 S
D730521 Braido et al. May 2015 S
9023100 Quadri et al. May 2015 B2
9034032 McLean et al. May 2015 B2
9034033 McLean et al. May 2015 B2
9039757 McLean et al. May 2015 B2
D732666 Nguyen et al. Jun 2015 S
9048676 Tsuji et al. Jun 2015 B2
9050188 Schweich, Jr. et al. Jun 2015 B2
9060858 Thornton et al. Jun 2015 B2
9072603 Tuval et al. Jul 2015 B2
9095434 Rowe Aug 2015 B2
9119719 Zipory et al. Sep 2015 B2
9125738 Figulla et al. Sep 2015 B2
9125740 Morriss et al. Sep 2015 B2
9132006 Spenser et al. Sep 2015 B2
9132009 Hacohen et al. Sep 2015 B2
9138312 Tuval et al. Sep 2015 B2
9155619 Liu et al. Oct 2015 B2
9173659 Bodewadt et al. Nov 2015 B2
9173738 Murray, III et al. Nov 2015 B2
9220594 Braido et al. Dec 2015 B2
9226820 Braido et al. Jan 2016 B2
9226839 Kariniemi et al. Jan 2016 B1
9232995 Kovalsky et al. Jan 2016 B2
9241790 Lane et al. Jan 2016 B2
9241791 Braido et al. Jan 2016 B2
9241792 Benichou et al. Jan 2016 B2
9241794 Braido et al. Jan 2016 B2
9248014 Lane et al. Feb 2016 B2
9277994 Miller et al. Mar 2016 B2
9289290 Alkhatib et al. Mar 2016 B2
9289291 Gorman, III et al. Mar 2016 B2
9295550 Nguyen et al. Mar 2016 B2
9295551 Straubinger et al. Mar 2016 B2
9295552 McLean et al. Mar 2016 B2
9301836 Buchbinder et al. Apr 2016 B2
9320591 Bolduc Apr 2016 B2
D755384 Pesce et al. May 2016 S
9326852 Spenser May 2016 B2
9326876 Acosta et al. May 2016 B2
9345573 Nyuli et al. May 2016 B2
9387078 Gross et al. Jul 2016 B2
9393110 Levi et al. Jul 2016 B2
9421098 Gifford, III et al. Aug 2016 B2
9427303 Liddy et al. Aug 2016 B2
9427316 Schweich, Jr. et al. Aug 2016 B2
9439757 Wallace et al. Sep 2016 B2
9463102 Kelly Oct 2016 B2
9474599 Keranen Oct 2016 B2
9474638 Robinson et al. Oct 2016 B2
9480559 Vidlund et al. Nov 2016 B2
9492273 Wallace et al. Nov 2016 B2
9498314 Behan Nov 2016 B2
9532870 Cooper et al. Jan 2017 B2
9554897 Lane et al. Jan 2017 B2
9554899 Granada et al. Jan 2017 B2
9561103 Granada et al. Feb 2017 B2
9566152 Schweich, Jr. et al. Feb 2017 B2
9597182 Straubinger et al. Mar 2017 B2
9629716 Seguin Apr 2017 B2
9662203 Sheahan et al. May 2017 B2
9681952 Hacohen Jun 2017 B2
9717591 Chau et al. Aug 2017 B2
9743932 Amplatz et al. Aug 2017 B2
9763657 Hacohen et al. Sep 2017 B2
9763817 Roeder Sep 2017 B2
9770256 Cohen et al. Sep 2017 B2
D800908 Hariton et al. Oct 2017 S
9788941 Hacohen Oct 2017 B2
9895226 Harari et al. Feb 2018 B1
9987132 Hariton et al. Jun 2018 B1
10010414 Cooper et al. Jul 2018 B2
10076415 Metchik et al. Sep 2018 B1
10105222 Metchik et al. Oct 2018 B1
10111751 Metchik et al. Oct 2018 B1
10123873 Metchik et al. Nov 2018 B1
10130475 Metchik et al. Nov 2018 B1
10136993 Metchik et al. Nov 2018 B1
10143552 Wallace et al. Dec 2018 B2
10149761 Granada et al. Dec 2018 B2
10154906 Granada et al. Dec 2018 B2
10159570 Metchik et al. Dec 2018 B1
10182908 Tubishevitz et al. Jan 2019 B2
10226341 Gross et al. Mar 2019 B2
10231837 Metchik et al. Mar 2019 B1
10238493 Metchik et al. Mar 2019 B1
10245143 Gross et al. Apr 2019 B2
10245144 Metchik et al. Apr 2019 B1
10258471 Lutter et al. Apr 2019 B2
10292816 Raanani et al. May 2019 B2
10299927 McLean et al. May 2019 B2
10321995 Christianson et al. Jun 2019 B1
10322020 Lam et al. Jun 2019 B2
10327895 Lozonschi et al. Jun 2019 B2
10335278 McLean et al. Jul 2019 B2
10376361 Gross et al. Aug 2019 B2
10507108 Delgado et al. Dec 2019 B2
10507109 Metchik et al. Dec 2019 B2
10512456 Hacohen et al. Dec 2019 B2
10517719 Miller et al. Dec 2019 B2
10524792 Hemandez et al. Jan 2020 B2
10531866 Hariton et al. Jan 2020 B2
10531872 Hacohen et al. Jan 2020 B2
10548731 Lashinski et al. Feb 2020 B2
10575948 Iamberger et al. Mar 2020 B2
10595992 Chambers Mar 2020 B2
10595997 Metchik et al. Mar 2020 B2
10610358 Vidlund et al. Apr 2020 B2
10646342 Marr et al. May 2020 B1
10702385 Hacohen et al. Jul 2020 B2
10758342 Chau et al. Sep 2020 B2
10813760 Metchik et al. Oct 2020 B2
10820998 Marr et al. Nov 2020 B2
10842627 Delgado et al. Nov 2020 B2
10856975 Hariton et al. Dec 2020 B2
10856978 Straubinger et al. Dec 2020 B2
10874514 Dixon et al. Dec 2020 B2
10888425 Delgado et al. Jan 2021 B2
10888644 Ratz et al. Jan 2021 B2
10905552 Dixon et al. Feb 2021 B2
10905554 Cao Feb 2021 B2
10918483 Metchik et al. Feb 2021 B2
10925732 Delgado et al. Feb 2021 B2
10945843 Delgado et al. Mar 2021 B2
10945844 McCann et al. Mar 2021 B2
10993809 McCann et al. May 2021 B2
11065114 Raanani et al. Jul 2021 B2
11083582 McCann et al. Aug 2021 B2
11147672 McCann et al. Oct 2021 B2
11179240 Delgado et al. Nov 2021 B2
11291545 Hacohen Apr 2022 B2
11291546 Gross et al. Apr 2022 B2
11291547 Gross et al. Apr 2022 B2
20010002445 Vesely May 2001 A1
20010005787 Oz et al. Jun 2001 A1
20010021872 Bailey et al. Sep 2001 A1
20010056295 Solem Dec 2001 A1
20020013571 Goldfarb et al. Jan 2002 A1
20020032481 Gabbay Mar 2002 A1
20020099436 Thornton et al. Jul 2002 A1
20020151970 Garrison et al. Oct 2002 A1
20020177894 Acosta et al. Nov 2002 A1
20030036791 Philipp et al. Feb 2003 A1
20030050694 Yang et al. Mar 2003 A1
20030060875 Wittens Mar 2003 A1
20030069635 Cartledge et al. Apr 2003 A1
20030074052 Besselink Apr 2003 A1
20030083742 Spence et al. May 2003 A1
20030105519 Fasol et al. Jun 2003 A1
20030158578 Pantages et al. Aug 2003 A1
20040010272 Manetakis et al. Jan 2004 A1
20040030382 St. Goar et al. Feb 2004 A1
20040039414 Carley et al. Feb 2004 A1
20040093060 Seguin et al. May 2004 A1
20040122503 Campbell et al. Jun 2004 A1
20040122514 Fogarty et al. Jun 2004 A1
20040133267 Lane Jul 2004 A1
20040143315 Bruun et al. Jul 2004 A1
20040176839 Huynh et al. Sep 2004 A1
20040186558 Pavcnik et al. Sep 2004 A1
20040186565 Schreck Sep 2004 A1
20040186566 Hindrichs et al. Sep 2004 A1
20040210244 Vargas et al. Oct 2004 A1
20040210304 Seguin et al. Oct 2004 A1
20040220593 Greenhalgh Nov 2004 A1
20040225354 Allen et al. Nov 2004 A1
20040236354 Seguin Nov 2004 A1
20040249433 Freitag Dec 2004 A1
20040260389 Case et al. Dec 2004 A1
20040260394 Douk et al. Dec 2004 A1
20050004668 Aklog et al. Jan 2005 A1
20050021056 St. Goar et al. Jan 2005 A1
20050027305 Shiu et al. Feb 2005 A1
20050027348 Case et al. Feb 2005 A1
20050038494 Eidenschink Feb 2005 A1
20050055086 Stobie Mar 2005 A1
20050075731 Artof et al. Apr 2005 A1
20050080430 Wright, Jr. et al. Apr 2005 A1
20050080474 Andreas et al. Apr 2005 A1
20050085900 Case et al. Apr 2005 A1
20050137686 Salahieh et al. Jun 2005 A1
20050137688 Salahieh et al. Jun 2005 A1
20050137689 Salahieh et al. Jun 2005 A1
20050137690 Salahieh et al. Jun 2005 A1
20050137691 Salahieh et al. Jun 2005 A1
20050137692 Haug et al. Jun 2005 A1
20050137695 Salahieh et al. Jun 2005 A1
20050137697 Salahieh et al. Jun 2005 A1
20050143809 Salahieh et al. Jun 2005 A1
20050154443 Linder et al. Jul 2005 A1
20050182486 Gabbay Aug 2005 A1
20050197695 Stacchino et al. Sep 2005 A1
20050203549 Realyvasquez Sep 2005 A1
20050203618 Sharkawy et al. Sep 2005 A1
20050216079 MaCoviak Sep 2005 A1
20050234508 Cummins et al. Oct 2005 A1
20050240200 Bergheim Oct 2005 A1
20050251251 Cribier Nov 2005 A1
20050256566 Gabbay Nov 2005 A1
20050267573 Macoviak et al. Dec 2005 A9
20060004439 Spenser et al. Jan 2006 A1
20060004469 Sokel Jan 2006 A1
20060015171 Armstrong Jan 2006 A1
20060020275 Goldfarb et al. Jan 2006 A1
20060020327 Lashinski et al. Jan 2006 A1
20060020333 Lashinski Jan 2006 A1
20060041189 Vancaillie Feb 2006 A1
20060047297 Case Mar 2006 A1
20060052867 Revuelta et al. Mar 2006 A1
20060089627 Burnett et al. Apr 2006 A1
20060111773 Rittgers et al. May 2006 A1
20060116750 Hebert et al. Jun 2006 A1
20060135964 Vesely Jun 2006 A1
20060155357 Melsheimer Jul 2006 A1
20060178700 Quinn Aug 2006 A1
20060178740 Stacchino et al. Aug 2006 A1
20060184203 Martin et al. Aug 2006 A1
20060190036 Wendel et al. Aug 2006 A1
20060190038 Carley et al. Aug 2006 A1
20060195183 Navia et al. Aug 2006 A1
20060195184 Lane et al. Aug 2006 A1
20060201519 Frazier et al. Sep 2006 A1
20060212111 Case et al. Sep 2006 A1
20060216404 Seyler et al. Sep 2006 A1
20060229708 Powell et al. Oct 2006 A1
20060241656 Starksen et al. Oct 2006 A1
20060241745 Solem Oct 2006 A1
20060241748 Lee et al. Oct 2006 A1
20060247680 Amplatz et al. Nov 2006 A1
20060253191 Salahieh et al. Nov 2006 A1
20060259136 Nguyen et al. Nov 2006 A1
20060259137 Artof et al. Nov 2006 A1
20060271166 Thill et al. Nov 2006 A1
20060271171 McQuinn et al. Nov 2006 A1
20060282150 Olson et al. Dec 2006 A1
20060287719 Rowe et al. Dec 2006 A1
20070016286 Herrmann et al. Jan 2007 A1
20070016288 Gurskis et al. Jan 2007 A1
20070027528 Agnew Feb 2007 A1
20070027549 Godin Feb 2007 A1
20070038293 St. Goar et al. Feb 2007 A1
20070038295 Case et al. Feb 2007 A1
20070043435 Seguin Feb 2007 A1
20070055340 Pryor Mar 2007 A1
20070056346 Spenser et al. Mar 2007 A1
20070078510 Ryan Apr 2007 A1
20070112422 Dehdashtian May 2007 A1
20070118141 Davidson May 2007 A1
20070162103 Case et al. Jul 2007 A1
20070162107 Haug et al. Jul 2007 A1
20070162111 Fukamachi et al. Jul 2007 A1
20070173932 Cali et al. Jul 2007 A1
20070197858 Goldfarb et al. Aug 2007 A1
20070198077 Cully et al. Aug 2007 A1
20070198097 Zegdi Aug 2007 A1
20070213810 Newhauser et al. Sep 2007 A1
20070213813 Von Segesser et al. Sep 2007 A1
20070219630 Chu Sep 2007 A1
20070225759 Thommen et al. Sep 2007 A1
20070225760 Moszner et al. Sep 2007 A1
20070233186 Meng Oct 2007 A1
20070233237 Krivoruchko Oct 2007 A1
20070239272 Navia et al. Oct 2007 A1
20070239273 Allen Oct 2007 A1
20070244546 Francis Oct 2007 A1
20070255400 Parravicini et al. Nov 2007 A1
20080004688 Spenser et al. Jan 2008 A1
20080004697 Lichtenstein et al. Jan 2008 A1
20080051703 Thornton et al. Feb 2008 A1
20080065204 Macoviak et al. Mar 2008 A1
20080071361 Tuval et al. Mar 2008 A1
20080071363 Tuval et al. Mar 2008 A1
20080071366 Tuval Mar 2008 A1
20080071369 Tuval et al. Mar 2008 A1
20080077235 Kirson Mar 2008 A1
20080082083 Forde et al. Apr 2008 A1
20080082159 Tseng et al. Apr 2008 A1
20080082166 Styrc et al. Apr 2008 A1
20080086164 Rowe Apr 2008 A1
20080086204 Rankin Apr 2008 A1
20080091261 Long et al. Apr 2008 A1
20080097595 Gabbay Apr 2008 A1
20080132989 Snow et al. Jun 2008 A1
20080140003 Bei et al. Jun 2008 A1
20080147182 Righini et al. Jun 2008 A1
20080161910 Revuelta et al. Jul 2008 A1
20080167705 Agnew Jul 2008 A1
20080167714 St. Goar et al. Jul 2008 A1
20080188929 Schreck Aug 2008 A1
20080195200 Vidlund et al. Aug 2008 A1
20080200980 Robin et al. Aug 2008 A1
20080208328 Antocci et al. Aug 2008 A1
20080208332 Lamphere et al. Aug 2008 A1
20080221672 Lamphere et al. Sep 2008 A1
20080234814 Salahieh et al. Sep 2008 A1
20080243245 Thambar et al. Oct 2008 A1
20080255580 Hoffman et al. Oct 2008 A1
20080262609 Gross et al. Oct 2008 A1
20080269879 Sathe et al. Oct 2008 A1
20080281411 Berreklouw Nov 2008 A1
20080294234 Hartley et al. Nov 2008 A1
20090005863 Goetz et al. Jan 2009 A1
20090036966 O'Connor et al. Feb 2009 A1
20090054969 Salahieh et al. Feb 2009 A1
20090082844 Zacharias et al. Mar 2009 A1
20090088836 Bishop et al. Apr 2009 A1
20090099554 Forster et al. Apr 2009 A1
20090099650 Bolduc et al. Apr 2009 A1
20090112159 Slattery et al. Apr 2009 A1
20090125098 Chuter May 2009 A1
20090157175 Benichou Jun 2009 A1
20090163934 Raschdorf, Jr. et al. Jun 2009 A1
20090171363 Chocron Jul 2009 A1
20090177278 Spence Jul 2009 A1
20090210052 Forster et al. Aug 2009 A1
20090222081 Linder et al. Sep 2009 A1
20090240320 Tuval et al. Sep 2009 A1
20090241656 Jacquemin Oct 2009 A1
20090259306 Rowe Oct 2009 A1
20090264859 Mas Oct 2009 A1
20090264994 Saadat Oct 2009 A1
20090276040 Rowe et al. Nov 2009 A1
20090281619 Le et al. Nov 2009 A1
20090287304 Dahlgren et al. Nov 2009 A1
20090299449 Styrc Dec 2009 A1
20090306768 Quadri et al. Dec 2009 A1
20090319037 Rowe et al. Dec 2009 A1
20100022823 Goldfarb et al. Jan 2010 A1
20100023117 Yoganathan et al. Jan 2010 A1
20100023120 Holecek et al. Jan 2010 A1
20100036479 Hill et al. Feb 2010 A1
20100049313 Alon et al. Feb 2010 A1
20100069852 Kelley Mar 2010 A1
20100076548 Konno Mar 2010 A1
20100100167 Bortlein et al. Apr 2010 A1
20100114299 Ben Muvhar et al. May 2010 A1
20100131054 Tuval et al. May 2010 A1
20100137979 Tuval et al. Jun 2010 A1
20100160958 Clark Jun 2010 A1
20100161036 Pintor et al. Jun 2010 A1
20100161042 Maisano et al. Jun 2010 A1
20100174363 Castro Jul 2010 A1
20100179643 Shalev Jul 2010 A1
20100179648 Richter et al. Jul 2010 A1
20100179649 Richter et al. Jul 2010 A1
20100217382 Chau et al. Aug 2010 A1
20100222810 DeBeer et al. Sep 2010 A1
20100228285 Miles et al. Sep 2010 A1
20100234940 Dolan Sep 2010 A1
20100249908 Chau et al. Sep 2010 A1
20100249917 Zhang Sep 2010 A1
20100256737 Pollock et al. Oct 2010 A1
20100262232 Annest Oct 2010 A1
20100280603 Maisano et al. Nov 2010 A1
20100280606 Naor Nov 2010 A1
20100312333 Navia et al. Dec 2010 A1
20100324595 Linder et al. Dec 2010 A1
20100331971 Keranen Dec 2010 A1
20110004227 Goldfarb et al. Jan 2011 A1
20110004296 Lutter et al. Jan 2011 A1
20110004299 Navia et al. Jan 2011 A1
20110015729 Carpentier et al. Jan 2011 A1
20110021985 Spargias Jan 2011 A1
20110022165 Oba et al. Jan 2011 A1
20110029072 Gabbay Feb 2011 A1
20110040374 Goetz et al. Feb 2011 A1
20110040375 Letac et al. Feb 2011 A1
20110046662 Moszner et al. Feb 2011 A1
20110054466 Rothstein et al. Mar 2011 A1
20110054596 Taylor Mar 2011 A1
20110054598 Johnson Mar 2011 A1
20110066233 Thornton et al. Mar 2011 A1
20110071626 Wright et al. Mar 2011 A1
20110077730 Fenster Mar 2011 A1
20110082538 Dahlgren et al. Apr 2011 A1
20110087322 Letac et al. Apr 2011 A1
20110093063 Schreck Apr 2011 A1
20110098525 Kermode et al. Apr 2011 A1
20110106247 Miller et al. May 2011 A1
20110112625 Ben-Muvhar et al. May 2011 A1
20110112632 Chau et al. May 2011 A1
20110118830 Liddicoat et al. May 2011 A1
20110125257 Seguin et al. May 2011 A1
20110125258 Centola May 2011 A1
20110137326 Bachman Jun 2011 A1
20110137397 Chau Jun 2011 A1
20110137409 Yang et al. Jun 2011 A1
20110137410 Hacohen Jun 2011 A1
20110144742 Madrid et al. Jun 2011 A1
20110166636 Rowe Jul 2011 A1
20110172784 Richter et al. Jul 2011 A1
20110178597 Navia et al. Jul 2011 A9
20110184510 Maisano et al. Jul 2011 A1
20110190877 Lane et al. Aug 2011 A1
20110190879 Bobo et al. Aug 2011 A1
20110202076 Richter Aug 2011 A1
20110208283 Rust Aug 2011 A1
20110208293 Tabor Aug 2011 A1
20110208298 Tuval et al. Aug 2011 A1
20110213459 Garrison et al. Sep 2011 A1
20110213461 Seguin et al. Sep 2011 A1
20110218619 Benichou et al. Sep 2011 A1
20110218620 Meiri et al. Sep 2011 A1
20110224785 Hacohen Sep 2011 A1
20110238159 Guyenot et al. Sep 2011 A1
20110245911 Quill et al. Oct 2011 A1
20110245917 Savage et al. Oct 2011 A1
20110251675 Dwork Oct 2011 A1
20110251676 Sweeney et al. Oct 2011 A1
20110251678 Eidenschink et al. Oct 2011 A1
20110251679 Wiemeyer et al. Oct 2011 A1
20110251680 Tran et al. Oct 2011 A1
20110251682 Murray, III et al. Oct 2011 A1
20110251683 Tabor Oct 2011 A1
20110257721 Tabor Oct 2011 A1
20110257729 Spenser et al. Oct 2011 A1
20110257736 Marquez et al. Oct 2011 A1
20110257737 Fogarty et al. Oct 2011 A1
20110264191 Rothstein Oct 2011 A1
20110264196 Savage et al. Oct 2011 A1
20110264198 Murray, III et al. Oct 2011 A1
20110264199 Tran et al. Oct 2011 A1
20110264200 Tran et al. Oct 2011 A1
20110264201 Yeung et al. Oct 2011 A1
20110264202 Murray, III et al. Oct 2011 A1
20110264203 Dwork et al. Oct 2011 A1
20110264206 Tabor Oct 2011 A1
20110264208 Duffy et al. Oct 2011 A1
20110270276 Rothstein et al. Nov 2011 A1
20110271967 Mortier et al. Nov 2011 A1
20110282438 Drews et al. Nov 2011 A1
20110282439 Thill et al. Nov 2011 A1
20110282440 Cao et al. Nov 2011 A1
20110283514 Fogarty et al. Nov 2011 A1
20110288632 White Nov 2011 A1
20110288634 Tuval et al. Nov 2011 A1
20110295354 Bueche et al. Dec 2011 A1
20110295363 Girard et al. Dec 2011 A1
20110301688 Dolan Dec 2011 A1
20110301701 Padala et al. Dec 2011 A1
20110301702 Rust et al. Dec 2011 A1
20110306916 Nitzan et al. Dec 2011 A1
20110307049 Kao Dec 2011 A1
20110313452 Carley et al. Dec 2011 A1
20110313515 Quadri et al. Dec 2011 A1
20110319989 Lane et al. Dec 2011 A1
20110319991 Hariton et al. Dec 2011 A1
20120010694 Lutter et al. Jan 2012 A1
20120016468 Robin et al. Jan 2012 A1
20120022629 Perera et al. Jan 2012 A1
20120022633 Olson et al. Jan 2012 A1
20120022637 Ben-Muvhar Jan 2012 A1
20120022639 Hacohen et al. Jan 2012 A1
20120022640 Gross et al. Jan 2012 A1
20120035703 Lutter et al. Feb 2012 A1
20120035713 Lutter et al. Feb 2012 A1
20120035722 Tuval Feb 2012 A1
20120041547 Duffy et al. Feb 2012 A1
20120041551 Spenser et al. Feb 2012 A1
20120046738 Lau et al. Feb 2012 A1
20120046742 Tuval et al. Feb 2012 A1
20120053676 Ku et al. Mar 2012 A1
20120053682 Kovalsky et al. Mar 2012 A1
20120053688 Fogarty et al. Mar 2012 A1
20120059454 Millwee et al. Mar 2012 A1
20120059458 Buchbinder et al. Mar 2012 A1
20120065464 Ellis et al. Mar 2012 A1
20120078237 Wang et al. Mar 2012 A1
20120078353 Quadri et al. Mar 2012 A1
20120078357 Conklin Mar 2012 A1
20120083832 Delaloye et al. Apr 2012 A1
20120083839 Letac et al. Apr 2012 A1
20120083879 Eberhardt et al. Apr 2012 A1
20120089223 Nguyen et al. Apr 2012 A1
20120101570 Tuval et al. Apr 2012 A1
20120101571 Thambar et al. Apr 2012 A1
20120101572 Kovalsky et al. Apr 2012 A1
20120123511 Brown May 2012 A1
20120123530 Carpentier et al. May 2012 A1
20120130473 Norris et al. May 2012 A1
20120130474 Buckley May 2012 A1
20120130475 Shaw May 2012 A1
20120136434 Carpentier et al. May 2012 A1
20120150218 Sandgren et al. Jun 2012 A1
20120165915 Melsheimer et al. Jun 2012 A1
20120165930 Gifford, III et al. Jun 2012 A1
20120179244 Schankereli et al. Jul 2012 A1
20120197292 Chin-Chen et al. Aug 2012 A1
20120283824 Lutter et al. Nov 2012 A1
20120290062 McNamara et al. Nov 2012 A1
20120296360 Norris et al. Nov 2012 A1
20120296418 Bonyuet et al. Nov 2012 A1
20120300063 Majkrzak et al. Nov 2012 A1
20120310328 Olson et al. Dec 2012 A1
20120323316 Chau et al. Dec 2012 A1
20120330408 Hillukkia et al. Dec 2012 A1
20130006347 McHugo Jan 2013 A1
20130018450 Hunt Jan 2013 A1
20130018458 Yohanan et al. Jan 2013 A1
20130030519 Tran et al. Jan 2013 A1
20130035759 Gross et al. Feb 2013 A1
20130041451 Patterson et al. Feb 2013 A1
20130046373 Cartledge et al. Feb 2013 A1
20130066341 Ketai et al. Mar 2013 A1
20130066342 Dell et al. Mar 2013 A1
20130079872 Gallagher Mar 2013 A1
20130116780 Miller et al. May 2013 A1
20130123896 Bloss et al. May 2013 A1
20130123900 Eblacas et al. May 2013 A1
20130150945 Crawford et al. Jun 2013 A1
20130150956 Yohanan et al. Jun 2013 A1
20130158647 Norris et al. Jun 2013 A1
20130166017 Cartledge et al. Jun 2013 A1
20130166022 Conklin Jun 2013 A1
20130172978 Vidlund et al. Jul 2013 A1
20130172992 Gross et al. Jul 2013 A1
20130178930 Straubinger et al. Jul 2013 A1
20130190861 Chau et al. Jul 2013 A1
20130211501 Buckley et al. Aug 2013 A1
20130245742 Norris Sep 2013 A1
20130253643 Rolando et al. Sep 2013 A1
20130261737 Costello Oct 2013 A1
20130261738 Clague et al. Oct 2013 A1
20130274870 Lombardi et al. Oct 2013 A1
20130282059 Ketai et al. Oct 2013 A1
20130289711 Liddy et al. Oct 2013 A1
20130289740 Liddy et al. Oct 2013 A1
20130297013 Klima et al. Nov 2013 A1
20130304197 Buchbinder et al. Nov 2013 A1
20130304200 McLean et al. Nov 2013 A1
20130310928 Morriss et al. Nov 2013 A1
20130325114 McLean et al. Dec 2013 A1
20130331929 Mitra et al. Dec 2013 A1
20140000112 Braido et al. Jan 2014 A1
20140005778 Buchbinder et al. Jan 2014 A1
20140018911 Zhou et al. Jan 2014 A1
20140018915 Biadillah et al. Jan 2014 A1
20140031928 Murphy et al. Jan 2014 A1
20140046430 Shaw Feb 2014 A1
20140052237 Lane et al. Feb 2014 A1
20140067050 Costello et al. Mar 2014 A1
20140067054 Chau et al. Mar 2014 A1
20140081376 Burkart et al. Mar 2014 A1
20140106951 Brandon Apr 2014 A1
20140120287 Jacoby et al. May 2014 A1
20140121749 Roeder May 2014 A1
20140121763 Duffy et al. May 2014 A1
20140135894 Norris et al. May 2014 A1
20140135895 Andress et al. May 2014 A1
20140142681 Norris May 2014 A1
20140142688 Duffy et al. May 2014 A1
20140148891 Johnson May 2014 A1
20140163690 White Jun 2014 A1
20140172069 Roeder et al. Jun 2014 A1
20140172077 Bruchman et al. Jun 2014 A1
20140172082 Bruchman et al. Jun 2014 A1
20140188210 Beard et al. Jul 2014 A1
20140188221 Chung et al. Jul 2014 A1
20140194981 Menk et al. Jul 2014 A1
20140194983 Kovalsky et al. Jul 2014 A1
20140207231 Hacohen et al. Jul 2014 A1
20140214157 Bortlein et al. Jul 2014 A1
20140214159 Vidlund et al. Jul 2014 A1
20140222136 Geist et al. Aug 2014 A1
20140222142 Kovalsky et al. Aug 2014 A1
20140236287 Clague et al. Aug 2014 A1
20140236289 Alkhatib Aug 2014 A1
20140249622 Carmi et al. Sep 2014 A1
20140257461 Robinson et al. Sep 2014 A1
20140257467 Lane et al. Sep 2014 A1
20140257475 Gross et al. Sep 2014 A1
20140257476 Montorfano et al. Sep 2014 A1
20140277358 Slazas Sep 2014 A1
20140277409 Bortlein et al. Sep 2014 A1
20140277411 Börtlein et al. Sep 2014 A1
20140277418 Miller Sep 2014 A1
20140277422 Ratz et al. Sep 2014 A1
20140277427 Ratz et al. Sep 2014 A1
20140296962 Cartledge et al. Oct 2014 A1
20140296969 Tegels et al. Oct 2014 A1
20140324164 Gross et al. Oct 2014 A1
20140331475 Duffy et al. Nov 2014 A1
20140336744 Tani et al. Nov 2014 A1
20140343670 Bakis et al. Nov 2014 A1
20140358222 Gorman, III et al. Dec 2014 A1
20140358224 Tegels et al. Dec 2014 A1
20140379065 Johnson et al. Dec 2014 A1
20140379074 Spence et al. Dec 2014 A1
20140379076 Vidlund et al. Dec 2014 A1
20150018944 O'Connell et al. Jan 2015 A1
20150032205 Matheny Jan 2015 A1
20150045881 Lim Feb 2015 A1
20150094802 Buchbinder et al. Apr 2015 A1
20150119970 Nakayama et al. Apr 2015 A1
20150127097 Neumann et al. May 2015 A1
20150142100 Morriss et al. May 2015 A1
20150142103 Vidlund May 2015 A1
20150157458 Tharnbar et al. Jun 2015 A1
20150164640 McLean et al. Jun 2015 A1
20150173896 Richter et al. Jun 2015 A1
20150173897 Raanani et al. Jun 2015 A1
20150196390 Ma et al. Jul 2015 A1
20150196393 Vidlund et al. Jul 2015 A1
20150216661 Hacohen et al. Aug 2015 A1
20150238313 Spence et al. Aug 2015 A1
20150245934 Lombardi et al. Sep 2015 A1
20150250588 Yang et al. Sep 2015 A1
20150272730 Melnick et al. Oct 2015 A1
20150272734 Sheps et al. Oct 2015 A1
20150282964 Beard et al. Oct 2015 A1
20150320556 Levi et al. Nov 2015 A1
20150327994 Morriss et al. Nov 2015 A1
20150328000 Ratz et al. Nov 2015 A1
20150335429 Morriss et al. Nov 2015 A1
20150351903 Morriss et al. Dec 2015 A1
20150351904 Cooper et al. Dec 2015 A1
20150359629 Ganesan et al. Dec 2015 A1
20160008129 Siegel Jan 2016 A1
20160030169 Shahriari Feb 2016 A1
20160030171 Quijano et al. Feb 2016 A1
20160089482 Siegenthaler Mar 2016 A1
20160095700 Righini Apr 2016 A1
20160100939 Armstrong et al. Apr 2016 A1
20160106539 Buchbinder et al. Apr 2016 A1
20160113766 Ganesan et al. Apr 2016 A1
20160113768 Ganesan et al. Apr 2016 A1
20160125160 Heneghan et al. May 2016 A1
20160175095 Dienno et al. Jun 2016 A1
20160220367 Barrett Aug 2016 A1
20160228247 Maimon et al. Aug 2016 A1
20160242902 Morriss et al. Aug 2016 A1
20160270911 Ganesan et al. Sep 2016 A1
20160310268 Oba et al. Oct 2016 A1
20160310274 Gross et al. Oct 2016 A1
20160317301 Quadri et al. Nov 2016 A1
20160317305 Pelled et al. Nov 2016 A1
20160324633 Gross et al. Nov 2016 A1
20160324635 Vidlund et al. Nov 2016 A1
20160324640 Gifford, III et al. Nov 2016 A1
20160331526 Schweich, Jr. et al. Nov 2016 A1
20160331527 Vidlund et al. Nov 2016 A1
20160338706 Rowe Nov 2016 A1
20160367360 Cartledge et al. Dec 2016 A1
20160367368 Vidlund et al. Dec 2016 A1
20160374801 Jimenez et al. Dec 2016 A1
20160374802 Levi et al. Dec 2016 A1
20170042678 Ganesan et al. Feb 2017 A1
20170049435 Sauer et al. Feb 2017 A1
20170056166 Ratz et al. Mar 2017 A1
20170056171 Cooper et al. Mar 2017 A1
20170065411 Grundeman et al. Mar 2017 A1
20170100236 Robertson et al. Apr 2017 A1
20170128205 Tamir et al. May 2017 A1
20170135816 Lashinski et al. May 2017 A1
20170189174 Braido et al. Jul 2017 A1
20170196688 Christianson et al. Jul 2017 A1
20170196692 Kirk et al. Jul 2017 A1
20170209264 Chau et al. Jul 2017 A1
20170216026 Quill et al. Aug 2017 A1
20170224323 Rowe et al. Aug 2017 A1
20170231757 Gassler Aug 2017 A1
20170231759 Geist et al. Aug 2017 A1
20170231760 Lane et al. Aug 2017 A1
20170239048 Goldfarb et al. Aug 2017 A1
20170333183 Backus Nov 2017 A1
20170333187 Hariton et al. Nov 2017 A1
20180000580 Wallace et al. Jan 2018 A1
20180014930 Hariton et al. Jan 2018 A1
20180021129 Peterson et al. Jan 2018 A1
20180028215 Cohen Feb 2018 A1
20180049873 Manash et al. Feb 2018 A1
20180055628 Patel et al. Mar 2018 A1
20180055630 Patel et al. Mar 2018 A1
20180098850 Rafiee et al. Apr 2018 A1
20180116790 Ratz et al. May 2018 A1
20180116843 Schreck et al. May 2018 A1
20180125644 Conklin May 2018 A1
20180132999 Perouse May 2018 A1
20180153689 Maimon et al. Jun 2018 A1
20180161159 Lee et al. Jun 2018 A1
20180177594 Patel et al. Jun 2018 A1
20180206983 Noe et al. Jul 2018 A1
20180214263 Rolando et al. Aug 2018 A1
20180243086 Barbarino et al. Aug 2018 A1
20180250126 O'connor et al. Sep 2018 A1
20180250147 Syed Sep 2018 A1
20180296333 Dixon et al. Oct 2018 A1
20180296336 Cooper et al. Oct 2018 A1
20180296341 Noe et al. Oct 2018 A1
20180344457 Gross et al. Dec 2018 A1
20180353294 Calomeni et al. Dec 2018 A1
20180360457 Ellis et al. Dec 2018 A1
20190000613 Delgado et al. Jan 2019 A1
20190015200 Delgado et al. Jan 2019 A1
20190021852 Delgado et al. Jan 2019 A1
20190053896 Adamek-bowers et al. Feb 2019 A1
20190060060 Chau et al. Feb 2019 A1
20190060068 Cope et al. Feb 2019 A1
20190060070 Groothuis et al. Feb 2019 A1
20190069997 Ratz et al. Mar 2019 A1
20190083261 Perszyk et al. Mar 2019 A1
20190105153 Barash et al. Apr 2019 A1
20190117391 Humair Apr 2019 A1
20190167423 Hariton et al. Jun 2019 A1
20190175339 Vidlund Jun 2019 A1
20190183639 Moore Jun 2019 A1
20190192295 Spence et al. Jun 2019 A1
20190216602 Lozonschi Jul 2019 A1
20190336280 Naor Nov 2019 A1
20190350701 Adamek-bowers et al. Nov 2019 A1
20190365530 Hoang et al. Dec 2019 A1
20190388218 Vidlund et al. Dec 2019 A1
20190388220 Vidlund et al. Dec 2019 A1
20200000449 Goldfarb et al. Jan 2020 A1
20200000579 Manash et al. Jan 2020 A1
20200015964 Noe et al. Jan 2020 A1
20200030098 Delgado et al. Jan 2020 A1
20200054335 Hemandez et al. Feb 2020 A1
20200060818 Geist et al. Feb 2020 A1
20200113677 McCann et al. Apr 2020 A1
20200113689 McCann et al. Apr 2020 A1
20200113692 McCann et al. Apr 2020 A1
20200138567 Marr et al. May 2020 A1
20200163761 Hariton et al. May 2020 A1
20200214832 Metchik et al. Jul 2020 A1
20200237512 McCann et al. Jul 2020 A1
20200246136 Marr et al. Aug 2020 A1
20200246140 Hariton et al. Aug 2020 A1
20200253600 Darabian Aug 2020 A1
20200261094 Goldfarb et al. Aug 2020 A1
20200315786 Metchik et al. Oct 2020 A1
20200337842 Metchik et al. Oct 2020 A1
20210093449 Hariton et al. Apr 2021 A1
20210113331 Quadri et al. Apr 2021 A1
20210137680 Kizuka et al. May 2021 A1
20210259835 Tyler, II et al. Aug 2021 A1
Foreign Referenced Citations (100)
Number Date Country
2822801 Aug 2006 CA
103974674 Aug 2014 CN
1264582 Nov 2002 EP
1637092 Mar 2006 EP
1768630 Jan 2015 EP
2349124 Oct 2018 EP
3583922 Dec 2019 EP
3270825 Apr 2020 EP
2485795 Sep 2020 EP
S53152790 Dec 1978 JP
2001-0046894 Jun 2001 KR
9843557 Oct 1998 WO
9930647 Jun 1999 WO
0047139 Aug 2000 WO
0162189 Aug 2001 WO
0182832 Nov 2001 WO
0187190 Nov 2001 WO
2003020179 Mar 2003 WO
0328558 Apr 2003 WO
2004028399 Apr 2004 WO
2005107650 Nov 2005 WO
2006007389 Jan 2006 WO
2006007401 Jan 2006 WO
2006054930 Jul 2006 WO
2006070372 Jul 2006 WO
2006086434 Aug 2006 WO
2006089236 Aug 2006 WO
2006116558 Nov 2006 WO
2006128193 Nov 2006 WO
2007047488 Apr 2007 WO
207059252 May 2007 WO
2008013915 Jan 2008 WO
2008029296 Mar 2008 WO
2008070797 Jun 2008 WO
2008103722 Aug 2008 WO
2009033469 Mar 2009 WO
2009053497 Apr 2009 WO
2009091509 Jul 2009 WO
2010006627 Jan 2010 WO
2010027485 Mar 2010 WO
2010037141 Apr 2010 WO
2010045297 Apr 2010 WO
2010057262 May 2010 WO
2010073246 Jul 2010 WO
2010081033 Jul 2010 WO
2010121076 Oct 2010 WO
2011025972 Mar 2011 WO
2011069048 Jun 2011 WO
2011106137 Sep 2011 WO
2011111047 Sep 2011 WO
2011137531 Nov 2011 WO
2011143263 Nov 2011 WO
2011144351 Nov 2011 WO
2011154942 Dec 2011 WO
2012011108 Jan 2012 WO
2012024428 Feb 2012 WO
2012036740 Mar 2012 WO
2012048035 Apr 2012 WO
2012127309 Sep 2012 WO
2012177942 Dec 2012 WO
2013021374 Feb 2013 WO
2013021375 Feb 2013 WO
2013021384 Feb 2013 WO
2013059747 Apr 2013 WO
2013072496 May 2013 WO
2013078497 Jun 2013 WO
2013128436 Jun 2013 WO
2013114214 Aug 2013 WO
2013175468 Nov 2013 WO
2014022124 Feb 2014 WO
2014076696 May 2014 WO
2014115149 Jul 2014 WO
2014144937 Sep 2014 WO
2014145338 Sep 2014 WO
2014164364 Oct 2014 WO
2014194178 Dec 2014 WO
2015173794 Nov 2015 WO
2016016899 Feb 2016 WO
2016093877 Jun 2016 WO
2016125160 Aug 2016 WO
2017223486 Dec 2017 WO
2018025260 Feb 2018 WO
2018025263 Feb 2018 WO
2018039631 Feb 2018 WO
2018039631 Mar 2018 WO
2018106837 Jun 2018 WO
2018112429 Jun 2018 WO
2018118717 Jun 2018 WO
2018131042 Jul 2018 WO
2018131043 Jul 2018 WO
2019026059 Feb 2019 WO
2019027507 Feb 2019 WO
2019030753 Feb 2019 WO
2019077595 Apr 2019 WO
2019116369 Jun 2019 WO
2019138400 Jul 2019 WO
2019195860 Oct 2019 WO
2019202579 Oct 2019 WO
2020058972 Mar 2020 WO
2020167677 Aug 2020 WO
Non-Patent Literature Citations (226)
Entry
ISR and WO mailed Feb. 6, 2013; PCT/IL2012/00292.
ISR and WO mailed Feb. 6, 2013; PCT/IL2012/000293.
ISR and WO mailed Sep. 4, 2014 PCT/IL2014/050087.
ISR and WO mailed Oct. 27, 2015; PCT/IL2015/050792.
ISR and WO mailed May 30, 2016; PCT/IL2016/050125.
Alexander Geha, et al; “Replacement of Degenerated Mitral and Aortic Bioprostheses Without Explantation”, Ann. Thorac. Surg. Jun. 2001, 72: 1509-1514.
Dominique Himbert MD; Mitral Regurgitation and Stenosis from Bioprosthesis and Annuloplasty Failure: Transcatheter Approaches and Outcomes:, 24 pages, Oct. 28, 2013.
Saturn Project; “A Novel Solution for Transcatheter Heart Valve Replacement Specifically Designed to Address Clinical Therapeutic Needs on Mitral Valve”, Dec. 2016; 8 pages.
Frank Langer MD et al; “Ring plus String; Papillary Muscle Repositioning as an Adjunctive Repair Technique for Ischemic Mitral Regurgitation”, J. Thoracic Cardiovasc. Surg. 133: 247-9, Jan. 2007.
Frank Langer MD et al; “Ring+String Successful Repair Technique for ischemic Mitral Regurgitation With Severe Leaflet Tethering”, Circulation 120[suppl 1]; S85-S91, Sep. 2009.
Francesco Maisano MD; Valvetech Cardiovalve: Novel Design Feature and Clinical Update, 2015; TCR Presentation re Cardiovalve; 10 pages.
Giovanni Righini; Righini presentation EuroPCR May 2015 (Saturn)-(downloaded from: https://www.pcronline.com/Cases-resourcesimages/Resources/Course-videos-slides/2015/Cardiovascularinnovation-pipeline-Mitral-and-tricuspid-valve-interventions).
John G. Webb, et al; “Transcatheter Valve-in-Valve Implantation for Failed Bioprosthetic Heart Valves”, Circulation 2010; 1121; 1848-1847, originally published online Apr. 12, 2010.
S. Willeke, et al; Detachable shape-memory sewing ring for heart valves:, Artificial Organs, 16: 294-297; 1992 (an abstract).
U.S. Appl. No. 61/283,819.
U.S. Appl. No. 61/492,449
U.S. Appl. No. 61/515,372.
U.S. Appl. No. 61/525,281.
U.S. Appl. No. 61/537,276.
U.S. Appl. No. 61/555,160.
U.S. Appl. No. 61/588,892.
USPTO NFOA dated Oct. 23, 2017 in connection with U.S. Appl. No. 14/763,004.
USPTO FOA dated Jan. 17, 2018 in connection with U.S. Appl. No. 14/763,004.
USPTO NFOA dated Feb. 27, 2018 in connection with U.S. Appl. No. 15/197,069.
USPTO NFOA dated Dec. 7, 2017 in connection with U.S. Appl. No. 15/213,791.
USPTO Interview Summary dated Feb. 8, 2018 in connection with U.S. Appl. No. 15/213,791.
USPTO NFOA dated Jan. 5, 2018 in connection with U.S. Appl. No. 15/541,783.
USPTO NFOA dated Feb. 2, 2018 in connection with U.S. Appl. No. 15/329,920.
Invitation to pay additional fees dated Jan. 2, 2018; PCT/IL2017/050849.
IPRP issued Feb. 5, 2019; PCT/IL2017/050849.
IPRP issued Feb. 12, 2019; PCT/IL2017/050873.
ISR and WO mailed Dec. 5, 2018; PCT/IL2018/050725.
ISR and WO mailed Nov. 9, 2018; PCT/IL2018/050869.
ISR and WO mailed Jan. 25, 2019; PCT/IL2018/051122.
ISR and WO mailed May 13, 2019: PCT/IL2018/051350.
ISR and WO mailed Apr. 25, 2019; PCT/IL2019/050142.
EPO OA dated Mar. 25, 2019; Appln. No. 14710060.6.
USPTO FOA dated Mar. 4, 2019 in connection with U.S. Appl. No. 14/763,004.
USPTO FOA dated Jan. 30, 2019 in connection with U.S. Appl. No. 15/872,501.
USPTO FOA dated Feb. 5, 2019 in connection with U.S. Appl. No. 15/899,858.
USPTO NFOA dated Oct. 25, 2018 in connection with U.S. Appl. No. 14/763,004.
USPTO NFOA dated Jan. 9, 2019 in connection with U.S. Appl. No. 15/329,920.
USPTO NFOA dated May 23, 2019 in connection with U.S. Appl. No. 15/668,659.
EESR dated Sep. 26, 2018; Appln. No. 1816784.7.
First Chinese Office Action dated Nov. 5, 2018; Appln. No. 201680008328.5.
Invite to pay additional fees dated Oct. 11, 2018; PCTI/IL2018/050725.
USPTO NFOA dated Dec. 4, 2018 in connection with U.S. Appl. No. 16/045,059.
USPTO NOA mailed Sep. 25, 2018 in connection with U.S. Appl. No. 15/188,507.
USPTO FOA dated Feb. 10, 2014 in connection with U.S. Appl. No. 13/033,852.
USPTO FOA dated Feb. 15, 2013 in connection with U.S. Appl. No. 12/840,463.
USPTO FOA dated Feb. 25, 2016 in connection with U.S. Appl. No. 14/522,987.
USPTO FOA dated Mar. 25, 2015 in connection with U.S. Appl. No. 12/840,463.
USPTO FOA dated Apr. 13, 2016 in connection with U.S. Appl. No. 14/626,267.
USPTO FOA dated May 23, 2014 in connection with U.S. Appl. No. 13/412,814.
USPTO FOA dated Jul. 18, 2013 in connection with U.S. Appl. No. 13/044,694.
USPTO FOA dated Jul. 23, 2013 in connection with U.S. Appl. No. 12/961,721.
USPTO FOA dated Sep. 12, 2013 in connection with U.S. Appl. No. 13/412,814.
USPTO NFOA dated Jan. 18, 2017 in connection with U.S. Appl. No. 14/626,267.
USPTO NFOA dated Jan. 21, 2016 in connection with U.S. Appl. No. 14/237,264.
USPTO NFOA dated Feb. 6, 2013 in connection with U.S. Appl. No. 13/412,814.
USPTO NFOA dated Feb. 7, 2017 in connection with U.S. Appl. No. 14/689,608.
An International Preliminary Report on Patentability dated Oct. 20, 2020, which issued during the prosecution of Applicants PCT/IL2019/050142.
An Office Action dated Oct. 5, 2020, which issued during the prosecution of Canadian Patent Application No. 2,973,940.
Notice of Allowance dated Nov. 19, 2020, which issued during the prosecution of U.S. Appl. No. 16/318,025.
An Office Action dated Sep. 24, 2020, which issued during the prosecution of U.S. Appl. No. 16/811,732.
An Office Action summarized English translation and Search Report dated Nov. 25, 2020, which issued during the prosecution of Chinese Patent Application No. 201910449820.1.
An Office Action dated Nov. 30, 2020, which issued during the prosecution of U.S. Appl. No. 16/138,129.
USPTO NFOA dated Jun. 4, 2014 in connection with U.S. Appl. No. 12/840,463.
USPTO NFOA dated Jun. 17, 2014 in connection with U.S. Appl. No. 12/961,721.
USPTO NFOA dated Jun. 30, 2015 in connection with U.S. Appl. No. 14/522,987.
USPTO NFOA dated Jul. 2, 2014 in connection with U.S. Appl. No. 13/811,308.
USPTO NFOA dated Jul. 3, 2014 in connection with U.S. Appl. No. 13/033,852.
USPTO NFOA dated Aug. 2, 2013 in connection with U.S. Appl. No. 13/033,852.
USPTO NFOA dated Sep. 19, 2014 in connection with U.S. Appl. No. 13/044,694.
USPTO NFOA dated Nov. 8, 2013 in connection with U.S. Appl. No. 12/840,463.
USPTO NFOA dated Nov. 23, 2012 in connection with U.S. Appl. No. 13/033,852.
USPTO NFOA dated Nov. 27, 2015 in connection with U.S. Appl. No. 14/626,267.
USPTO NFOA dated Nov. 28, 2012 in connection with U.S. Appl. No. 12/961,721.
USPTO NFOA dated Dec. 10, 2015 in connection with U.S. Appl. No. 14/237,258.
USPTO NFOA dated Dec. 31, 2012 in connection with U.S. Appl. No. 13/044,694.
USPTO NFOA dated May 29, 2012 in connection with U.S. Appl. No. 12/840,463.
USPTO NOA dated May 20, 2016 in connection with U.S. Appl. No. 14/237,258.
USPTO NOA dated Jul. 6, 2017 in connection with U.S. Appl. No. 14/689,608.
USPTO NOA dated Aug. 18, 2017 in connection with U.S. Appl. No. 14/689,608.
USPTO NOA mailed Feb. 11, 2015 in connection with U.S. Appl. No. 13/033,852.
USPTO NOA mailed Mar. 10, 2015 in connection with U.S. Appl. No. 13/811,308.
USPTO NOA mailed Apr. 8, 2016 in connection with U.S. Appl. No. 14/237,258.
USPTO NOA mailed May 5, 2015 in connection with U.S. Appl. No. 12/840,463.
USPTO NOA dated May 10, 2016 in connection with U.S. Appl. No. 14/237,258.
USPTO NOA mailed May 22, 2017 in connection with U.S. Appl. No. 14/689,608.
USPTO NOA mailed Aug. 15, 2014 in connection with U.S. Appl. No. 13/412,814.
USPTO RR dated Jan. 20, 2016 in connection with U.S. Appl. No. 14/161/921.
USPTO RR dated Feb. 3, 2014 in connection with U.S. Appl. No. 13/811,308.
USPTO RR dated Apr. 21, 2017 in connection with U.S. Appl. No. 15/213,791.
USPTO RR dated Jul. 2, 2012 in connection with U.S. Appl. No. 13/033,852.
USPTO RR dated Aug. 13, 2012 in connection with U.S. Appl. No. 13/044,694.
USPTO RR dated Aug. 14, 2012 in connection with U.S. Appl. No. 12/961,721.
USPTO RR dated Aug. 28, 2015 in connection with U.S. Appl. No. 14/237,264.
USPTO RR dated Sep. 26, 2016 in connection with U.S. Appl. No. 14/763,004.
Invitation to pay Additional Fees dated Jun. 12, 2014; PCT/IL2014/050087.
Invitation to pay Additional Fees dated Sep. 29, 2017; PCT/IL2017/050873.
EESR dated Jun. 29, 2017; Appln. No. 11809374.9.
EESR dated Feb. 18, 2015; Appln. No. 12821522.5.
EPO Office Action dated Feb. 10, 2017; Appln. No. 12821522.5.
UK Office Action dated Feb. 7, 2017; Appln. GB1613219.3.
IPRP issued Dec. 2, 2013; PCT/IL2011/000582.
IPRP issued Sep. 11, 2012; PCT/IL2011/000231.
IPRP issued Feb. 11, 2014; PCT/IL2012/000292.
IPRP issued Feb. 11, 2014 PCT/IL2012/000293.
ISR and WO mailed Dec. 5, 2011; PCT/IL11/00582.
ISR and WO mailed Mar. 17, 2014; PCT/IL13/50937.
ISR and WO mailed Oct. 13, 2011; PCT/IL11/00231.
An Office Action dated Jun. 25, 2019, which issued during the prosecution of U.S. Appl. No. 15/329,920.
An Office Action dated May 16, 2019, which issued during the prosecution of U.S. Appl. No. 15/433,547.
An Office Action dated Aug. 1, 2019, which issued during the prosecution of U.S. Appl. No. 15/668,559.
An Office Action dated Aug. 16, 2019, which issued during the prosecution of U.S. Appl. No. 15/668,659.
An Office Action dated Jun. 19, 2019, which issued during the prosecution of U.S. Appl. No. 15/682,789.
An Office Action dated Jun. 14, 2019, which issued during the prosecution of U.S. Appl. No. 15/703,385.
An Office Action dated Oct. 4, 2019, which issued during the prosecution of U.S. Appl. No. 16/183,140.
An Office Action dated Jun. 13, 2019, which issued during the prosecution of U.S. Appl. No. 16/388,038.
An Office Action dated Sep. 13, 2019, which issued during the prosecution of U.S. Appl. No. 16/460,313.
An Office Action dated Nov. 26, 2019, which issued during the prosecution of U.S. Appl. No. 16/532,945.
An Office Action dated Nov. 1, 2019, which issued during the prosecution of U.S. Appl. No. 15/872,501.
U.S. Appl. No. 14/689,608, filed Apr. 17, 2015, published as 2015/0216661, issued as U.S. Pat. No. 9,763,657.
U.S. Appl. No. 15/691,032, filed Aug. 30, 2017, published as 2017/0360426, issued as U.S. Pat. No. 10,512,456.
U.S. Appl. No. 61/492,449, filed Jun. 2, 2011.
U.S. Appl. No. 12/840,463, filed Jul. 21, 2010, published as 2012/0022639, issued as U.S. Pat. No. 9,132,009.
U.S. Appl. No. 13/033,852, filed Feb. 24, 2011, published as 2012/0022640, issued as U.S. Pat. No. 8,992,604.
U.S. Appl. No. 13/811,308, filed Mar. 7, 2013, published as 2013/0172992, issued as U.S. Pat. No. 9,017,399.
Notice of Allowance dated May 7, 2020, which issued during the prosecution of U.S. Appl. No. 16/637,166.
Sündermann, Simon H., et al. “Feasibility of the Engager™ aortic transcatheter valve system using a flexible over-the-wire design.” European Journal of Cardio-Thoracic Surgery 42.4 (2012): e48-e52.
An Office Action summarized English translation and Search Report dated Jul. 3, 2020, which issued during the prosecution of Chinese Patent Application No. 201780061210.3.
Serruys, P. W., Piazza, N., Cribier, A., Webb, J., Laborde, J. C., & de Jaegere, P. (Eds.). (2009). Transcatheter aortic valve implantation: tips and tricks to avoid failure. CRC Press.—Screenshots from Google Books downloaded from: https://books.google.co.il/books?id=FLzLBQAAQBAJ&Ipg=PA198&ots=soqWrDH-y_&dq=%20%22Edwards%20SAPIEN%22&Ir&pg=PA20#v=onepage&q=%22Edwards%20SAPIEN%22&f=false ; Downloaded on Jun. 18, 2020.
An International Search Report and a Written Opinion both dated Jun. 24, 2020, which issued during the prosecution of Applicant's PCT/IL2019/051398.
An Office Action dated Jul. 14, 2020, which issued during the prosecution of U.S. Appl. No. 16/324,339.
Notice of Allowance dated Aug. 28, 2020, which issued during the prosecution of U.S. Appl. No. 16/324,339.
Notice of Allowance dated Jul. 29, 2020, which issued during the prosecution of U.S. Appl. No. 16/132,937.
An Office Action dated Jul. 29, 2020, which issued during the prosecution of U.S. Appl. No. 16/269,328.
Notice of Allowance dated Aug. 26, 2020, which issued during the prosecution of U.S. Appl. No. 16/269,328.
An Office Action dated Aug. 7, 2020, which issued during the prosecution of U.S. Appl. No. 15/668,659.
Tchetche, D. and Nicolas M. Van Mieghem: “New-generation TAVI devices: description and specifications” EuroIntervention, 2014, No. 10:U90-U100.
Symetis S.A.: “Acurate neo™ Aortic Bioprosthesis for Implantation using the ACURATE neo™ TA Transapical Delivery System in Patients with Severe Aortic Stenosis,” Clinical Investigation Plan, Protocol No. 2015-01, Vs. No. 2, 2015:1-76.
Notice of Allowance dated Sep. 10, 2020, which issued during the prosecution of U.S. Appl. No. 15/600,190.
An Office Action dated Jan. 6, 2020, which issued during the prosecution of U.S. Appl. No. 16/660,231.
An Office Action dated Dec. 31, 2019, which issued during the prosecution of U.S. Appl. No. 16/183,140.
An Office Action dated Jan. 14, 2020, which issued during the prosecution of U.S. Appl. No. 16/284,331.
Notice of Allowance dated Jan. 13, 2020, which issued during the prosecution of U.S. Appl. No. 15/956,956.
European Search European Search Report dated Mar. 5, 2020 which issued during the prosecution of Applicant's European App No. 17752184.6.
European Search Report dated Mar. 4, 2020 which issued during the prosecution of Applicant's European App No. 16706913.7.
Notice of Allowance dated Mar. 12, 2020, which issued during the prosecution of U.S. Appl. No. 16/460,313.
An Office Action dated Jan. 9, 2020, which issued during the prosecution of U.S. Appl. No. 15/600,190.
An Office Action dated Jan. 3, 2020, which issued during the prosecution of U.S. Appl. No. 16/678,355.
An Office Action dated Feb. 6, 2020, which issued during the prosecution of U.S. Appl. No. 15/668,659.
Poirier, Nancy C., et al. “A novel repair for patients with atrioventricular septal defect requiring reoperation for left atrioventricular valve regurgitation.” European journal of cardio-thoracic surgery 18.1 (2000): 54-61.
An Office Action dated Mar. 29, 2021, which issued during the prosecution of U.S. Appl. No. 16/738,516.
Ando, Tomo, et al. “Iatrogenic ventricular septal defect following transcatheter aortic valve replacement: a systematic review.” Heart, Lung and Circulation 25.10 (2016): 968-974.
Urena, Marina, et al. “Transseptal transcatheter mitral valve replacement using balloon-expandable transcatheter heart valves: a step-by-step approach.” JACC: Cardiovascular Interventions 10.19 (2017): 1905-1919.
An English summary of an Official Action dated Mar. 29, 2021, which issued during the prosecution of Chinese Patent Application No. 201780061210.3.
An International Search Report and a Written Opinion both dated Jan. 28, 2020, which issued during the prosecution of Applicant's PCT/IL2019/051031.
An International Preliminary Report on Patentability dated Mar. 9, 2021, which issued during the prosecution of Applicant's PCT/IL2019/051031.
An Office Action dated May 4, 2021, which issued during the prosecution of U.S. Appl. No. 16/636,204.
Notice of Allowance dated May 17, 2021, which issued during the prosecution of U.S. Appl. No. 16/138,129.
Notice of Allowance dated Jun. 4, 2021, which issued during the prosecution of U.S. Appl. No. 16/802,353.
An Office Action dated May 12, 2021, which issued during the prosecution of Canadian Patent Application No. 2,973,940.
Petition for Inter Partes Review of U.S. Pat. No. 10,702,385—dated Jun. 4, 2021.
Declaration of Ivan Vesely, Ph.D. In Support of Petition for Inter Partes Review of U.S. Pat. No. 10,702,385—dated Jun. 4, 2021.
European Search Report dated Jun. 10, 2021 which issued during the prosecution of Applicant's European App No. 21157988.3.
An Invitation to pay additional fees dated May 19, 2021, which issued during the prosecution of Applicant's PCT/IL2021/050132.
An International Search Report and a Written Opinion both dated Jul. 12, 2021, which issued during the prosecution of Applicant's PCT/IL2021/050132.
IPR2021-00383 Petitioners' Authorized Reply to Patent Owner's Preliminary Response dated May 27, 2021.
Exhibit 1014—Transcript of proceedings held May 20, 2021 (Edwards Lifesciences vs. Cardiovalve).
Exhibit 1015—Facilitate, Meriam-Webster.com, https://www.merriamwebster.com/dictionary/facilitate (visited May 26, 2021).
Patent Owner's Authorized Surreply to Petitioner's Reply to Patent Owner's Preliminary Response dated Jun. 4, 2021 (Edwards Lifesciences vs. Cardiovalve).
An Office Action dated Aug. 18, 2021, which issued during the prosecution of U.S. Appl. No. 17/210,183.
Institution decision dated Jul. 20, 2021(Edwards Lifesciences vs. Cardiovalve).
An Office Action dated Dec. 24, 2020, which issued during the prosecution of U.S. Appl. No. 16/144,054.
An Office Action dated Feb. 2, 2021, which issued during the prosecution of U.S. Appl. No. 16/811,732.
An Office Action dated Jan. 13, 2021, which issued during the prosecution of European Patent Application No. 15751089.2.
Maisano, F., et al. “The edge-to-edge technique: a simplified method to correct mitral insufficiency.” European journal of cardio-thoracic surgery 13.3 (1998): 240-246.
Declaration of Dr. Ivan Vesely, Ph.D. in Support of Petition for Inter Partes Review of U.S. Pat. No. 10,226,341—dated Dec. 17, 2020.
Petition for Inter Partes Review of U.S. Pat. No. 10,226,341 and Exhibits 1001-1013—dated Dec. 29, 2020.
An Office Action together with an English summary dated Mar. 3, 2021, which issued during the prosecution of Chinese Patent Application No. 201780047391.4.
Fucci, C., et al. “Improved results with mitral valve repair using new surgical techniques.” European journal of cardio-thoracic surgery 9.11 (1995): 621-627.
Declaration of Ivan Vesely, Ph.D., in Support of Petition for Inter PartesReview of U.S. Pat. No. 7,563,267—dated May 29, 2019.
U.S. Appl. No. 60/128,690, filed Apr. 9, 1999.
Batista, Randas JV, et al. “Partial left ventriculectomy to treat end-stage heart disease.” The Annals of thoracic surgery 64.3 (1997): 634-638.
Beall Jr, Arthur C., et al. “Clinical experience with a dacron velour-covered teflon-disc mitral-valve prosthesis.” The Annals of thoracic surgery 5.5 (1968): 402-410.
Kalbacher, D., et al. “1000 MitraClip™ procedures: Lessons learnt from the largest single-centre experience worldwide.” (2019): 3137-3139.
U.S. Appl. No. 60/613,867, filed Sep. 27, 2004.
Mitral Valve Academic Research Consortium. “Clinical Trial Design Principles and Endpoint Definitions for Transcatheter Mitral Valve Repair and Replacement: Part 1: Clinical Trial Design Principles a Consensus Document from the Mitral Valve Academic Research Consortium.” Journal of the American College of Cardiology 66.3 (2015): 278-307.
Office Action dated Apr. 11, 2022 in U.S. Appl. No. 17/473,472.
Office Action dated Jan. 26, 2022 in U.S. Appl. No. 16/888,210.
Notice of Allowance dated Jan. 31, 2022 in U.S. Appl. No. 17/479,418.
Preliminary Guidance Patent Owner's Motion to Amend dated Jan. 31, 2022 in IPR2021-00383.
Office Action dated Mar. 18, 2022 in U.S. Appl. No. 16/746,489.
Notice of Allowance dated Mar. 4, 2022 in U.S. Appl. No. 16/768,909.
Notice of Allowance dated Mar. 22, 2022 in U.S. Appl. No. 17/366,711.
Office Action dated Jan. 24, 2022 in U.S. Appl. No. 16/135,466.
Office Action dated Dec. 9, 2021 in U.S. Appl. No. 16/135,969.
An Office Action dated Nov. 25, 2021, which issued during the prosecution of European Patent Application No. 18826823.9.
IPR2021-01051 Institution decision dated Dec. 10, 2021.
Notice of Allowance dated Dec. 7, 2021, which issued during the prosecution of U.S. Appl. No. 17/394,807.
Notice of Allowance dated Dec. 6, 2021, which issued during the prosecution U.S. Appl. No. 16/738,516.
Notice of Allowance dated Dec. 29, 2021, which issued during the prosecution of U.S. Appl. No. 17/210,183.
IPR2021-00383 Petitioners' Reply to Patent Owner's Response dated Jan. 5, 2022.
IPR2021-00383 Petitioners' Opposition to Patent Owner's Contingent Motion to Amend dated Jan. 5, 2022.
An Office Action dated Sep. 22, 2021, which issued during the prosecution of European Patent Application No. 20714289.4.
Summary of Examination Notice dated Jan. 6, 2022, which issued during the prosecution of Chinese Patent Application No. 201880064313.X.
An Office Action dated Jan. 12, 2022, which issued during the prosecution of U.S. Appl. No. 17/101,787.
An Office Action dated Sep. 9, 2021, which issued during the prosecution of U.S. Appl. No. 16/768,909.
An Office Action dated Sep. 15, 2021, which issued during the prosecution of U.S. Appl. No. 16/135,599.
IPR2021-00383 Deposition of Dr. Ivan Vesely, dated Sep. 22, 2021.
An Office Action dated Oct. 21, 2021, which issued during the prosecution of U.S. Appl. No. 17/335,845.
European Search Report dated Oct. 11, 2021 which issued during the prosecution of Applicant's European App No. 21176010.3.
Fann, James I., et al. “Beating heart catheter-based edge-to-edge mitral valve procedure in a porcine model: efficacy and healing response.” Circulation 110.8 (2004): 988-993.
Feldman, Ted, et al. “Percutaneous mitral repair with the MitraClip system: safety and midterm durability in the initial Everest (Endovascular Valve Edge-to-Edge REpair Study) cohort.” Journal of the American College of Cardiology 54.8 (2009): 686-694.
IPR2021-00383 Patent Owner's Contingent Motion to Amend Under 37 C.F.R. §42.121 dated Oct. 13, 2021.
IPR2021-00383 Patent Owner's Response Pursuant to 37 C.F.R. § 42.120 dated Oct. 13, 2021.
IPR2021-00383 Second Declaration of Dr. Michael Sacks dated Oct. 13, 2021.
An Office Action dated Oct. 21, 2021, which issued during the prosecution of U.S. Appl. No. 17/306,231.
Maisano, Francesco, et al. “The evolution from surgery to percutaneous mitral valve interventions: the role of the edge-to-edge technique.” Journal of the American College of Cardiology 58.21 (2011): 2174-2182.
Cardiovalve Exhibit 2009—Percutaneous Mitral Leaflet Repair: MitraClip® Therapy for Mitral Regurgitation (2012).
Feldman, Ted, et al. “Percutaneous mitral valve repair using the edge-to-edge technique: six-month results of the Everest Phase I Clinical Trial.” Journal of the American College of Cardiology 46.11 (2005): 2134-2140.
An Office Action summarized English translation and Search Report dated Oct. 8, 2021, which issued during the prosecution of Chinese Patent Application No. 201780061210.3.
An Office Action dated Nov. 4, 2021, which issued during the prosecution of U.S. Appl. No. 17/366,711.
An Office Action summarized English translation and Search Report dated Aug. 12, 2021, which issued during the prosecution of Chinese Patent Application No. 201880058940.2.
Related Publications (1)
Number Date Country
20200078002 A1 Mar 2020 US
Provisional Applications (1)
Number Date Country
61492449 Jun 2011 US
Continuations (3)
Number Date Country
Parent 15691032 Aug 2017 US
Child 16680739 US
Parent 14689608 Apr 2015 US
Child 15691032 US
Parent 13811308 US
Child 14689608 US
Continuation in Parts (3)
Number Date Country
Parent 13033852 Feb 2011 US
Child 13811308 US
Parent 12840463 Jul 2010 US
Child 13033852 US
Parent 12840463 Jul 2010 US
Child PCT/IL2011/000582 US